BioMedLib Search Engine
[ goto HOMEPAGE ]
Don't miss relevant answers!
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
basal cell carcinoma of skin diagnosis 2005:2010[pubdate] *count=100
5086 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
basal cell carcinoma of skin diagnosis
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 5086
1.
Eide MJ, Weinstock MA, Dufresne RG Jr, Neelagaru S, Risica P, Burkholder GJ, Upegui D, Phillips KA, Armstrong BK, Robinson-Bostom L:
Relationship of treatment delay with surgical defect size from keratinocyte carcinoma (basal cell carcinoma and squamous cell carcinoma of the skin).
J Invest Dermatol
; 2005 Feb;124(2):308-14
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Relationship of treatment delay with surgical defect size from keratinocyte
carcinoma
(
basal cell carcinoma
and squamous
cell carcinoma
of the
skin
).
Larger keratinocyte
carcinoma
(KC) lesions are associated with higher morbidity.
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Eur J Cancer. 2001 May;37(7):843-8
[
11313171.001
]
[Cites]
Br J Dermatol. 2001 Mar;144(3):476-83
[
11260002.001
]
[Cites]
Dermatol Surg. 2001 Nov;27(11):955-9
[
11737130.001
]
[Cites]
Br J Dermatol. 2002 Jul;147(1):48-54
[
12100184.001
]
[Cites]
Arch Dermatol. 2002 Aug;138(8):1043-51
[
12164742.001
]
[Cites]
Melanoma Res. 2002 Aug;12(4):389-94
[
12170189.001
]
[Cites]
Ann Plast Surg. 2002 Oct;49(4):439-42
[
12370654.001
]
[Cites]
CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26
[
12568441.001
]
[Cites]
Br J Dermatol. 2004 Jul;151(1):141-7
[
15270883.001
]
[Cites]
Br J Psychiatry. 1967 Jan;113(494):89-93
[
6029373.001
]
[Cites]
J Dermatol Surg Oncol. 1981 Apr;7(4):311-6
[
7240532.001
]
[Cites]
Prog Clin Biol Res. 1984;156:169-79
[
6473424.001
]
[Cites]
J Psychosom Res. 1985;29(2):139-53
[
4009515.001
]
[Cites]
J Am Acad Dermatol. 1988 Mar;18(3):591-8
[
3351022.001
]
[Cites]
J Dermatol Surg Oncol. 1989 Mar;15(3):315-28
[
2646336.001
]
[Cites]
Eur J Surg Oncol. 1989 Apr;15(2):143-8
[
2703058.001
]
[Cites]
Arch Dermatol. 1991 Mar;127(3):356-61
[
1998366.001
]
[Cites]
J Am Acad Dermatol. 1991 Jan;24(1):1-13
[
1999506.001
]
[Cites]
Postgrad Med. 1991 Mar;89(4):151-2, 155-8
[
2000349.001
]
[Cites]
Ann R Coll Surg Engl. 1991 Jul;73(4):248-52
[
1863047.001
]
[Cites]
J Dermatol Surg Oncol. 1991 Sep;17(9):713-8
[
1890243.001
]
[Cites]
Cancer. 1991 Nov 1;68(9):2064-8
[
1913555.001
]
[Cites]
Dermatol Surg. 1996 Mar;22(3):255-61
[
8599737.001
]
[Cites]
J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):422-9
[
9308558.001
]
[Cites]
Arch Dermatol. 1999 Mar;135(3):269-74
[
10086447.001
]
[Cites]
Arch Dermatol. 1999 Mar;135(3):339-40
[
10086457.001
]
[Cites]
J Clin Epidemiol. 1999 Nov;52(11):1111-6
[
10527006.001
]
[Cites]
Br J Dermatol. 1999 Nov;141(5):783-7
[
10583157.001
]
[Cites]
Br J Dermatol. 1999 Nov;141(5):876-9
[
10583170.001
]
[Cites]
Int J Cancer. 2000 May 20;89(3):271-9
[
10861504.001
]
[Cites]
Int J Cancer. 2000 May 20;89(3):280-5
[
10861505.001
]
[Cites]
Arch Dermatol. 2001 Aug;137(8):1055-8
[
11493098.001
]
(PMID = 15675948.001).
[ISSN]
0022-202X
[Journal-full-title]
The Journal of investigative dermatology
[ISO-abbreviation]
J. Invest. Dermatol.
[Language]
ENG
[Grant]
United States / NIMH NIH HHS / MH / K24 MH063975; United States / NCI NIH HHS / CA / R01 CA078800; United States / AHRQ HHS / HS / T32 HS000011; United States / NCI NIH HHS / CA / CA 78800
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
[Other-IDs]
NLM/ NIHMS12744; NLM/ PMC1613794
2.
Niederkohr RD, Gamie SH:
F-18 FDG PET as an imaging tool for detecting and staging metastatic basal-cell carcinoma.
Clin Nucl Med
; 2007 Jun;32(6):491-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
F-18 FDG PET as an imaging tool for detecting and staging metastatic
basal
-
cell carcinoma
.
[MeSH-major]
Carcinoma
,
Basal Cell
/ radionuclide imaging. Fluorodeoxyglucose F18. Radiopharmaceuticals.
Skin
Neoplasms / radionuclide imaging. Tomography, Emission-Computed
[MeSH-minor]
Diagnosis
, Differential. Humans. Male. Middle Aged.
Neoplasm
Metastasis. Whole Body Imaging
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17515767.001).
[ISSN]
0363-9762
[Journal-full-title]
Clinical nuclear medicine
[ISO-abbreviation]
Clin Nucl Med
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
3.
Baker SH, Roy M, Thornton SC, Qureshi M, Binns C:
Probing atomic structure in magnetic core/shell nanoparticles using synchrotron radiation.
J Phys Condens Matter
; 2010 Sep 29;22(38):385301
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
For Fe/Cu nanoparticles, a Cu shell ∼ 20 monolayers thick appears similar in structure to bulk Cu and is sufficient to cause the structure in the Fe core to switch from body centred cubic (
bcc
; as in bulk Fe) to face centred cubic.
This is not
the case
for thinner Cu shells, 1-2 monolayers in thickness, in which there is a considerable contraction in nearest-neighbour interatomic distance as the shell structure changes to
bcc
.
In Fe/Au nanoparticles, the crystal structure in the Fe core remains
bcc
for all Au thicknesses although there is some stretching of the lattice.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
IRON, ELEMENTAL
.
Hazardous Substances Data Bank.
COPPER, ELEMENTAL
.
Hazardous Substances Data Bank.
GOLD, ELEMENTAL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21386550.001).
[ISSN]
1361-648X
[Journal-full-title]
Journal of physics. Condensed matter : an Institute of Physics journal
[ISO-abbreviation]
J Phys Condens Matter
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
7440-57-5 / Gold; 789U1901C5 / Copper; E1UOL152H7 / Iron
Advertisement
4.
Limtong S, Kaewwichian R, Am-In S, Boonmak C, Jindamorakot S, Yongmanitchai W, Srisuk N, Kawasaki H, Nakase T:
Three anamorphic yeast species Candida sanitii sp. nov., Candida sekii sp. nov. and Candida suwanaritii, three novel yeasts in the Saturnispora clade isolated in Thailand.
FEMS Yeast Res
; 2010 Feb;10(1):114-22
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The type strain is RV152(T) (
BCC
25967(T)=NBRC 103864(T)=CBS 10864(T)).
The type strain is EA1(T) (
BCC
29900(T)=NBRC 104877(T)=CBS 11021(T)).
The type strain is ST84(T) (
BCC
8320(T)=NBRC 105671(T)=CBS 10931(T)).
SILVA.
SILVA LSU Database
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19765089.001).
[ISSN]
1567-1364
[Journal-full-title]
FEMS yeast research
[ISO-abbreviation]
FEMS Yeast Res.
[Language]
eng
[Databank-accession-numbers]
GENBANK/ AB332397/ AB332399/ AB332401/ AB332402/ AB332403/ AB439256/ AB495287/ AB495288/ DQ404448
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / DNA, Fungal; 0 / DNA, Ribosomal Spacer
5.
Zaballos P, Blazquez S, Puig S, Salsench E, Rodero J, Vives JM, Malvehy J:
Dermoscopic pattern of intermediate stage in seborrhoeic keratosis regressing to lichenoid keratosis: report of 24 cases.
Br J Dermatol
; 2007 Aug;157(2):266-72
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Dermoscopic pattern of intermediate stage in seborrhoeic keratosis regressing to lichenoid keratosis: report of 24
cases
.
OBJECTIVES: To evaluate the dermoscopic criteria of a series of
cases
of LK with remaining areas of seborrhoeic keratosis which were both dermoscopically and histologically diagnosed.
), at 10-fold magnification, at the Dermatology Department of Hospital
de
Sant Pau i Santa Tecla (Tarragona, Spain), between 1 January 2003 and 31 December 2005.
RESULTS: In total, 24
cases
of lesions with dermoscopic areas of seborrhoeic keratosis and LK were collected.
In four lesions (17%), the clinical differential
diagnosis
without dermoscopy included
malignant
melanoma and in seven lesions (29%),
basal cell carcinoma
.
The
diagnosis of
LK was clinically considered without dermoscopy in only six
cases
(25%).
This pattern consisted of the presence of brownish-grey, bluish-grey or whitish-grey coarse granules that formed, in 11
cases
(46%), globules and/or short lines.
[MeSH-major]
Keratosis /
diagnosis
. Lichenoid Eruptions /
diagnosis
[MeSH-minor]
Adult. Aged. Aged, 80 and over.
Carcinoma
,
Basal Cell
/
diagnosis
. Dermoscopy.
Diagnosis
, Differential.
Disease
Progression. Female. Humans. Keratosis, Seborrheic /
diagnosis
. Keratosis, Seborrheic / pathology. Male. Melanoma /
diagnosis
. Middle Aged. Prospective Studies.
Skin
Neoplasms /
diagnosis
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17553042.001).
[ISSN]
0007-0963
[Journal-full-title]
The British journal of dermatology
[ISO-abbreviation]
Br. J. Dermatol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
6.
Shome D, Bell D, Esmaeli B:
Eyelid carcinoma in patients with systemic lymphoma.
J Ophthalmic Vis Res
; 2010 Jan;5(1):38-43
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Eyelid
carcinoma
in patients with systemic lymphoma.
PURPOSE: To describe a series of patients with Non-Hodgkin's lymphoma (NHL) and concomitant eyelid
carcinoma
.
METHODS: In this non-comparative interventional
case
series, we retrospectively reviewed the medical records of 5 patients with NHL who developed eyelid
carcinoma
.
Systemic lymphoma had been diagnosed 1 to 72 months prior to development of the eyelid
carcinoma
.
The lesions were
basal cell carcinoma
in three, and squamous
cell carcinoma
in two
cases
.
Four patients underwent surgical excision of the
carcinoma
and one patient was awaiting surgical treatment after completing systemic chemotherapy.
Three subjects had high-grade
carcinomas
.
CONCLUSIONS: Systemic lymphoma may be associated with aggressive eyelid
carcinomas
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
JAMA. 1975 Apr 21;232(3):267-9
[
47401.001
]
[Cites]
J Natl Cancer Inst. 1978 Aug;61(2):337-40
[
277720.001
]
[Cites]
J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7
[
1512794.001
]
[Cites]
BMJ. 1995 Jun 10;310(6993):1491-5
[
7787593.001
]
[Cites]
Curr Opin Hematol. 2000 Jul;7(4):223-34
[
10882178.001
]
[Cites]
J Natl Cancer Inst. 2005 Feb 2;97(3):199-209
[
15687363.001
]
[Cites]
Ophthal Plast Reconstr Surg. 2008 Nov-Dec;24(6):444-9
[
19033839.001
]
[Cites]
Am J Ophthalmol. 1986 Apr 15;101(4):480-2
[
3515953.001
]
[Cites]
Arch Ophthalmol. 1980 Oct;98(10):1771-2
[
7000053.001
]
[Cites]
Eur J Haematol. 1994 Oct;53(4):218-22
[
7957806.001
]
[Cites]
Br J Cancer. 1996 Dec;74(11):1847-50
[
8956805.001
]
[Cites]
Acta Haematol. 1997;98(1):44-6
[
9210914.001
]
[Cites]
Int J Cancer. 1999 Mar 1;80(5):641-5
[
10048959.001
]
[Cites]
Dermatology. 2001;202(4):359-61
[
11455161.001
]
[Cites]
J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20
[
12077575.001
]
[Cites]
Curr Treat Options Oncol. 2004 Jun;5(3):215-23
[
15115650.001
]
[Cites]
Leuk Lymphoma. 2004 Mar;45(3):507-13
[
15160912.001
]
[Cites]
Histopathology. 2004 Aug;45(2):162-70
[
15279635.001
]
[Cites]
Arch Dermatol. 2004 Aug;140(8):985-8
[
15313816.001
]
[Cites]
Oncogene. 2004 Aug 23;23(38):6524-34
[
15322522.001
]
[Cites]
Leuk Lymphoma. 2005 Jan;46(1):49-54
[
15621780.001
]
[Cites]
Dermatol Surg. 2005 Jan;31(1):38-42; discussion 42
[
15720094.001
]
[Cites]
Leuk Lymphoma. 2005 Jul;46(7):1051-5
[
16019557.001
]
[Cites]
Skinmed. 2005 Sep-Oct;4(5):300-4
[
16282752.001
]
[Cites]
Australas J Dermatol. 2006 Nov;47(4):231-6
[
17034463.001
]
(PMID = 22737325.001).
[ISSN]
2008-2010
[Journal-full-title]
Journal of ophthalmic & vision research
[ISO-abbreviation]
J Ophthalmic Vis Res
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Iran
[Other-IDs]
NLM/ PMC3380669
[Keywords]
NOTNLM ; Eyelid Cancer / Immunosuppression / Squamous Cell Carcinoma / Systemic Lymphoma
7.
Madey TE, Chen W, Wang H, Kaghazchi P, Jacob T:
Nanoscale surface chemistry over faceted substrates: structure, reactivity and nanotemplates.
Chem Soc Rev
; 2008 Oct;37(10):2310-27
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Planar metal surfaces that are rough on the atomic scale, such as
bcc
W(111), fcc Ir(210) and hcp
Re
(1231), are morphologically unstable when covered by monolayer films of oxygen, or by certain other gases or metals, becoming "nanotextured" when heated to temperatures above approximately 700 K.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18818829.001).
[ISSN]
0306-0012
[Journal-full-title]
Chemical Society reviews
[ISO-abbreviation]
Chem Soc Rev
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
8.
Shivakumar D, Deng Y, Roux B:
Computations of Absolute Solvation Free Energies of Small Molecules Using Explicit and Implicit Solvent Model.
J Chem Theory Comput
; 2009 Apr 14;5(4):919-30
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Because of the crucial role of electrostatics in solvation free energy, the results from various commonly used charge generation models based on the semiempirical (AM1-
BCC
) and QM calculations [charge fitting using ChelpG and RESP] are compared.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 26609601.001).
[ISSN]
1549-9618
[Journal-full-title]
Journal of chemical theory and computation
[ISO-abbreviation]
J Chem Theory Comput
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
9.
Apaydin R, Gürbüz Y, Bayramgürler D, Bilen N:
Cytokeratin contents of basal cell carcinoma, epidermis overlying tumour, and associated stromal amyloidosis: an immunohistochemical study.
Amyloid
; 2005 Mar;12(1):41-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cytokeratin contents
of basal cell carcinoma
, epidermis overlying tumour, and associated stromal amyloidosis: an immunohistochemical study.
We investigated the expression of CKs immunohistochemically in
basal cell
carcinomas
(
BCCs
), epidermis overlying tumour, and
skin
tumor-associated amyloidosis (STA).
Twenty
cases
of
BCC
, 11 of which had STA were included to the study.
In
BCCs
without STA, CK1-8, CK14 and CK17 antibodies were expressed by tumour tissue in all biopsy specimens.
In
the BCCs
with STA, tumour tissue was immunoreactive always with CK1-8 and CK17 antibodies, and commonly immunoreactive with anti-CK 14 antibody.
In conclusion, we could not find a significant CK expression difference between
BCCs
with and without STA.
Weak positivity and a few number of CKs were shown in STA when compared with those of
BCC
and epidermis overlying tumour tissue expressing the more variable CKs.
[MeSH-major]
Amyloidosis / metabolism.
Carcinoma
,
Basal Cell
/ metabolism. Epidermis / metabolism. Keratins / metabolism.
Skin
Neoplasms / metabolism. Stromal Cells / metabolism
Genetic Alliance.
consumer health - Amyloidosis
.
MedlinePlus Health Information.
consumer health - Amyloidosis
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16076610.001).
[ISSN]
1350-6129
[Journal-full-title]
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
[ISO-abbreviation]
Amyloid
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
68238-35-7 / Keratins
10.
Nan H, Kraft P, Hunter DJ, Han J:
Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians.
Int J Cancer
; 2009 Aug 15;125(4):909-17
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Genetic variants in pigmentation genes, pigmentary phenotypes, and risk
of skin
cancer
in Caucasians.
Although a large number of single nucleotide polymorphisms (SNPs) have been identified in pigmentation genes, very few SNPs have been examined in relation to human pigmentary phenotypes and
skin
cancer
risk.
We evaluated the associations between 15 SNPs in 8 candidate pigmentation genes (TYR, TYRP1, OCA2, SLC24A5, SLC45A2, POMC, ASIP and ATRN) and both pigmentary phenotypes (hair color,
skin
color and tanning ability) and
skin
cancer
risk in a nested
case
-control study of Caucasians within the Nurses' Health Study (NHS) among 218 melanoma
cases
, 285 squamous
cell carcinoma
(SCC)
cases
, 300
basal cell carcinoma
(
BCC
)
cases
and 870 common controls.
We found that the TYR Arg402Gln variant was significantly associated with
skin
color (p-value = 7.7 x 10(-4)) and tanning ability (p-value = 7.3 x 10(-4)); the SLC45A2 Phe374Leu variant was significantly associated with hair color (black to blonde) (p-value = 2.4 x 10(-7)),
skin
color (p-value = 1.1 x 10(-7)) and tanning ability (p-value = 2.5 x 10(-4)).
No significant associations were found between these polymorphisms and the risk
of skin
cancer
.
The OCA2 Arg419Gln and ASIP g.8818 A>G were associated with
BCC
risk (OR, 1.50; 95% CI, 1.06-2.13 and OR, 0.73; 95% CI, 0.53-1.00, respectively).
The haplotype near ASIP (rs4911414[T] and rs1015362[G]) was significantly associated with fair
skin
color (OR, 2.28; 95% CI, 1.46-3.57) as well as the risks of melanoma (OR, 1.68; 95% CI, 1.18-2.39) and SCC (OR, 1.54; 95% CI, 1.08-2.19).
Our study provides evidence for the contribution of pigmentation genetic variants, in addition to the MC1R variants, to variation in human pigmentary phenotypes and possibly the development
of skin
cancer
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nature. 1993 Jan 7;361(6407):72-6
[
8421497.001
]
[Cites]
Ann Epidemiol. 1990 Oct;1(1):13-23
[
1669486.001
]
[Cites]
J Clin Invest. 1994 May;93(5):2258-62
[
8182158.001
]
[Cites]
Hum Mol Genet. 1994;3 Spec No:1469-75
[
7849740.001
]
[Cites]
Annu Rev Genet. 1994;28:189-217
[
7893123.001
]
[Cites]
Nat Genet. 1995 Jan;9(1):92-5
[
7704033.001
]
[Cites]
Hum Mol Genet. 1995 Feb;4(2):223-30
[
7757071.001
]
[Cites]
Nat Genet. 1995 Nov;11(3):328-30
[
7581459.001
]
[Cites]
Genomics. 1995 Sep 1;29(1):24-34
[
8530077.001
]
[Cites]
Int J Epidemiol. 1996 Apr;25(2):245-51
[
9119548.001
]
[Cites]
Pigment Cell Res. 1996 Aug;9(4):191-203
[
8948501.001
]
[Cites]
Am J Med Genet. 1997 Jul 11;71(1):57-62
[
9215770.001
]
[Cites]
Exp Clin Immunogenet. 1998;15(1):19-32
[
9619397.001
]
[Cites]
J Hered. 1998 Nov-Dec;89(6):546-51
[
9864865.001
]
[Cites]
Nature. 1999 Mar 11;398(6723):152-6
[
10086356.001
]
[Cites]
Ann Hum Genet. 1964 Sep;28:27-37
[
14204850.001
]
[Cites]
Hum Mutat. 2005 Mar;25(3):278-84
[
15714523.001
]
[Cites]
Genet Epidemiol. 2005 Apr;28(3):261-72
[
15637718.001
]
[Cites]
Hum Genet. 2005 Apr;116(5):402-6
[
15726415.001
]
[Cites]
Eur J Hum Genet. 2005 Aug;13(8):913-20
[
15889046.001
]
[Cites]
J Dermatol Sci. 2005 Nov;40(2):133-6
[
16183259.001
]
[Cites]
Science. 2005 Dec 16;310(5755):1782-6
[
16357253.001
]
[Cites]
Pigment Cell Res. 2006 Feb;19(1):76-89
[
16420249.001
]
[Cites]
Pigment Cell Res. 2006 Jun;19(3):226-31
[
16704456.001
]
[Cites]
Int J Cancer. 2006 Oct 15;119(8):1976-84
[
16721784.001
]
[Cites]
Nature. 2006 Sep 21;443(7109):340-4
[
16988713.001
]
[Cites]
Nat Genet. 2007 Dec;39(12):1443-52
[
17952075.001
]
[Cites]
Nat Genet. 2008 Mar;40(3):340-5
[
18246066.001
]
[Cites]
Nat Genet. 2008 May;40(5):491-2
[
18443580.001
]
[Cites]
PLoS Genet. 2008 May;4(5):e1000074
[
18483556.001
]
[Cites]
Nat Genet. 2008 Jul;40(7):838-40
[
18488026.001
]
[Cites]
Nat Genet. 2008 Jul;40(7):886-91
[
18488027.001
]
[Cites]
Nat Genet. 2008 Jul;40(7):835-7
[
18488028.001
]
[Cites]
PLoS One. 2008;3(7):e2551
[
18596976.001
]
[Cites]
Nature. 2007 Feb 22;445(7130):843-50
[
17314970.001
]
[Cites]
Am J Hum Genet. 2000 Jan;66(1):176-86
[
10631149.001
]
[Cites]
Ann N Y Acad Sci. 1999 Oct 20;885:254-61
[
10816658.001
]
[Cites]
J Hum Evol. 2000 Jul;39(1):57-106
[
10896812.001
]
[Cites]
J Invest Dermatol. 2000 Oct;115(4):607-13
[
10998131.001
]
[Cites]
Hum Mol Genet. 2000 Oct 12;9(17):2531-7
[
11030758.001
]
[Cites]
Pigment Cell Res. 2000;13 Suppl 8:48-53
[
11041357.001
]
[Cites]
Pigment Cell Res. 2000;13 Suppl 8:110-7
[
11041367.001
]
[Cites]
Nat Genet. 2001 Jan;27(1):40-7
[
11137996.001
]
[Cites]
Exp Cell Res. 2001 Jan 15;262(2):197-208
[
11139343.001
]
[Cites]
Am J Hum Genet. 2001 Apr;68(4):884-94
[
11254446.001
]
[Cites]
J Invest Dermatol. 2001 Aug;117(2):294-300
[
11511307.001
]
[Cites]
Ann Hum Genet. 2006 Nov;70(Pt 6):802-11
[
17044855.001
]
[Cites]
Int J Epidemiol. 2006 Dec;35(6):1514-21
[
16943234.001
]
[Cites]
Hum Mutat. 2007 Jul;28(7):710-7
[
17358008.001
]
[Cites]
Nat Genet. 2007 Jul;39(7):870-4
[
17529973.001
]
[Cites]
Am J Hum Genet. 2007 Nov;81(5):1084-97
[
17924348.001
]
[Cites]
Pigment Cell Res. 2001 Oct;14(5):337-47
[
11601655.001
]
[Cites]
Gene. 2001 Oct 17;277(1-2):49-62
[
11602344.001
]
[Cites]
Melanoma Res. 2002 Oct;12(5):513-9
[
12394194.001
]
[Cites]
Mol Biol Cell. 2002 Dec;13(12):4206-20
[
12475946.001
]
[Cites]
Ann N Y Acad Sci. 2003 Jun;994:133-40
[
12851308.001
]
[Cites]
Cancer Detect Prev. 2003;27(4):311-5
[
12893080.001
]
[Cites]
Annu Rev Genet. 2003;37:67-90
[
14616056.001
]
[Cites]
Pflugers Arch. 2004 Feb;447(5):683-8
[
14770312.001
]
[Cites]
Exp Cell Res. 2004 Aug 15;298(2):521-34
[
15265699.001
]
[Cites]
Am J Hum Genet. 2004 Nov;75(5):739-51
[
15372380.001
]
[Cites]
Am J Phys Anthropol. 1981 Jun;55(2):203-8
[
7258341.001
]
[Cites]
Am J Epidemiol. 1986 May;123(5):894-900
[
3962971.001
]
[Cites]
Hum Mol Genet. 2001 Oct 1;10(21):2397-402
[
11689486.001
]
[Cites]
Am J Hum Genet. 2002 Mar;70(3):770-5
[
11833005.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):782-4
[
12163334.001
]
(PMID = 19384953.001).
[ISSN]
1097-0215
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R03 CA132175-02; United States / NCI NIH HHS / CA / R03 CA132175; United States / NCI NIH HHS / CA / R03 CA128080-02; United States / NCI NIH HHS / CA / CA128080; United States / NCI NIH HHS / CA / CA132175; United States / NCI NIH HHS / CA / CA128080-02; United States / NCI NIH HHS / CA / CA132175-02; United States / NCI NIH HHS / CA / R03 CA128080
[Publication-type]
Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / ASIP protein, human; 0 / ATRN protein, human; 0 / Agouti Signaling Protein; 0 / Antiporters; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / Membrane Transport Proteins; 0 / Neoplasm Proteins; 0 / OCA2 protein, human; 0 / SLC24A5 protein, human; 0 / SLC44A2 protein, human; EC 1.- / Oxidoreductases; EC 1.14.18.- / TYRP1 protein, human; EC 3.4.- / Proprotein Convertases
[Other-IDs]
NLM/ NIHMS92488; NLM/ PMC2700213
11.
Kritz-Silverstein D, Schneider DL, Sandwell J:
Breast cancer and bone mass in older women: is bone density prescreening for mammography useful?
Osteoporos Int
; 2006;17(8):1196-201
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Breast cancer
and bone mass in older women: is bone density prescreening for mammography useful?
This
case
-control study compares BMD at multiple sites in women with and without
breast cancer
to determine if BMD prescreening is useful in selecting women for continued screening mammograms.
METHODS: Women diagnosed with
breast cancer
in the preceding 4 months and age-matched controls (+/-2 years) with a normal mammogram, all aged 65 years and older, were recruited on a 1:2 basis; 237 women participated: 79 women (
cases
) with
breast cancer
and 158 controls.
RESULTS: Among women with
breast cancer
, 17.1% had stage 0, 41.5% stage I, 40.0% stage II, and 1.4% stage III.
Women with
breast cancer
had larger waist circumferences (p=0.002) and waist-hip ratios (p=0.01), and they exercised less (p=0.002) than women of the control group.
However, there were no differences between
the cases
and controls for age, obesity, and reproductive and menopausal history variables, or other covariates (p>0.10).
There were no differences in lumbar spine, total hip, femoral neck, midshaft radius, or total body BMD (p>0.10), although
the cases
had higher BMD at the ultradistal radius than the controls (means: 0.527 vs. 0.516, respectively; p=0.014).
There were no differences in
breast cancer
risk by tertile of BMD or osteoporosis status at the hip or spine.
CONCLUSION: There is little difference in BMD between women with and without
breast cancer
.
BMD is not useful as a prescreening predicator of mammography in older women and using it as such would result in
cases
of
breast cancer
being missed.
[MeSH-major]
Bone Density.
Breast
Neoplasms / etiology. Mammography
[MeSH-minor]
Aged. Aged, 80 and over.
Case
-Control Studies. Exercise. Female. Humans. Risk Factors. Vitamin D / administration & dosage
Genetic Alliance.
consumer health - Bone Cancer
.
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Bone Density
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Mammography
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Bone. 2003 Mar;32(3):211-6
[
12667548.001
]
[Cites]
Cancer Causes Control. 1994 Nov;5(6):523-8
[
7827239.001
]
[Cites]
Am J Epidemiol. 1990 Nov;132(5):877-83
[
2239902.001
]
[Cites]
Environ Health Perspect. 1997 Apr;105 Suppl 3:583-5
[
9167999.001
]
[Cites]
JAMA. 1999 Dec 8;282(22):2156-63
[
10591338.001
]
[Cites]
J Clin Endocrinol Metab. 1995 Apr;80(4):1118-23
[
7714079.001
]
[Cites]
J Natl Cancer Inst. 1998 Jun 3;90(11):814-23
[
9625169.001
]
[Cites]
Am J Epidemiol. 2001 Jun 1;153(11):1071-8
[
11390325.001
]
[Cites]
Endocr Rev. 1994 Jun;15(3):275-300
[
8076582.001
]
[Cites]
J Natl Cancer Inst. 1995 Feb 1;87(3):190-7
[
7707406.001
]
[Cites]
Ann Intern Med. 1997 Dec 1;127(11):955-65
[
9412300.001
]
[Cites]
World Health Organ Tech Rep Ser. 1994;843:1-129
[
7941614.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1996 Jul;5(7):533-9
[
8827358.001
]
[Cites]
Science. 1988 Jul 1;241(4861):84-6
[
3388021.001
]
[Cites]
JAMA. 1996 Nov 6;276(17):1404-8
[
8892715.001
]
[Cites]
J Natl Cancer Inst. 2001 Jun 20;93(12):930-6
[
11416114.001
]
[Cites]
Bone Miner. 1993 Feb;20(2):141-9
[
8453330.001
]
[Cites]
J Clin Epidemiol. 2001 Apr;54(4):417-22
[
11297892.001
]
[Cites]
Environ Health Perspect. 1997 Apr;105 Suppl 3:593-9
[
9168001.001
]
[Cites]
J Chronic Dis. 1987;40(2):105-13
[
3818863.001
]
[Cites]
J Am Acad Nurse Pract. 2001 Jun;13(6):276-84
[
11930870.001
]
[Cites]
N Engl J Med. 1997 Feb 27;336(9):611-7
[
9032046.001
]
[Cites]
Eur J Cancer. 1998 Jul;34(8):1163-74
[
9849474.001
]
[Cites]
JAMA. 1999 Jun 16;281(23):2189-97
[
10376571.001
]
(PMID = 16699738.001).
[ISSN]
0937-941X
[Journal-full-title]
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
[ISO-abbreviation]
Osteoporos Int
[Language]
eng
[Grant]
United States / NCRR NIH HHS / RR / M01 RR00827
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
England
[Chemical-registry-number]
1406-16-2 / Vitamin D
12.
Qing Y, Cen Y, Wang H, Liu Y:
[Surgical treatment of scalp malignant tumor].
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
; 2008 Jan;22(1):59-62
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Surgical treatment of scalp
malignant
tumor].
OBJECTIVE: To investigate the effects of different surgical methods in treating scalp
malignant
tumors.
METHODS: From January 1995 to September 2004, 70 patients with scalp
malignant
tumor were treated with different surgical methods.
The course of
disease
ranged from 2 weeks to 3 years (mean 3.5 months).
There were 31
cases
of basal cell carcinoma
, 24
cases
of squamous
carcinoma
, 8
cases
of melanocarcinoma, 4
cases
of fibrous sarcoma, 2
cases
of liposarcoma, and 1
case
of vasculosarcoma.
Defect was repaired withfree
skin
transplantation in 51
cases
, scalp flap in 12
cases
, cervico-shoulder flap in 2
cases
, trapizius myocutaneous flap in 3
cases
, and radial artery retro-island flap in 2
cases
.
RESULTS: Of 70
cases
, 67
skin
flaps survived and incision healed by first intention; 2 flaps necrosed at distal part (< 1 cm) and healed by second intention after dressing change; 1 flap infected and was treated with symptomatic medication.
Fifty-five patients were followed up for 1 to 5 years and 5
cases
had tumor recurrence.
In patients receiving
skin
transplantation, 1
case
of squamous
carcinoma
and 1
case
of fibrous sarcoma relapsed after 1 year and 2.5 years respectively and were given radical resection and
skin
flap grafting; in patients receiving
skin
flap grafting, 1
case
of vasculosarcoma and 1
case
of squamous
carcinoma
relapsed after 6 months and 3 months respectively, and gave up treatment; 1
case
of fibrous sarcoma relapsed after 2 years and was given radical resection and
skin
flap grafting.
The other
cases
survived and had no tumor recurrence.
CONCLUSION: Scalp
malignant
tumors should be diagnosised and treated as early as possible.
[MeSH-major]
Carcinoma
, Squamous
Cell
/ surgery. Scalp.
Skin
Neoplasms / surgery.
Skin
Transplantation / methods. Surgical Flaps
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18361240.001).
[ISSN]
1002-1892
[Journal-full-title]
Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
[ISO-abbreviation]
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
13.
Bridges MN, Doval M:
Cutaneous squamous cell carcinoma of the external auditory canal.
Dermatol Online J
; 2009;15(2):13
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cutaneous squamous
cell carcinoma
of the external auditory canal.
Cutaneous squamous
cell carcinoma
(SCC) along with
basal cell carcinoma
(
BCC
), collectively known as Nonmelanoma
skin
cancer
(NMSC), are the most common cancers in the United States.
Squamous
cell carcinoma
of the
skin
is less common than
BCC
, but is known to be more aggressive with a higher mortality rate.
Squamous
cell carcinoma
of the external auditory canal (EAC) is rare when compared to SCC on other cutaneous sites.
This is
a case
of a 76-year-old man who initially presented with actinic keratosis of the EAC that died in just over a year from metastatic cutaneous SCC.
[MeSH-major]
Carcinoma
, Squamous
Cell
/ pathology. Ear Canal.
Neoplasm
Invasiveness / pathology. Otologic Surgical Procedures / methods.
Skin
Neoplasms / pathology
[MeSH-minor]
Aged. Fatal Outcome. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male.
Neoplasm
Staging. Risk Assessment. Surgical Flaps. Time Factors. Treatment Outcome
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19336030.001).
[ISSN]
1087-2108
[Journal-full-title]
Dermatology online journal
[ISO-abbreviation]
Dermatol. Online J.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
14.
Jackson JE, Dickie GJ, Wiltshire KL, Keller J, Tripcony L, Poulsen MG, Hughes M, Allison RW, Martin JM:
Radiotherapy for perineural invasion in cutaneous head and neck carcinomas: toward a risk-adapted treatment approach.
Head Neck
; 2009 May;31(5):604-10
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Radiotherapy for perineural invasion in cutaneous head and neck
carcinomas
: toward a risk-adapted treatment approach.
BACKGROUND: We retrospectively reviewed outcomes in patients treated with radiotherapy (RT) for cutaneous head and neck
carcinoma
with perineural invasion (PNI), with the aim of developing risk-adapted treatment guidelines.
The pPNI and cPNI groups also differed in relapse-free survival (76% vs 46%, p = .003),
disease
-specific survival (90% vs 76%, p = .002), and overall survival (69% vs 57%, p = .03).
pPNI patients with
BCC
histology (n = 42) had better LC (97% vs 84%, p = .02) than pPNI SCC (n = 55).
CONCLUSION: Surgery plus RT provides a high rate of LC in patients with pPNI, particularly those with
BCC
.
[MeSH-major]
Carcinoma
,
Basal Cell
/ radiotherapy.
Carcinoma
, Squamous
Cell
/ radiotherapy. Head and Neck Neoplasms / radiotherapy. Peripheral Nerves / pathology. Peripheral Nervous System Neoplasms / radiotherapy.
Skin
Neoplasms / radiotherapy
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged.
Neoplasm
Invasiveness.
Neoplasm
Recurrence, Local. Radiotherapy, Adjuvant. Retrospective Studies. Risk Assessment
MedlinePlus Health Information.
consumer health - Head and Neck Cancer
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Head Neck. 2009 Nov;31(11):1531; author reply 1532-3
[
19787793.001
]
(PMID = 19132719.001).
[ISSN]
1097-0347
[Journal-full-title]
Head & neck
[ISO-abbreviation]
Head Neck
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
15.
de Villiers EM, Sandstrom RE, zur Hausen H, Buck CE:
Presence of papillomavirus sequences in condylomatous lesions of the mamillae and in invasive carcinoma of the breast.
Breast Cancer Res
; 2005;7(1):R1-11
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Presence of papillomavirus sequences in condylomatous lesions of the mamillae and in invasive
carcinoma of
the breast
.
BACKGROUND: Viruses including Epstein-Barr virus (EBV), a human equivalent of murine mammary tumour virus (MMTV) and human papillomavirus (HPV) have been implicated in the aetiology of human
breast cancer
.
We report the presence of HPV DNA sequences in areolar tissue and tumour tissue samples from female patients with
breast
carcinoma
.
The presence of virus in the areolar-nipple
complex
suggests to us a potential pathogenic mechanism.
METHODS: Polymerase chain reaction (PCR) was undertaken to amplify HPV types in areolar and tumour tissue from
breast cancer cases
.
RESULTS: Papillomavirus DNA was present in 25 of 29 samples of
breast
carcinoma
and in 20 of 29 samples from the corresponding mamilla.
The most prevalent type in both
carcinomas
and nipples was HPV 11, followed by HPV 6.
Other types detected were HPV 16, 23, 27 and 57 (nipples and
carcinomas
), HPV 20, 21, 32, 37, 38, 66 and GA3-1 (nipples only) and HPV 3, 15, 24, 87 and DL473 (
carcinomas
only).
Multiple types were demonstrated in seven
carcinomas
and ten nipple samples.
CONCLUSIONS: The data demonstrate the occurrence of HPV in nipple and areolar tissues in patients with
breast
carcinoma
.
[MeSH-major]
Breast
Neoplasms / virology.
Carcinoma
/ virology. Nipples / virology. Papillomaviridae / genetics. Papillomaviridae / pathogenicity
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Pathol Res Pract. 1992 Apr;188(3):384-6
[
1320761.001
]
[Cites]
J Natl Cancer Inst. 2001 Jun 6;93(11):824-42
[
11390532.001
]
[Cites]
Cancer Res. 1992 Nov 1;52(21):5872-8
[
1327518.001
]
[Cites]
EMBO J. 1993 May;12(5):1847-52
[
8387914.001
]
[Cites]
J Gen Virol. 1994 May;75 ( Pt 5):1157-62
[
8176376.001
]
[Cites]
Curr Top Microbiol Immunol. 1994;186:1-12
[
8205835.001
]
[Cites]
J Dermatol. 1994 Oct;21(10):709-15
[
7798425.001
]
[Cites]
Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7829-33
[
7644500.001
]
[Cites]
Virology. 1996 Jun 1;220(1):1-9
[
8659100.001
]
[Cites]
Breast Cancer Res Treat. 1996;39(2):197-202
[
8872328.001
]
[Cites]
Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78
[
8876633.001
]
[Cites]
Breast Cancer Res Treat. 1996;41(1):51-7
[
8932876.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1996 Dec;5(12):961-5
[
8959317.001
]
[Cites]
J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62
[
9049358.001
]
[Cites]
Int J Cancer. 1997 Nov 4;73(3):356-61
[
9359482.001
]
[Cites]
Mol Cell Biol. 1998 Apr;18(4):1793-801
[
9528751.001
]
[Cites]
J Virol. 2001 Dec;75(23):11791-802
[
11689660.001
]
[Cites]
Nat Rev Cancer. 2002 May;2(5):342-50
[
12044010.001
]
[Cites]
J Hum Virol. 2001 Nov-Dec;4(6):329-34
[
12082399.001
]
[Cites]
Int J Cancer. 2002 Jul 10;100(2):214-9
[
12115572.001
]
[Cites]
J Virol. 2002 Oct;76(20):10559-68
[
12239337.001
]
[Cites]
Lancet. 2002 Oct 5;360(9339):1044-9
[
12383984.001
]
[Cites]
Int J Cancer. 2002 Nov 20;102(3):304-7
[
12397656.001
]
[Cites]
Br J Cancer. 2002 Nov 18;87(11):1234-45
[
12439712.001
]
[Cites]
Cancer. 2002 Dec 15;95(12):2571-6
[
12467072.001
]
[Cites]
J Natl Cancer Inst. 2002 Dec 18;94(24):1832-6
[
12488476.001
]
[Cites]
J Virol. 2003 Jan;77(2):1551-63
[
12502868.001
]
[Cites]
J Med Virol. 2004 Mar;72(3):473-7
[
14748072.001
]
[Cites]
Int J Cancer. 2004 Mar 20;109(2):253-8
[
14750177.001
]
[Cites]
Breast Cancer Res Treat. 2004 Mar;84(2):131-7
[
14999143.001
]
[Cites]
Int J Cancer. 1982 Feb 15;29(2):143-6
[
6277807.001
]
[Cites]
Int J Cancer. 1985 Nov 15;36(5):575-8
[
2997044.001
]
[Cites]
J Virol. 1986 Jan;57(1):353-6
[
3001357.001
]
[Cites]
J Virol. 1986 Jun;58(3):963-6
[
3009899.001
]
[Cites]
Cancer. 1987 Oct 15;60(8):1832-5
[
2820563.001
]
[Cites]
Virology. 1988 Jul;165(1):225-33
[
2838960.001
]
[Cites]
Virology. 1989 Nov;173(1):284-90
[
2554574.001
]
[Cites]
Proc Natl Acad Sci U S A. 1990 Jan;87(1):463-7
[
2153303.001
]
[Cites]
Br J Dermatol. 1990 Jun;122(6):757-62
[
2164414.001
]
[Cites]
Am J Clin Pathol. 1991 Feb;95(2):117-24
[
1846996.001
]
[Cites]
Virology. 1991 Nov;185(1):484-7
[
1656601.001
]
[Cites]
Br J Cancer. 1992 Jun;65(6):891-4
[
1319728.001
]
[Cites]
J Invest Dermatol. 1998 May;110(5):752-5
[
9579540.001
]
[Cites]
Laryngoscope. 1998 May;108(5):735-40
[
9591556.001
]
[Cites]
Biomed Pharmacother. 1998;52(1):26-33
[
9755792.001
]
[Cites]
Int J Cancer. 1999 Mar 1;80(5):681-4
[
10048966.001
]
[Cites]
Int J Cancer. 1999 Apr 12;81(2):225-8
[
10188723.001
]
[Cites]
Breast Cancer Res Treat. 1999 Jan;53(2):121-35
[
10326789.001
]
[Cites]
Oncogene. 1999 Apr 1;18(13):2201-11
[
10327066.001
]
[Cites]
J Gen Virol. 1999 Jun;80 ( Pt 6):1513-7
[
10374970.001
]
[Cites]
J Virol. 1999 Sep;73(9):7297-307
[
10438818.001
]
[Cites]
J Natl Cancer Inst. 1999 Aug 18;91(16):1349-50
[
10451431.001
]
[Cites]
J Gen Virol. 1999 Sep;80 ( Pt 9):2437-43
[
10501499.001
]
[Cites]
J Exp Clin Cancer Res. 1999 Sep;18(3):369-77
[
10606184.001
]
[Cites]
Semin Cancer Biol. 1999 Dec;9(6):413-22
[
10712888.001
]
[Cites]
J Biol Chem. 2000 May 19;275(20):14824-30
[
10809724.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2000 Jul;9(7):697-703
[
10919740.001
]
[Cites]
Breast Cancer. 2000 Jan;7(1):33-6
[
11029768.001
]
[Cites]
J Virol. 2000 Dec;74(24):11636-41
[
11090162.001
]
[Cites]
J Virol. 2001 Jan;75(1):151-60
[
11119584.001
]
[Cites]
Arch Virol. 2001;146(1):171-80
[
11266212.001
]
[Cites]
Anticancer Res. 2001 Jan-Feb;21(1B):797-801
[
11299846.001
]
[Cites]
Breast Cancer Res Treat. 1992;21(2):95-100
[
1320958.001
]
(PMID = 15642157.001).
[ISSN]
1465-542X
[Journal-full-title]
Breast cancer research : BCR
[ISO-abbreviation]
Breast Cancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / DNA, Viral
[Other-IDs]
NLM/ PMC1064094
16.
Beatty JD, Atwood M, Tickman R, Reiner M:
Metaplastic breast cancer: clinical significance.
Am J Surg
; 2006 May;191(5):657-64
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Metaplastic
breast cancer
: clinical significance.
BACKGROUND: Metaplastic
breast
carcinoma
(MBC) is a rare poorly differentiated
breast cancer
characterized by coexistence of ductal
carcinoma
with areas of matrix producing, spindle-
cell
, sarcomatous, or squamous differentiation; ER/PR/HER2 negativity; and a reputation for poor outcome.
METHODS: The Swedish
Cancer
Institute prospective
breast cancer
database (> 6500 patients; 1990-2005) has 24 MBC
cases
that were compared with typical
breast cancer cases
matched for age, date
of diagnosis
, stage, and ER/PR/HER2 status.
The histological/nuclear grade was high in 21 of 24
cases
.
ER and/or PR receptor status was negative in all
cases
.
HER2 was negative in 10 of 11
cases
tested.
EGFR (HER1) was positive in 7 of 7
cases
tested.
Four patients had distant recurrences 5 to 88 months from
diagnosis
.
Comparison with matched typical
breast cancer cases
revealed no major significant difference in multidisciplinary treatment patterns, recurrence, or survival.
CONCLUSION: MBC is associated with poor prognostic indicators, but outcomes comparable with matched typical
breast cancer cases
can be achieved with routine aggressive multidisciplinary care.
[MeSH-major]
Breast
Neoplasms / pathology
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Middle Aged.
Neoplasm
Metastasis. Prospective Studies. Risk Factors. Survival Rate. Sweden / epidemiology
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16647355.001).
[ISSN]
0002-9610
[Journal-full-title]
American journal of surgery
[ISO-abbreviation]
Am. J. Surg.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
17.
Jani P, Chetty R, Ghazarian DM:
An unusual composite pilomatrix carcinoma with intralesional melanocytes: differential diagnosis, immunohistochemical evaluation, and review of the literature.
Am J Dermatopathol
; 2008 Apr;30(2):174-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
An unusual composite pilomatrix
carcinoma
with intralesional melanocytes: differential
diagnosis
, immunohistochemical evaluation, and review of the literature.
We report
a case
of an extremely rare histologic combination of pilomatrix or pilomatrical
carcinoma
with admixed melanocytes within the same tumor mass.
Pilomatrix
carcinoma
is
a neoplasm
of low-grade malignancy that is characterized by a tendency for recurrence but low risk of metastasis.
In addition, intermingled with the pilomatrix
carcinoma
, several easily identified pigmented cells with dendritic processes were present singly and as small aggregates.
Pilomatrix
carcinoma
with melanocytes should be distinguished from the conventional pilomatrixoma with pigmentation, melanocytic matricoma, melanoma, and pigmented
basal cell carcinoma
with matrical differentiation.
Clinicians and pathologists should be aware of the occurrence of pilomatrix
carcinoma
with melanocytes because of its potential for
diagnosis
as melanoma.
It is possible that sun damage played a role in stimulating migration of melanocytes among matrical cells in this
case
.
[MeSH-major]
Carcinoma
,
Skin
Appendage / pathology. Hair Diseases / pathology. Melanocytes / pathology. Pilomatrixoma / pathology.
Skin
Neoplasms / pathology
[MeSH-minor]
Aged. Biopsy, Needle.
Diagnosis
, Differential. Follow-Up Studies. Humans. Immunohistochemistry. Male.
Neoplasm
Staging. Nose. Risk Assessment. Treatment Outcome
MedlinePlus Health Information.
consumer health - Hair Problems
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18360125.001).
[ISSN]
1533-0311
[Journal-full-title]
The American Journal of dermatopathology
[ISO-abbreviation]
Am J Dermatopathol
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
United States
[Number-of-references]
30
18.
Suomela S, Elomaa O, Skoog T, Ala-aho R, Jeskanen L, Pärssinen J, Latonen L, Grénman R, Kere J, Kähäri VM, Saarialho-Kere U:
CCHCR1 is up-regulated in skin cancer and associated with EGFR expression.
PLoS One
; 2009;4(6):e6030
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
CCHCR1 is up-regulated in
skin
cancer
and associated with EGFR expression.
Despite chronic inflammation, psoriatic lesions hardly ever progress to
skin
cancer
.
As CCHCR1 is expressed in certain cancers and regulates keratinocyte (KC) proliferation in a transgenic mouse model, we studied its relation to proliferation in cutaneous squamous
cell
cancer
(SCC)
cell
lines by expression arrays and quantitative RT-PCR and in
skin
tumors by immunohistochemistry.
CCHCR1 protein was detected in the pushing border of SCC and lining
basal cell carcinoma
islands.
The most aggressive and invasive tumor
cell
lines (RT3, FaDu) expressed CCHCR1 mRNA less than non-tumorigenic HaCaT cells.
[MeSH-major]
Gene Expression Regulation, Neoplastic. Intracellular Signaling Peptides and Proteins / genetics. Intracellular Signaling Peptides and Proteins / physiology. Psoriasis / metabolism. Receptor, Epidermal Growth Factor / biosynthesis.
Skin
Neoplasms / metabolism. Up-Regulation
[MeSH-minor]
Cell
Line, Tumor.
Cell
Proliferation. Humans. Immunohistochemistry / methods. Inflammation. Ki-67 Antigen / biosynthesis. Lymphocytes / metabolism. Models, Biological. Reverse Transcriptase Polymerase Chain Reaction
MedlinePlus Health Information.
consumer health - Psoriasis
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Oncogene. 2007 Aug 9;26(36):5267-79
[
17334397.001
]
[Cites]
J Mol Med (Berl). 2007 Jun;85(6):589-601
[
17221218.001
]
[Cites]
Am J Pathol. 2008 Jul;173(1):14-24
[
18556782.001
]
[Cites]
J Invest Dermatol. 2009 Jan;129(1):119-30
[
18633436.001
]
[Cites]
Hum Exp Toxicol. 1999 Oct;18(10):634-9
[
10557016.001
]
[Cites]
Hum Mol Genet. 2000 Jun 12;9(10):1533-42
[
10888604.001
]
[Cites]
J Cutan Pathol. 2001 Feb;28(2):57-64
[
11168753.001
]
[Cites]
Arch Dermatol Res. 2001 Apr;293(4):206-13
[
11380154.001
]
[Cites]
Gene. 2001 Jul 25;273(1):1-11
[
11483355.001
]
[Cites]
Hum Mol Genet. 2002 Mar 1;11(5):589-97
[
11875053.001
]
[Cites]
J Invest Dermatol. 2002 May;118(5):759-66
[
11982752.001
]
[Cites]
Arch Dermatol Res. 2002 Jul;294(5):243-5
[
12115028.001
]
[Cites]
J Biol Chem. 2002 Oct 11;277(41):38965-71
[
12181310.001
]
[Cites]
FEBS Lett. 2003 Jul 17;547(1-3):15-9
[
12860379.001
]
[Cites]
J Invest Dermatol. 2003 Dec;121(6):1360-4
[
14675183.001
]
[Cites]
Lab Invest. 2003 Dec;83(12):1887-99
[
14691307.001
]
[Cites]
Cancer Res. 2004 Jun 1;64(11):3934-9
[
15173005.001
]
[Cites]
Hum Mol Genet. 2004 Aug 1;13(15):1551-61
[
15190014.001
]
[Cites]
Arch Dermatol. 2004 Jul;140(7):805-10
[
15262690.001
]
[Cites]
FASEB J. 2004 Aug;18(11):1252-4
[
15208259.001
]
[Cites]
Acta Derm Venereol. 2004;84(4):308-9
[
15339078.001
]
[Cites]
Cell. 1980 Jan;19(1):245-54
[
6153576.001
]
[Cites]
J Cell Biol. 1988 Mar;106(3):761-71
[
2450098.001
]
[Cites]
Cell Growth Differ. 1994 Nov;5(11):1205-13
[
7848922.001
]
[Cites]
J Biol Chem. 1995 Nov 10;270(45):27136-42
[
7592968.001
]
[Cites]
Semin Cancer Biol. 1995 Aug;6(4):239-48
[
8541519.001
]
[Cites]
Biochem Biophys Res Commun. 1996 Nov 12;228(2):586-95
[
8920955.001
]
[Cites]
J Biol Chem. 1999 Jan 8;274(2):1124-30
[
9873060.001
]
[Cites]
Matrix Biol. 1998 Dec;17(8-9):547-57
[
9923649.001
]
[Cites]
Nature. 2004 Nov 18;432(7015):324-31
[
15549094.001
]
[Cites]
Br J Dermatol. 2005 Jun;152(6):1248-55
[
15948989.001
]
[Cites]
J Cell Sci. 2005 Sep 15;118(Pt 18):4253-60
[
16141233.001
]
[Cites]
Carcinogenesis. 2006 Feb;27(2):225-31
[
16123117.001
]
[Cites]
FEBS Lett. 2006 Mar 20;580(7):1859-64
[
16516204.001
]
[Cites]
Int J Biochem Cell Biol. 2006;38(7):1043-9
[
16423552.001
]
[Cites]
Br J Dermatol. 2006 Jul;155(1):213-4
[
16792781.001
]
[Cites]
Exp Dermatol. 2006 Oct;15(10):775-83
[
16984259.001
]
[Cites]
J Investig Dermatol Symp Proc. 2006 Sep;11(1):16-29
[
17069007.001
]
[Cites]
Steroids. 2007 Feb;72(2):210-7
[
17173942.001
]
[Cites]
Am J Pathol. 2007 Jun;170(6):2089-99
[
17525275.001
]
[Cites]
Hum Mol Genet. 2008 Apr 1;17(7):1043-51
[
18174193.001
]
(PMID = 19551138.001).
[ISSN]
1932-6203
[Journal-full-title]
PloS one
[ISO-abbreviation]
PLoS ONE
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / CCHCR1 protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Ki-67 Antigen; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
[Other-IDs]
NLM/ PMC2696036
19.
Syeed N, Husain SA, Abdullah S, Sameer AS, Chowdri NA, Nanda MS, Siddiqi MA:
Mutational profile of the CAV-1 gene in breast cancer cases in the ethnic Kashmiri population.
Asian Pac J Cancer Prev
; 2010;11(4):1099-105
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Mutational profile of the CAV-1 gene in
breast cancer cases
in the ethnic Kashmiri population.
The role of caveolae and the caveolin proteins in
cancer
has been the subject of extensive research.
It has been suggested that Caveolin-1 may contribute to certain steps of carcinogenesis in various types of
cancer
.
Therefore in our study we focused on the potential clinical relevance of Caveolin-1 in 130
malignant breast
tissue specimens along with their adjacent normal tissues.
Caveolin-1 was identified in a screen for genes involved in
breast cancer
progression and we demonstrated 29.2% mutational status in our Kashmiri ethnic population.
[MeSH-major]
Breast
Neoplasms / genetics.
Breast
Neoplasms, Male / genetics. Caveolin 1 / genetics
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Male Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21133631.001).
[ISSN]
2476-762X
[Journal-full-title]
Asian Pacific journal of cancer prevention : APJCP
[ISO-abbreviation]
Asian Pac. J. Cancer Prev.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Thailand
[Chemical-registry-number]
0 / Caveolin 1; 0 / Codon, Nonsense
20.
Zemelman V, Silva P, Sazunic I:
Basal cell carcinoma: analysis of regression after incomplete excision.
Clin Exp Dermatol
; 2009 Oct;34(7):e425
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Basal cell carcinoma
: analysis of regression after incomplete excision.
[MeSH-major]
Carcinoma
,
Basal Cell
/ surgery.
Skin
Neoplasms / surgery
[MeSH-minor]
Female. Humans. Male.
Neoplasm
Regression, Spontaneous.
Neoplasm
, Residual. Reoperation
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19686288.001).
[ISSN]
1365-2230
[Journal-full-title]
Clinical and experimental dermatology
[ISO-abbreviation]
Clin. Exp. Dermatol.
[Language]
eng
[Publication-type]
Letter
[Publication-country]
England
21.
Kunte C, Konz B:
[Current recommendations in the treatment of basal cell carcinoma and squamous cell carcinoma of the skin].
Hautarzt
; 2007 May;58(5):419-26
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Current recommendations in the treatment
of basal cell carcinoma
and squamous
cell carcinoma
of the
skin
].
[Transliterated title]
Aktuelle Therapieempfehlungen für das
Basalzellkarzinom
und Plattenepithelkarzinom der Haut.
The incidence of the most common tumors of the
skin
,
basal cell carcinoma
and squamous
cell carcinoma
, has risen rapidly in recent years.
[MeSH-major]
Carcinoma
,
Basal Cell
/ surgery.
Carcinoma
, Squamous
Cell
/ surgery. Facial Neoplasms / surgery.
Skin
Neoplasms / surgery
[MeSH-minor]
Combined Modality Therapy. Humans.
Neoplasm
Invasiveness.
Neoplasm
, Residual / pathology.
Neoplasm
, Residual / radiotherapy.
Neoplasm
, Residual / surgery. Prognosis. Radiotherapy, Adjuvant.
Skin
/ pathology. Surgical Flaps
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Strahlenther Onkol. 2001 May;177(5):240-6
[
11398609.001
]
[Cites]
Facial Plast Surg. 1997 Apr;13(2):79-82
[
9243982.001
]
[Cites]
Hautarzt. 2005 May;56(5):430-40
[
15815888.001
]
[Cites]
J Am Acad Dermatol. 2004 May;50(5):722-33
[
15097956.001
]
[Cites]
J Dermatol Surg Oncol. 1994 May;20(5):350
[
8176049.001
]
[Cites]
Recent Results Cancer Res. 2002;160:219-24
[
12079216.001
]
[Cites]
Cancer. 1997 Mar 1;79(5):915-9
[
9041153.001
]
[Cites]
BMJ. 2004 Sep 25;329(7468):705
[
15364703.001
]
[Cites]
Dermatol Surg. 2000 Aug;26(8):759-64
[
10940063.001
]
[Cites]
Br J Dermatol. 2000 Apr;142(4):752-7
[
10792227.001
]
[Cites]
Int J Cancer. 1999 May 17;81(4):555-9
[
10225444.001
]
[Cites]
Acta Derm Venereol. 2004;84(3):218-22
[
15202839.001
]
[Cites]
J Am Acad Dermatol. 2007 Jan;56(1):91-5
[
17190625.001
]
[Cites]
Br J Dermatol. 2006 Jun;154(6):1202-3
[
16704658.001
]
[Cites]
Lancet. 1988 Apr 9;1(8589):795-7
[
2895318.001
]
[Cites]
Dermatol Surg. 2006 Nov;32(11):1309-21
[
17083582.001
]
[Cites]
J Eur Acad Dermatol Venereol. 2006 Sep;20(8):926-30
[
16922939.001
]
[Cites]
J Dtsch Dermatol Ges. 2006 Mar;4(3):260-2
[
16626324.001
]
[Cites]
J Dermatol Surg Oncol. 1991 Jul;17(7):574-8
[
1860987.001
]
[Cites]
Br J Cancer. 1997;76(1):100-6
[
9218740.001
]
[Cites]
Arch Dermatol. 2004 Oct;140(10 ):1286-7
[
15492202.001
]
[Cites]
Hautarzt. 1975 Dec;26(12):647-50
[
1213885.001
]
[Cites]
Dermatol Surg. 2004 Apr;30(4 Pt 2):642-50
[
15061849.001
]
[Cites]
J Dtsch Dermatol Ges. 2006 May;4(5):441-3
[
16686614.001
]
[Cites]
Hautarzt. 1995 Sep;46(9):607-14
[
7591764.001
]
[Cites]
J Am Acad Dermatol. 2007 Jan;56(1):125-43
[
17190630.001
]
[Cites]
J Am Acad Dermatol. 2003 Sep;49(3):483-6
[
12963913.001
]
[Cites]
Eur J Dermatol. 2002 Nov-Dec;12 (6):569-72
[
12459530.001
]
[Cites]
Br J Dermatol. 2002 Dec;147(6):1227-36
[
12452875.001
]
[Cites]
Recent Results Cancer Res. 2002;160:240-5
[
12079219.001
]
(PMID = 17443305.001).
[ISSN]
0017-8470
[Journal-full-title]
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
[ISO-abbreviation]
Hautarzt
[Language]
ger
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Germany
[Number-of-references]
31
22.
Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R:
Cutaneous squamous carcinoma in situ (Bowen's disease): treatment with Mohs micrographic surgery.
J Am Acad Dermatol
; 2005 Jun;52(6):997-1002
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cutaneous squamous
carcinoma
in situ (Bowen's
disease
): treatment with Mohs micrographic surgery.
BACKGROUND: Bowen's
disease
(BD), also known as squamous intraepidermal
carcinoma
, is
a malignant
skin
tumor with a potential to progress to invasive
carcinoma
.
METHODS: This prospective, multicenter,
case
series included all patients in Australia treated with MMS for BD, who were monitored by the
Skin
and
Cancer
Foundation between 1993 and 2002.
RESULTS: There were 270
cases
; the majority (93.4%) were located in the head and neck area.
In 50.7% of
cases
it was a recurrent tumor.
In 20% the tumor was initially misdiagnosed as
basal cell carcinoma
or squamous
cell carcinoma
.
No
cases
with perineural invasion were diagnosed.
There were 6
cases
of recurrence (6.3%) of 95 patients who completed a 5-year follow-up period after MMS.
[MeSH-major]
Bowen's
Disease
/ surgery. Mohs Surgery.
Skin
Neoplasms / surgery
Genetic Alliance.
consumer health - Bowen's Disease
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15928618.001).
[ISSN]
1097-6787
[Journal-full-title]
Journal of the American Academy of Dermatology
[ISO-abbreviation]
J. Am. Acad. Dermatol.
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article; Multicenter Study
[Publication-country]
United States
23.
McKeon S, McClean S, Callaghan M:
Macrophage responses to CF pathogens: JNK MAP kinase signaling by Burkholderia cepacia complex lipopolysaccharide.
FEMS Immunol Med Microbiol
; 2010 Oct;60(1):36-43
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Macrophage responses to CF pathogens: JNK MAP kinase signaling by Burkholderia
cepacia complex
lipopolysaccharide.
Burkholderia
cepacia complex
(
Bcc
) organisms pose a particular challenge in CF lung
disease
, due in part to their ability to trigger a fulminant pneumonia.
This study compares the U937 macrophage response to two
Bcc
species, B. cenocepacia and Burkholderia multivorans, against Pseudomonas aeruginosa and Staphylococcus aureus.
The two
Bcc
strains demonstrated higher levels of U937 macrophage internalization compared with both P. aeruginosa and S. aureus.
Both
the Bcc
strains also stimulated significantly greater levels of tumor necrosis factor-α and interleukin-1β from macrophages when compared with P. aeruginosa.
Further examination of the macrophage response to B. multivorans demonstrated that the lipopolysaccharide component of these bacteria was a potent inducer of proinflammatory cytokines and was shown to signal predominantly through
the c
-Jun N-terminal kinase mitogen-activated protein kinase pathway.
These studies further characterize the host response to
Bcc
and in particular B. multivorans, now the predominant
Bcc
species in many CF populations.
[MeSH-major]
Burkholderia
cepacia complex
/ immunology. Cytokines / secretion. JNK Mitogen-Activated Protein Kinases / metabolism. Lipopolysaccharides / immunology. Macrophages / immunology. Signal Transduction
[MeSH-minor]
Cell
Line. Cytoplasm / microbiology. Humans. Pseudomonas aeruginosa / immunology. Staphylococcus aureus / immunology
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
© 2010 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved.
(PMID = 20602636.001).
[ISSN]
1574-695X
[Journal-full-title]
FEMS immunology and medical microbiology
[ISO-abbreviation]
FEMS Immunol. Med. Microbiol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Cytokines; 0 / Lipopolysaccharides; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
24.
Love RR, Uy GB:
Surgical oophorectomy for breast cancer: back to the future.
Future Oncol
; 2008 Dec;4(6):785-92
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Surgical oophorectomy for
breast cancer
: back to the future.
While the preponderance of current scientific presentations on
breast cancer
therapies has focused on chemotherapeutic strategies, targeted therapy with tyrosine kinase inhibitors and hormonal therapies for postmenopausal women, the majority of worldwide
cases
of
breast cancer
occur in premenopausal women, for whom practical inexpensive hormonal therapy, surgical oophorectomy, is the most common attainable treatment.
In hormone-receptor-positive
breast cancer
, meta-analysis data from older trials, and more specific recent trial data have made clearer the chronic natural history of this broad subtype of
disease
and the central role of hormonal therapy in its control.
Greater understanding of the critical variables in pathology procedures for
breast
tumor tissue hormonal receptor testing is leading to better definitions of the specific patients for whom hormonal therapies are indicated.
Closer examination of outcomes following surgical oophorectomy has suggested that more than just downregulation of estrogen stimulated
breast cancer
growth; the reduction of systemic estrogen levels also occurs with this procedure.
This combination of circumstances suggests that this first hormonal therapy for
breast cancer
may once again, have a much greater role globally.
[MeSH-major]
Breast
Neoplasms / surgery. Ovariectomy
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
TAMOXIFEN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19086845.001).
[ISSN]
1744-8301
[Journal-full-title]
Future oncology (London, England)
[ISO-abbreviation]
Future Oncol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Estrogen Antagonists; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen
[Number-of-references]
44
25.
Chia KS:
Gene-environment interactions in breast cancer.
Novartis Found Symp
; 2008;293:143-50; discussion 150-5, 181-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Gene-environment interactions in
breast cancer
.
Breast cancer
is one of the most frequently diagnosed cancers in women.
It accounts for 23% of all cancers, with an estimated 1.15 million new
cases
in 2002.
Breast
cancers also tend to cluster in families and are more common in monozygotic twins.
Some of this clustering occurs as part of specific familial
breast cancer
syndromes where
disease
results from single alleles conferring a high risk.
However, such alleles are rare in the population, and highly penetrant variants of BRCA1 and BRCA2 account for less than 20% of the genetic risk of
breast cancer
.
The more common sporadic form of
breast cancer
are probably due to a polygenic inheritance of
breast cancer
susceptibility upon which environmental factors act upon resulting in
breast cancer
occurrence.
The lack of large prospective cohorts with thousands of incident
breast cancer cases
makes the study of gene-environment interactions using a nested
case
-control design extremely difficult.
[MeSH-major]
Breast
Neoplasms / etiology. Environment. Genes / physiology
[MeSH-minor]
Female. Genetic Predisposition to
Disease
. Humans. Risk Factors
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Genes and Gene Therapy
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18972750.001).
[ISSN]
1528-2511
[Journal-full-title]
Novartis Foundation symposium
[ISO-abbreviation]
Novartis Found. Symp.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Number-of-references]
32
26.
Zhang HT, Lu YF, Zeng J, Lin J, Liao QH, Wan FQ:
[Study of BRCA1 and BRCA2 gene mutations in human sporadic breast cancers].
Zhonghua Wai Ke Za Zhi
; 2007 Apr 1;45(7):480-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Study of BRCA1 and BRCA2 gene mutations in human sporadic
breast
cancers].
OBJECTIVE: To detect the mutations of BRCA1 and BRCA2 in sporadic
breast cancer
and study the relationship between BRCA1 and BRCA2 mutations and
breast cancer
.
METHODS:
Breast cancer
tissues of 144 patients and
breast
tissues of 30
cases
of healthy people who were treated from December 2000 to September 2005 were studied.
RESULTS: A total of 20 single nucleotide changes in BRCA1 were detected in the 144
cases
of
breast cancer
patients.
CONCLUSIONS: Mutations in BRCA1 may play an important role in evaluation of sick risk, earlier
diagnosis
and gene therapy of
breast cancer
in southern Chinese populations.
[MeSH-major]
BRCA1 Protein / genetics. BRCA2 Protein / genetics.
Breast
Neoplasms / genetics. Mutation
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17686308.001).
[ISSN]
0529-5815
[Journal-full-title]
Zhonghua wai ke za zhi [Chinese journal of surgery]
[ISO-abbreviation]
Zhonghua Wai Ke Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Chemical-registry-number]
0 / Apoptosis Regulatory Proteins; 0 / BLID protein, human; 0 / BRCA1 Protein; 0 / BRCA1 protein, human; 0 / BRCA2 Protein; 0 / BRCA2 protein, human
27.
Skeie G, Hjartåker A, Lund E:
Diet among breast cancer survivors and healthy women. The Norwegian Women and Cancer Study.
Eur J Clin Nutr
; 2006 Sep;60(9):1046-54
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Diet among
breast cancer
survivors and healthy women. The Norwegian Women and
Cancer
Study.
OBJECTIVE: To compare the diet and lifestyle in
breast cancer
survivors and healthy women.
DESIGN: Cross-sectional study in the population-based Norwegian Women and
Cancer
cohort study, using a postal questionnaire on diet, lifestyle and health.
Prevalent
breast cancer cases
(314 short-term with 1-5 years since
diagnosis
, 352 long-term with >5 years since
diagnosis
) were identified by linkage to the Norwegian
Cancer
Registry.
Short-term
breast cancer
survivors also had a higher use of dietary supplements and a lower level of physical activity, but did not differ from healthy women on other lifestyle factors.
CONCLUSION: Diet and lifestyle is generally similar between
breast cancer
survivors and healthy women, especially more than 5 years after
diagnosis
.
[MeSH-major]
Breast
Neoplasms / psychology. Diet Surveys. Food Habits / psychology. Health Status. Life Style
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Published online 15 February 2006.
(PMID = 16482067.001).
[ISSN]
0954-3007
[Journal-full-title]
European journal of clinical nutrition
[ISO-abbreviation]
Eur J Clin Nutr
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
England
28.
Krieger N, Chen JT, Waterman PD, Rehkopf DH, Yin R, Coull BA:
Race/ethnicity and changing US socioeconomic gradients in breast cancer incidence: California and Massachusetts, 1978-2002 (United States).
Cancer Causes Control
; 2006 Mar;17(2):217-26
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Race/ethnicity and changing US socioeconomic gradients in
breast cancer
incidence: California and Massachusetts, 1978-2002 (United States).
OBJECTIVE: We tested the hypothesis that the US socioeconomic gradient in
breast cancer
incidence is declining, with the decline most pronounced among racial/ethnic groups with the highest incidence rates.
METHODS: We geocoded the invasive incident
breast cancer cases
for three US population-based
cancer
registries covering: Los Angeles County, CA (1978-1982, 1988-1992, 1998-2002; n = 68,762
cases
), the San Francisco Bay Area, CA (1978-1982, 1988-1992, 1998-2002; n = 37,210
cases
) and Massachusetts (1988-1992, 1998-2002; n = 48,111
cases
), linked the records to census tract area-based socioeconomic measures, and, for each socioeconomic stratum, computed average annual
breast cancer
incidence rates for the 5-year period straddling the 1980, 1990, and 2000 census, overall and by race/ethnicity and gender.
RESULTS: Our findings indicate that the socioeconomic gradient in
breast cancer
incidence is: (a) relatively small (at most 1.2) and stable among US white non-Hispanic and black women;.
CONCLUSION: Our results indicate that secular changes in US socioeconomic gradients in
breast cancer
incidence exist and vary by race/ethnicity.
[MeSH-major]
Breast
Neoplasms / epidemiology
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16425100.001).
[ISSN]
0957-5243
[Journal-full-title]
Cancer causes & control : CCC
[ISO-abbreviation]
Cancer Causes Control
[Language]
eng
[Grant]
United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCI NIH HHS / CA / R01 CA095983-01
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
29.
Hadwin AM, Del Rio LF, Pinto LJ, Painter M, Routledge R, Moore MM:
Microbial communities in wetlands of the Athabasca oil sands: genetic and metabolic characterization.
FEMS Microbiol Ecol
; 2006 Jan;55(1):68-78
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Naphthenic acids are
a complex
family of naturally occurring cyclic and acyclic carboxylic acids that are present in the acidic fraction of petroleum.
In contrast, cluster diagrams produced from the denaturing gradient gel electrophoresis data clearly separated bacterial communities according to naphthenic acids
concentrations
, indicating that naphthenic acids content was a major influence on the composition of the bacterial community.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
NAPHTHENIC ACIDS
.
Hazardous Substances Data Bank.
NAPHTHENIC ACIDS, LEAD SALTS
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16420616.001).
[ISSN]
0168-6496
[Journal-full-title]
FEMS microbiology ecology
[ISO-abbreviation]
FEMS Microbiol. Ecol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Carboxylic Acids; 0 / DNA, Bacterial; 0 / Fatty Acids; 0 / Industrial Waste; 0 / Petroleum; 0 / Reagent Kits, Diagnostic; 1338-24-5 / naphthenic acid
30.
Hill TD, Khamis HJ, Tyczynski JE, Berkel HJ:
Comparison of male and female breast cancer incidence trends, tumor characteristics, and survival.
Ann Epidemiol
; 2005 Nov;15(10):773-80
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Comparison of male and female
breast cancer
incidence trends, tumor characteristics, and survival.
PURPOSE: To compare male and female
breast cancer
and to determine the predictors of tumor characteristics and survival in both genders.
METHODS: Male (n = 2923) and female
breast cancer cases
(n = 442,500) from the Surveillance, Epidemiology and End Results (SEER) registry were analyzed.
Cox proportional hazards regression modeling was used to determine significant predictors of death of
breast cancer
after adjusting for demographic factors.
RESULTS: Both men and women aged less than 50 years were at higher risk for advanced
breast
cancers.
The risk of
breast cancer
death among all
cases
was lower for each 10-year increase in age by 2%, higher for those who are unmarried than for those who are married by 12% and 13% higher for non-whites than for whites.
[MeSH-major]
Breast
Neoplasms / epidemiology.
Breast
Neoplasms / pathology.
Breast
Neoplasms, Male / epidemiology.
Breast
Neoplasms, Male / pathology. SEER Program / statistics & numerical data
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Female. Functional Laterality. Humans. Incidence. Male. Middle Aged.
Neoplasm
Staging. Prognosis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Regression Analysis. Risk Factors. Sex Factors. Survival
Genetic Alliance.
consumer health - Breast Cancer
.
Genetic Alliance.
consumer health - Breast Cancer, Male
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Male Breast Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16257362.001).
[ISSN]
1047-2797
[Journal-full-title]
Annals of epidemiology
[ISO-abbreviation]
Ann Epidemiol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Receptors, Estrogen; 0 / Receptors, Progesterone
31.
Szabo P, Dam TK, Smetana K Jr, Dvoránková B, Kübler D, Brewer CF, Gabius HJ:
Phosphorylated human lectin galectin-3: analysis of ligand binding by histochemical monitoring of normal/malignant squamous epithelia and by isothermal titration calorimetry.
Anat Histol Embryol
; 2009 Feb;38(1):68-75
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phosphorylated human lectin galectin-3: analysis of ligand binding by histochemical monitoring of normal/
malignant
squamous epithelia and by isothermal titration calorimetry.
We monitored normal and
malignant
squamous epithelia.
Basal cell
carcinomas
were invariably negative.
In all
cases
, binding was inhibitable by the presence of lactose, prompting further investigation of the activity of the lectin site by a sensitive biochemical method, i.e. isothermal titration calorimetry.
[MeSH-major]
Epithelial Cells / chemistry. Epithelium / metabolism. Galectin 3 / metabolism. Neoplasms, Squamous
Cell
/ metabolism. Phosphorylation
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18983621.001).
[ISSN]
1439-0264
[Journal-full-title]
Anatomia, histologia, embryologia
[ISO-abbreviation]
Anat Histol Embryol
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / Galectin 3
32.
Carless MA, Griffiths LR:
Cytogenetics of melanoma and nonmelanoma skin cancer.
Adv Exp Med Biol
; 2008;624:227-40
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cytogenetics of melanoma and nonmelanoma
skin
cancer
.
Cytogenetic analysis of melanoma and nonmelanoma
skin
cancers has revealed recurrent aberrations, the frequency of which is reflective of
malignant
potential.
Highly aberrant karyotypes are seen in melanoma, squamous
cell carcinoma
, solar keratosis and Merkel
cell carcinoma
with more stable karyotypes seen in
basal cell carcinoma
, keratoacanthoma, Bowen's
disease
, dermatofibrosarcoma protuberans and cutaneous lymphomas.
Some aberrations were common amongst a number
of skin
cancer
types including rearrangements and numerical abnormalities of chromosome 1, -3p, +3q, partial or entire trisomy 6, trisomy 7, +8q, -9p, +9q, partial or entire loss of chromosome 10, -17p, +17q and partial or entire gain of chromosome 20.
Combination of cytogenetic analysis with other molecular genetic techniques has enabled the identification of not only aberrant chromosomal regions, but also the genes that contribute to
a malignant
phenotype.
This review provides a comprehensive summary of the pertinent cytogenetic aberrations associated with a variety of melanoma and nonmelanoma
skin
cancers.
[MeSH-major]
Chromosome Aberrations. Cytogenetics. Melanoma / genetics.
Skin
Neoplasms / genetics
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18348460.001).
[ISSN]
0065-2598
[Journal-full-title]
Advances in experimental medicine and biology
[ISO-abbreviation]
Adv. Exp. Med. Biol.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
104
33.
Laska MJ, Nexø BA, Vistisen K, Poulsen HE, Loft S, Vogel U:
Polymorphisms in RAI and in genes of nucleotide and base excision repair are not associated with risk of testicular cancer.
Cancer Lett
; 2005 Jul 28;225(2):245-51
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Polymorphisms in RAI and in genes of nucleotide and base excision repair are not associated with risk of testicular
cancer
.
Testicular
cancer
has been suggested to be primed in utero and there is familiar occurrence, particularly brothers and sons of men with testicular
cancer
have increased risk.
Although no specific causative genotoxic agents have been identified, variations in DNA repair capacity could be associated with the risk of testicular
cancer
.
A case
-control study of 184 testicular
cancer cases
and 194 population-based controls living in the Copenhagen Greater Area in Denmark was performed.
We found that neither polymorphisms in several DNA repair genes nor alleles of several polymorphisms in the chromosomal of region 19q13.2-3, encompassing the genes ASE, ERCC1, RAI and XPD, were associated with risk of testicular
cancer
in Danish patients.
This is in contrast to other cancers, where we reported strong associations between polymorphisms in ERCC1, ASE and RAI and occurrence
of basal cell carcinoma
,
breast cancer
and lung.
To our knowledge this is the first study of DNA repair gene polymorphisms and risk of testicular
cancer
.
[MeSH-minor]
Case
-Control Studies. Denmark. Genetic Predisposition to
Disease
/ genetics. Humans. Male. Repressor Proteins
Genetic Alliance.
consumer health - Testicular cancer
.
MedlinePlus Health Information.
consumer health - Testicular Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15885892.001).
[ISSN]
0304-3835
[Journal-full-title]
Cancer letters
[ISO-abbreviation]
Cancer Lett.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Ireland
[Chemical-registry-number]
0 / Intracellular Signaling Peptides and Proteins; 0 / Nucleotides; 0 / PPP1R13L protein, human; 0 / Repressor Proteins
34.
Trzeciak S, Zanotti-Cavazzoni S, Parrillo JE, Dellinger RP:
Inclusion criteria for clinical trials in sepsis: did the American College of Chest Physicians/Society of Critical Care Medicine consensus conference definitions of sepsis have an impact?
Chest
; 2005 Jan;127(1):242-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Clinical trials published after the consensus conference (ACC; from 1993 to 2001) were compared with trials published before the consensus conference (
BCC
; from 1976 to 1992).
RESULTS: We identified 176 clinical trials (ACC, 119 trials;
BCC
, 57 trials).
The utilization of specified values for WBC count, temperature (T), heart rate (HR), and respiratory rate (RR) was significantly increased in the ACC group compared to
the BCC
group, as follows: WBC count, 62% vs 26%, respectively (p < 0.001); T, 89% vs 56%, respectively (p < 0.001); HR, 77% vs 26%, respectively (p < 0.001); and RR, respectively 76% vs 28% (p < 0.001).
(1) Since 1992 there has been a significant increase in the utilization of predefined sepsis criteria for patient enrollment in clinical trials, and this increase can be attributed to the existence of consensus conference definitions. (2) Compared to inclusion criteria
BCC
, inclusion criteria ACC were less reliant on blood culture positivity and were more likely to incorporate markers of organ dysfunction.
[MeSH-major]
Clinical Trials as Topic / standards. Consensus Development Conferences as Topic. Patient Selection. Sepsis /
diagnosis
MedlinePlus Health Information.
consumer health - Clinical Trials
.
MedlinePlus Health Information.
consumer health - Sepsis
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15653990.001).
[ISSN]
0012-3692
[Journal-full-title]
Chest
[ISO-abbreviation]
Chest
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
35.
Meunier A, Truchon JF:
Predictions of hydration free energies from continuum solvent with solute polarizable models: the SAMPL2 blind challenge.
J Comput Aided Mol Des
; 2010 Apr;24(4):361-72
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The usefulness of electronic polarization in predicting hydration free energies is assessed by comparing the Electronic Polarization from Internal Continuum model and the self consistent reaction field IEF-PCM to standard non-polarizable charge models such as RESP and AM1-
BCC
.
Hazardous Substances Data Bank.
GLUCOSE
.
Hazardous Substances Data Bank.
BENZENE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Phys Chem B. 2009 Apr 9;113(14):4501-7
[
19338360.001
]
[Cites]
J Comput Chem. 2002 Dec;23(16):1623-41
[
12395429.001
]
[Cites]
J Chem Theory Comput. 2009 Apr 14;5(4):919-30
[
26609601.001
]
[Cites]
J Phys Chem B. 2008 Jan 24;112(3):938-46
[
18171044.001
]
[Cites]
J Comput Chem. 2004 Jul 15;25(9):1157-74
[
15116359.001
]
[Cites]
Biochim Biophys Acta. 2006 Nov;1764(11):1647-76
[
17049320.001
]
[Cites]
J Chem Phys. 2007 Mar 7;126(9):094103
[
17362100.001
]
[Cites]
J Chem Theory Comput. 2009 Jul 14;5(7):1785-1802
[
24826083.001
]
[Cites]
Science. 1995 May 26;268(5214):1144-9
[
7761829.001
]
[Cites]
J Chem Phys. 2007 Mar 28;126(12):124114
[
17411115.001
]
[Cites]
J Chem Theory Comput. 2006 Jan;2(1):128-39
[
26626387.001
]
[Cites]
J Chem Inf Model. 2007 Jan-Feb;47(1):122-33
[
17238257.001
]
[Cites]
J Comput Chem. 2003 Jun;24(8):954-62
[
12720316.001
]
[Cites]
J Med Chem. 2008 Feb 28;51(4):769-79
[
18215013.001
]
[Cites]
Phys Rev A Gen Phys. 1988 Sep 15;38(6):3098-3100
[
9900728.001
]
[Cites]
J Am Chem Soc. 2009 Oct 28;131(42):15403-11
[
19778066.001
]
[Cites]
J Phys Chem B. 2009 Apr 9;113(14):4521-32
[
19281198.001
]
[Cites]
J Comput Chem. 2004 Jan 30;25(2):265-84
[
14648625.001
]
[Cites]
J Comput Chem. 2010 Mar;31(4):811-24
[
19598266.001
]
(PMID = 20354893.001).
[ISSN]
1573-4951
[Journal-full-title]
Journal of computer-aided molecular design
[ISO-abbreviation]
J. Comput. Aided Mol. Des.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Solutions; 0 / Solvents; A1TA934AKO / Xylose; IY9XDZ35W2 / Glucose; J64922108F / Benzene
36.
Cavalcante RB, Pereira KM, Nonaka CF, Nogueira RL, de Souza LB:
Immunohistochemical expression of MMPs 1, 7, and 26 in syndrome and nonsyndrome odontogenic keratocysts.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
; 2008 Jul;106(1):99-105
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Furthermore, the presence of these proteases at higher levels in SOKCs may help to explain increased OKC aggressiveness associated with nevoid
basal cell carcinoma
syndrome.
[MeSH-major]
Basal Cell
Nevus Syndrome / metabolism. Matrix Metalloproteinase 1 / biosynthesis. Matrix Metalloproteinase 7 / biosynthesis. Matrix Metalloproteinases, Secreted / biosynthesis. Odontogenic Cysts / enzymology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18585626.001).
[ISSN]
1528-395X
[Journal-full-title]
Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
[ISO-abbreviation]
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
68238-35-7 / Keratins; EC 3.4.24.- / MMP26 protein, human; EC 3.4.24.- / Matrix Metalloproteinases, Secreted; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.7 / Matrix Metalloproteinase 1
37.
Brownell I:
Nodular basal cell carcinoma: when in doubt, cut it out.
J Drugs Dermatol
; 2007 Dec;6(12):1245-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Nodular
basal cell carcinoma
: when in doubt, cut it out.
Treating superficial
basal cell
carcinomas
(
BCCs
) with photodynamic therapy or topical imiquimod can provide effective results in situations where an excisional approach is contraindicated or undesirable.
Numerous studies have sought to test these treatments for nodular
BCCs
.
[MeSH-major]
Carcinoma
,
Basal Cell
/ surgery.
Skin
Neoplasms / surgery
MedlinePlus Health Information.
consumer health - Skin Cancer
.
Hazardous Substances Data Bank.
Imiquimod
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18189068.001).
[ISSN]
1545-9616
[Journal-full-title]
Journal of drugs in dermatology : JDD
[ISO-abbreviation]
J Drugs Dermatol
[Language]
eng
[Publication-type]
News
[Publication-country]
United States
[Chemical-registry-number]
0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid; 99011-02-6 / imiquimod
38.
Vanhaecke L, Grootaert C, Verstraete W, Van de Wiele T:
Chemopreventive effects from prebiotic inulin towards microbial 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine bioactivation.
J Appl Microbiol
; 2009 Feb;106(2):474-85
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Additionally, the production of short-chain fatty acids increased with 12%, 3% and 7%, while ammonia
concentrations
decreased with 3%, 4% and 3% in the ascending, transverse and descending colon compartments, respectively.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19200315.001).
[ISSN]
1365-2672
[Journal-full-title]
Journal of applied microbiology
[ISO-abbreviation]
J. Appl. Microbiol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / 7-hydroxy-5-methyl-3-phenyl-6,7,8,9-tetrahydropyrido(3',2'-4,5)imidazo(1,2-a)pyrimidin-5-ium; 0 / Fatty Acids, Volatile; 0 / Imidazoles; 0 / Mutagens; 0 / Prebiotics; 0 / Pyrimidines; 9005-80-5 / Inulin; 909C6UN66T / 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
39.
Folman LB, Klein Gunnewiek PJ, Boddy L, de Boer W:
Impact of white-rot fungi on numbers and community composition of bacteria colonizing beech wood from forest soil.
FEMS Microbiol Ecol
; 2008 Feb;63(2):181-91
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Impact of white-rot fungi on numbers and community composition of bacteria colonizing beech wood from forest soil.
White-rot fungi are important wood-decomposing organisms in forest ecosystems.
Their ability to colonize and decompose woody resources may be strongly influenced by wood-inhabiting bacteria that grow on easily utilizable compounds e.g. oligomers of wood-polymers released by fungal enzymes.
However, so far, it is not known how white-rot fungi deal with the presence of potential competing bacteria.
Here, the effects of two white-rot fungi, Hypholoma fasciculare and Resinicium bicolor, on the numbers and composition of bacteria colonizing sterile beech wood blocks from forest soil are reported.
Both total numbers (microscopic counts) and the numbers of cultivable wood-inhabiting bacteria were considerably lower in wood blocks that became colonized by the white-rot fungi than in control blocks.
This points to the fungi out-competing the opportunistic bacteria.
The presence of white-rot fungi resulted in a change in the relative abundance of families of cultivable bacteria in wood and also in a change of denaturing gradient gel electrophoresis patterns of directly amplified 16S rRNA gene fragments.
Analysis of the bacterial community structure in soil adhering to exploratory mycelium (cords) indicated that fungal species-specific effects on bacterial community composition were also apparent in this fungal growth phase.
[MeSH-major]
Bacteria / isolation & purification. Basidiomycota. Soil Microbiology. Wood / microbiology
[MeSH-minor]
Base Sequence. Colony Count, Microbial. Fagus / microbiology. Molecular Sequence Data. Phylogeny. RNA, Bacterial / genetics. RNA, Ribosomal, 16S / genetics. Sequence Analysis, RNA
SILVA.
SILVA SSU Database
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18199083.001).
[ISSN]
0168-6496
[Journal-full-title]
FEMS microbiology ecology
[ISO-abbreviation]
FEMS Microbiol. Ecol.
[Language]
eng
[Databank-accession-numbers]
GENBANK/ EF027740/ EF027741/ EF027742/ EF027743/ EF027744/ EF027745/ EF027746/ EF027747/ EF027748/ EF027749/ EF027750/ EF027751/ EF027752/ EF027753/ EF027754/ EF027755/ EF027756/ EF027757/ EF027758/ EF027759/ EF027760/ EF027761/ EF027762/ EF027763/ EF027764/ EF027765/ EF027766/ EF027767/ EF027768/ EF027769/ EF027770/ EF027771/ EF027772/ EF027773/ EF027774/ EF027775/ EF027776/ EF027777/ EF027778/ EF027779/ EF027780/ EF027781/ EF027782/ EF027783/ EF027784/ EF027785/ EF027786/ EF027787/ EF027788/ EF027789/ EF027790/ EF027791/ EF027792/ EF027793/ EF027794/ EF027795/ EF027796/ EF027797/ EF027798/ EF027799/ EF027800/ EF027801/ EF027802/ EF027803/ EF027804/ EF027805/ EF027806/ EF027807/ EF027808/ EF027809/ EF027810/ EF027811/ EF027812/ EF027813/ EF027814/ EF027815/ EF027816/ EF027817/ EF027818/ EF027819/ EF027820/ EF027821/ EF027822/ EF027823/ EF027824/ EF027825/ EF027826/ EF027827/ EF027828/ EF027829/ EF027830/ EF027831/ EF027832/ EF027833/ EF027834/ EF027835/ EF027836/ EF027837/ EF027838/ EF027839/ EF027840/ EF027841/ EF027842/ EF027843/ EF027844/ EF027845/ EF027846/ EF027847/ EF027848/ EF027849/ EF027850/ EF027851/ EF027852/ EF027853/ EF027854/ EF027855/ EF027856/ EF027857/ EF027858
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / RNA, Bacterial; 0 / RNA, Ribosomal, 16S
40.
Fritzsche FR, Thomas A, Winzer KJ, Beyer B, Dankof A, Bellach J, Dahl E, Dietel M, Kristiansen G:
Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer.
Histol Histopathol
; 2007 11;22(11):1221-30
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Co-expression and prognostic value of gross cystic
disease
fluid protein 15 and mammaglobin in primary
breast cancer
.
Gross cystic
disease
fluid protein (GCDFP-15) and mammaglobin are both widely used and accepted markers for epithelia of
breast
origin.
We aimed to evaluate their relation of expression on parallel whole tissue sections in primary
breast cancer
by immunohistochemistry and also to correlate it with clinico-pathological parameters including patient survival.
Primary
breast carcinomas
from 165 patients with a mean clinical follow-up of 73 months were immunostained using commercially available antibodies against GCDFP-15 and mammaglobin.
Cytoplasmic expression of GCDFP-15 and mammaglobin was observed in 73.3% and 72.1% of invasive
breast carcinomas
respectively.
91.8% of
breast cancer cases
expressed at least one of both markers.
Additionally, GCDFP-15 negativity was significantly associated with shortened
disease
-free survival times in univariate and multivariate analyses.
We demonstrated the strong correlation of GCDFP-15 and mammaglobin with each other and showed that only very few primary
breast
cancers are completely negative for both markers.
The significantly longer
disease
free survival times for patients with GCDFP-15 positive tumours clearly warrants further study.
[MeSH-major]
Biomarkers, Tumor / metabolism.
Breast
Neoplasms / metabolism.
Carcinoma
, Ductal,
Breast
/ metabolism.
Carcinoma
, Lobular / metabolism. Carrier Proteins / metabolism. Glycoproteins / metabolism.
Neoplasm
Proteins / metabolism. Uteroglobin / metabolism
[MeSH-minor]
Cell
Count.
Disease
-Free Survival. Female. Humans. Mammaglobin A. Middle Aged. Survival Rate
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17647195.001).
[ISSN]
1699-5848
[Journal-full-title]
Histology and histopathology
[ISO-abbreviation]
Histol. Histopathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Spain
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / PIP protein, human; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
41.
Gautier T, Tietge UJ, Boverhof R, Perton FG, Le Guern N, Masson D, Rensen PC, Havekes LM, Lagrost L, Kuipers F:
Hepatic lipid accumulation in apolipoprotein C-I-deficient mice is potentiated by cholesteryl ester transfer protein.
J Lipid Res
; 2007 Jan;48(1):30-40
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In addition to the expected moderate reduction in plasma
cholesterol
levels, apoCIKO mice showed significant increases in the hepatic content of cholesteryl esters (+58%) and triglycerides (+118%) and in
biliary cholesterol concentration
(+35%) as compared with wild-type mice.
Biliary
levels of
cholesterol
, phospholipids, and bile acids were increased by 88, 77, and 20%, respectively, whereas total
cholesterol
, HDL
cholesterol
, and triglyceride
concentrations
in plasma were further reduced in CETPTg/apoCIKO mice versus CETPTg mice.
In line with the previously recognized inhibition of lipoprotein clearance by apoC-I, apoC-I deficiency led to decreased plasma lipid
concentration
, hepatic lipid accumulation, and increased
biliary
excretion of
cholesterol
.
The effect was even greater when the alternate reverse
cholesterol
transport pathway via VLDL/LDL was boosted in the presence of CETP.
[MeSH-major]
Apolipoprotein C-I / deficiency.
Cholesterol
Ester Transfer Proteins / metabolism. Lipids / physiology. Liver / metabolism
Jackson Laboratory JAX®Mice Database.
culture/stock collections - B6.CBA-Tg(CETP)5203Tall/J
(subscription/membership/fee required).
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
antibodies-online.
View related products from antibodies-online.com
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17053273.001).
[ISSN]
0022-2275
[Journal-full-title]
Journal of lipid research
[ISO-abbreviation]
J. Lipid Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Apolipoprotein C-I; 0 / Cholesterol Ester Transfer Proteins; 0 / Lipids; 63231-63-0 / RNA
42.
Clayton TH, Tait J, Whitehurst C, Yates VM:
Photodynamic therapy for superficial basal cell carcinoma and Bowen's disease.
Eur J Dermatol
; 2006 Jan-Feb;16(1):39-41
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Photodynamic therapy for superficial
basal cell carcinoma
and Bowen's
disease
.
Photodynamic therapy (PDT) is an effective treatment for superficial
basal cell carcinoma
(
BCCs
) and Bowen's
disease
.
Bowen's
disease
and superficial
basal cell
carcinomas
characteristically affect older patients who may also have associated difficulties with mobility.
[MeSH-major]
Bowen's
Disease
/ drug therapy.
Carcinoma
,
Basal Cell
/ drug therapy. Photochemotherapy / methods.
Skin
Neoplasms / drug therapy
[MeSH-minor]
Adult. Aged. Biopsy, Needle. Female. Great Britain / epidemiology. Humans. Immunohistochemistry. Male. Middle Aged.
Neoplasm
Staging. Prognosis. Prospective Studies. Risk Assessment. Survival Rate. Treatment Outcome
Genetic Alliance.
consumer health - Bowen's Disease
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16436340.001).
[ISSN]
1167-1122
[Journal-full-title]
European journal of dermatology : EJD
[ISO-abbreviation]
Eur J Dermatol
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
France
43.
Skelton LA:
The effective treatment of basal cell carcinoma.
Br J Nurs
; 2009 Mar 26-Apr 8;18(6):346, 348-50
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The effective treatment
of basal cell carcinoma
.
Basal cell carcinoma
(
BCC
) accounts for 75% of all
skin
cancers and its incidence is rising by between 3-8% each year (Szeimies and Karrer, 2006).
As a result, the development of new therapeutic strategies and treatment methods for the removal of
BCC
is crucial in combating what is a growing problem.
The aim of this article is to critically review some of the current literature in order to substantiate the efficacy of destructive and non-surgical techniques as reliable alternatives to surgery for the management/removal of
BCCs
.
However, in relation to success rates, patients tolerance of the treatment and cosmetic outcomes, and depending on the type of
BCC
involved, other treatment methods do offer reliable alternatives.
[MeSH-major]
Carcinoma
,
Basal Cell
/ therapy.
Skin
Neoplasms / therapy
[MeSH-minor]
Adjuvants, Immunologic / therapeutic use. Administration, Cutaneous. Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Causality. Cryosurgery. Curettage. Great Britain / epidemiology. Humans. Incidence. Interferon-alpha / therapeutic use. Laser Therapy. Mohs Surgery.
Neoplasm
Recurrence, Local / prevention & control. Nurse's Role. Oncology Nursing. Photochemotherapy. Recombinant Proteins
MedlinePlus Health Information.
consumer health - Skin Cancer
.
Hazardous Substances Data Bank.
Imiquimod
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19329898.001).
[ISSN]
0966-0461
[Journal-full-title]
British journal of nursing (Mark Allen Publishing)
[ISO-abbreviation]
Br J Nurs
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a; 99011-02-6 / imiquimod
[Number-of-references]
26
44.
Diaconu NC, Kaminska R, Naukkarinen A, Harvima RJ, Harvima IT:
The increase in tryptase- and chymase-positive mast cells is associated with partial inactivation of chymase and increase in protease inhibitors in basal cell carcinoma.
J Eur Acad Dermatol Venereol
; 2007 Aug;21(7):908-15
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The increase in tryptase- and chymase-positive mast cells is associated with partial inactivation of chymase and increase in protease inhibitors in
basal cell carcinoma
.
BACKGROUND: In
basal cell carcinoma
(
BCC
), mast cells accumulate in the peritumoral stroma.
The serine proteinases tryptase and chymase are the major mediators in mast
cell
granules and they may exert their enzymatic activity in
the BCC
lesion by inducing matrix remodeling and epithelial
cell
detachment.
OBJECTIVE: To analyse the numbers of mast cells showing tryptase enzyme activity, chymase enzyme activity and chymase immunoreactivity as well as the presence of chymase inhibitors alpha(1)-antichymotrypsin (alpha(1)-AC), alpha(1)-proteinase inhibitor (alpha(1)-PI) and squamous
cell carcinoma
antigen-2 (SCCA-2) in
BCC
.
METHODS: Eleven biopsies were taken from the lesion and healthy-looking
skin of
10 patients with superficial spreading
BCC
.
RESULTS: In
the BCC
lesion, the number of mast cells with tryptase activity and chymase immunoreactivity was significantly increased by 2.2- to 2.3-fold.
However, the ratio of cells with chymase activity to those with chymase immunoreactivity was significantly decreased from 49 +/- 19% in the healthy
skin
to 33 +/- 19% in
the BCC
lesion.
Instead, the percentage of mast cells displaying alpha(1)-AC or alpha(1)-PI immunoreactivity was significantly increased by 1.7-fold in
the BCC
lesion.
SCCA-2 expression was strongly increased in
the malignant BCC
epithelium but mostly in the suprabasal layers.
CONCLUSIONS: Tryptase- and chymase-positive mast cells (MC(TC)) increased in
the BCC
lesion.
SCCA-2 increased in
BCC
, but was localized mostly to the suprabasal layers, and thus it seems not to be crucial in inhibiting chymase.
[MeSH-major]
Carcinoma
,
Basal Cell
/ enzymology. Chymases / metabolism. Mast Cells / enzymology. Protease Inhibitors / metabolism.
Skin
Neoplasms / enzymology. Tryptases / metabolism
MedlinePlus Health Information.
consumer health - Skin Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17658999.001).
[ISSN]
0926-9959
[Journal-full-title]
Journal of the European Academy of Dermatology and Venereology : JEADV
[ISO-abbreviation]
J Eur Acad Dermatol Venereol
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Protease Inhibitors; EC 3.4.21.39 / Chymases; EC 3.4.21.59 / Tryptases
45.
Ohson K, DesGroseilliers JP, Weatherhead S, Weatherhead L:
Imiquimod 5% cream use for the treatment of basal cell carcinomas in elderly patients, in long-term care facilities, not amenable to surgical or radiation therapy.
J Cutan Med Surg
; 2006 Jul-Aug;10(4):201-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Imiquimod 5% cream use for the treatment
of basal cell
carcinomas
in elderly patients, in long-term care facilities, not amenable to surgical or radiation therapy.
[MeSH-major]
Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use.
Carcinoma
,
Basal Cell
/ drug therapy.
Skin
Neoplasms / drug therapy
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
Hazardous Substances Data Bank.
Imiquimod
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17234120.001).
[ISSN]
1203-4754
[Journal-full-title]
Journal of cutaneous medicine and surgery
[ISO-abbreviation]
J Cutan Med Surg
[Language]
eng
[Publication-type]
Letter
[Publication-country]
United States
[Chemical-registry-number]
0 / Aminoquinolines; 0 / Antineoplastic Agents; P1QW714R7M / imiquimod
46.
Hexsel CL, Eide MJ, Johnson CC, Krajenta R, Jacobsen G, Hamzavi I, Lim HW:
Incidence of nonmelanoma skin cancer in a cohort of patients with vitiligo.
J Am Acad Dermatol
; 2009 Jun;60(6):929-33
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Incidence of nonmelanoma
skin
cancer
in a cohort of patients with vitiligo.
BACKGROUND: Nonmelanoma
skin
cancer
(NMSC) incidence in patients with vitiligo has not been studied.
Age-adjusted incidence rates were:
basal cell carcinoma
, male 1382/100,000;
basal cell carcinoma
, female 0; squamous
cell carcinoma
, male 465/100,000; squamous
cell carcinoma
, female 156/100,000.
Except for
basal cell carcinoma
in females, all rates were higher than US rates but not statistically significant.
[MeSH-major]
Skin
Neoplasms / epidemiology. Vitiligo / complications
[MeSH-minor]
Adolescent. Adult.
Carcinoma
,
Basal Cell
/ epidemiology.
Carcinoma
, Squamous
Cell
/ epidemiology. Female. Humans. Male. Middle Aged. United States / epidemiology
Genetic Alliance.
consumer health - Vitiligo
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
MedlinePlus Health Information.
consumer health - Vitiligo
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
J Am Acad Dermatol. 2009 Dec;61(6):1080-1
[
19925933.001
]
[Cites]
Int J Cancer. 1991 Jan 2;47(1):12-9
[
1985867.001
]
[Cites]
N Engl J Med. 1974 Dec 5;291(23):1207-11
[
4422691.001
]
[Cites]
Clin Exp Dermatol. 1996 Jan;21(1):43-5
[
8689768.001
]
[Cites]
J Eur Acad Dermatol Venereol. 2003 Sep;17(5):578-80
[
12941100.001
]
[Cites]
J Am Acad Dermatol. 1998 May;38(5 Pt 1):647-66; quiz 667-8
[
9591808.001
]
[Cites]
N Engl J Med. 1979 Apr 12;300(15):809-13
[
423919.001
]
[Cites]
J Am Acad Dermatol. 2005 Aug;53(2):320-8
[
16021129.001
]
[Cites]
Br J Dermatol. 2000 Apr;142(4):824-5
[
10792246.001
]
[Cites]
Dermatol Surg. 2006 Dec;32(12):1473-9
[
17199655.001
]
[Cites]
Clin Exp Dermatol. 1997 Jan;22(1):54
[
9330057.001
]
[Cites]
Int J Cancer. 1999 May 17;81(4):555-9
[
10225444.001
]
[Cites]
Arch Dermatol. 1995 Jun;131(6):734-5
[
7778934.001
]
[Cites]
Int J Cancer. 1993 Apr 1;53(6):886-91
[
8473047.001
]
[Cites]
Arch Dermatol. 1976 Nov;112(11):1531-4
[
984858.001
]
[Cites]
J Am Acad Dermatol. 1998 Feb;38(2 Pt 1):268-70
[
9486686.001
]
[Cites]
Acta Derm Venereol. 1996 Nov;76(6):429-32
[
8982403.001
]
[Cites]
J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8
[
8176018.001
]
[Cites]
Acta Derm Venereol. 1992 Aug;72(4):305-6
[
1357897.001
]
[Cites]
J Am Acad Dermatol. 2006 Nov;55(5):741-60; quiz 761-4
[
17052479.001
]
[Cites]
Cancer. 1995 Jan 15;75(2 Suppl):667-73
[
7804993.001
]
[Cites]
J Am Acad Dermatol. 2001 Dec;45(6 Suppl):S227-9
[
11712068.001
]
[Cites]
Br J Dermatol. 2000 Jul;143(1):219-21
[
10886181.001
]
[Cites]
Photodermatol Photoimmunol Photomed. 2006 Aug;22(4):211-3
[
16869872.001
]
(PMID = 19375190.001).
[ISSN]
1097-6787
[Journal-full-title]
Journal of the American Academy of Dermatology
[ISO-abbreviation]
J. Am. Acad. Dermatol.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / R01 CA140754
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
47.
Yuan L, Goldbach A, Xu H:
Segregation and H2 transport rate control in body-centered cubic PdCu membranes.
J Phys Chem B
; 2007 Sep 20;111(37):10952-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The membrane underwent
a bcc
-fcc (body-centered cubic to face-centered cubic) phase transition between 723 and 873 K resulting in compositional segregation.
After reannealing at 723 K the alloy layer reverted to
a bcc
structure although a small fcc fraction remained behind.
The mixed-phase morphology was analyzed combining X-ray diffraction with scanning electron microscopy-energy-dispersive spectroscopic analysis (SEM-EDS) measurements, which revealed micrometer-scale Cu-enriched
bcc
and Cu-depleted fcc domains.
The prevalence of desorption as the permeation rate-limiting step below 454 K is attributed to the pairing of an extraordinarily high hydrogen diffusivity with a marginal hydrogen solubility in
bcc
PdCu alloys.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17715958.001).
[ISSN]
1520-6106
[Journal-full-title]
The journal of physical chemistry. B
[ISO-abbreviation]
J Phys Chem B
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
48.
Karen JK, Gareau DS, Dusza SW, Tudisco M, Rajadhyaksha M, Nehal KS:
Detection of basal cell carcinomas in Mohs excisions with fluorescence confocal mosaicing microscopy.
Br J Dermatol
; 2009 Jun;160(6):1242-50
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Detection
of basal cell
carcinomas
in Mohs excisions with fluorescence confocal mosaicing microscopy.
BACKGROUND: High-resolution real-time imaging of human
skin
is possible with a confocal microscope either in vivo or in freshly excised tissue ex vivo.
OBJECTIVES: To evaluate the sensitivity and specificity of ex vivo real-time imaging with fluorescence confocal mosaicing microscopy, using acridine orange, for the detection of residual
basal cell carcinoma
(
BCC
) in Mohs fresh tissue excisions.
METHODS: Forty-eight discarded
skin
excisions were collected following completion of Mohs surgery, consisting of excisions with and without residual
BCC
of all major subtypes.
Two Mohs surgeons, who were blinded to
the cases
, independently assessed confocal submosaics and recorded the presence or absence of
BCC
, location, and histological subtype(s).
RESULTS: The overall sensitivity and specificity of detecting residual
BCC
was 96.6% and 89.2%, respectively.
Very good correlation was observed between confocal mosaics and matched Mohs frozen sections for benign and
malignant
skin
structures, overall tumour burden and location, and identification of all major histological subtypes of
BCC
.
CONCLUSIONS: Fluorescent confocal mosaicing microscopy using acridine orange enables detection of residual
BCC
of all subtypes in Mohs fresh tissue excisions with high accuracy.
This observation is an important step towards the long-term clinical goal of using a noninvasive imaging modality for potential real-time surgical pathology-at-the-bedside for
skin
and other tissues.
[MeSH-major]
Carcinoma
,
Basal Cell
/ pathology. Mohs Surgery / methods.
Skin
Neoplasms / pathology
[MeSH-minor]
Diagnosis
, Differential. Humans. Microscopy, Confocal / methods. Microscopy, Fluorescence / methods. Sensitivity and Specificity
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Surgery. 2000 Dec;128(6):1088-1100; discussion 1100-1
[
11114647.001
]
[Cites]
J Microsc. 2009 Jan;233(1):149-59
[
19196421.001
]
[Cites]
Arch Dermatol. 2004 Jun;140(6):736-42
[
15210467.001
]
[Cites]
Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):923-8
[
15313861.001
]
[Cites]
J Cell Biol. 1985 Apr;100(4):1309-23
[
3920227.001
]
[Cites]
Dermatol Surg. 2004 Dec;30(12 Pt 1):1470-8
[
15606734.001
]
[Cites]
J Biomed Opt. 2005 May-Jun;10(3):034009
[
16229653.001
]
[Cites]
Br J Dermatol. 2006 Feb;154(2):305-9
[
16433801.001
]
[Cites]
Opt Lett. 2006 Apr 1;31(7):942-4
[
16599219.001
]
[Cites]
J Am Acad Dermatol. 2006 Sep;55(3):408-12
[
16908344.001
]
[Cites]
Opt Lett. 2006 Sep 15;31(18):2756-8
[
16936882.001
]
[Cites]
J Biomed Opt. 2007 Jan-Feb;12(1):014005
[
17343480.001
]
[Cites]
Appl Opt. 2007 Apr 1;46(10):1843-51
[
17356629.001
]
[Cites]
J Biomed Opt. 2007 May-Jun;12(3):034004
[
17614712.001
]
[Cites]
J Biomed Opt. 2007 May-Jun;12(3):034027
[
17614735.001
]
[Cites]
Lasers Surg Med. 2007 Oct;39(9):696-705
[
17960751.001
]
[Cites]
J Biomed Opt. 2007 Sep-Oct;12(5):051901
[
17994884.001
]
[Cites]
J Invest Dermatol. 2008 May;128(5):1248-55
[
17989735.001
]
[Cites]
J Biomed Opt. 2008 Mar-Apr;13(2):024013
[
18465976.001
]
[Cites]
Br J Dermatol. 2008 Jul;159(1):152-61
[
18460029.001
]
[Cites]
J Biomed Opt. 2008 Jul-Aug;13(4):044016
[
19021344.001
]
[Cites]
J Biomed Opt. 2008 Sep-Oct;13(5):054001
[
19021381.001
]
[Cites]
J Invest Dermatol. 2001 Nov;117(5):1137-43
[
11710924.001
]
(PMID = 19416248.001).
[ISSN]
1365-2133
[Journal-full-title]
The British journal of dermatology
[ISO-abbreviation]
Br. J. Dermatol.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / P30 CA008748; United States / NIBIB NIH HHS / EB / R01 EB002715; United States / NIBIB NIH HHS / EB / R01 EB002715-05; United States / NIBIB NIH HHS / EB / R01EB002715
[Publication-type]
Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Other-IDs]
NLM/ NIHMS95359; NLM/ PMC2693082
49.
Leite JL, Stolf HO, Reis NA, Ward LS:
Human herpesvirus type 6 and type 1 infection increases susceptibility to nonmelanoma skin tumors.
Cancer Lett
; 2005 Jun 28;224(2):213-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Human herpesvirus type 6 and type 1 infection increases susceptibility to nonmelanoma
skin
tumors.
In order to investigate herpesvirus (HHV) role in the susceptibility to
skin
cancer
, we compared HHV6 and HHV1 incidence in DNA samples extracted from 120 lesions and 41 normal
skin
tissues.
HHV6 (31.7%) and HHV1 (23.8%) were detected more frequently in
skin
cancer
than in control individuals (14.6 and 5%, respectively) (P=0.0391 and P=0.00094, respectively).
The risk of presenting
basal cell
carcinomas
(
BCC
) was more than 3 times higher for HHV-6 infected patients (OR=3.182; 95% CI: 1.125-8.997).
The risk for HHV-1 infected individuals of presenting
BCC
and squamous
cell
carcinomas
was increased 8 and 6 times, respectively (OR=8.125; 95% CI: 1.735-38.043 and OR=6.290; 95% CI: 1.283-30.856, respectively).
[MeSH-major]
Carcinoma
,
Basal Cell
/ etiology.
Carcinoma
,
Basal Cell
/ virology.
Carcinoma
, Squamous
Cell
/ etiology.
Carcinoma
, Squamous
Cell
/ virology. Herpes Simplex / complications. Herpesvirus 1, Human / pathogenicity. Herpesvirus 6, Human / pathogenicity. Roseolovirus Infections / complications.
Skin
Neoplasms / etiology.
Skin
Neoplasms / virology
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Biopsy.
Case
-Control Studies. Child. DNA, Viral / analysis. Female. Humans. Incidence. Male. Middle Aged. Odds Ratio. Polymerase Chain Reaction. Risk Factors
MedlinePlus Health Information.
consumer health - Herpes Simplex
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15914272.001).
[ISSN]
0304-3835
[Journal-full-title]
Cancer letters
[ISO-abbreviation]
Cancer Lett.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Ireland
[Chemical-registry-number]
0 / DNA, Viral
50.
Goldberg M, Rummelt C, Laerm A, Helmbold P, Holbach LM, Ballhausen WG:
Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas.
Br J Dermatol
; 2006 Dec;155(6):1154-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in
basal cell
carcinomas
.
BACKGROUND: Extensive exposure to ultraviolet radiation is associated with genetic alterations in
basal cell
carcinomas
(
BCCs
), which represent some 75%
of skin
cancers.
OBJECTIVES: As recent data suggested the fragile histidine triad (FHIT) gene product to participate in DNA damage responses we wished to address whether functional deletion of this tumour suppressor participates in the development of
BCC
.
METHODS: Paraffin-embedded specimens from 17 patients with
BCC
were available for methylation-specific polymerase chain reaction (MSP), combined bisulphite-dependent restriction analysis (COBRA) of the FHIT gene and immunohistochemistry of its product.
RESULTS: We report for the first time that 100% of
BCCs
are negative for FHIT by immunostaining.
Aberrant methylation of the FHIT promoter occurred in a significant portion of
BCCs
.
MSP detected hypermethylation of the FHIT/FRA3B locus in nine of nine (100%) periocular
BCCs
and in six of eight (75%)
BCCs
from other body regions.
COBRA yielded similar results, confirming that some 88% of the 17
BCCs
analysed harbour epigenetic silencing of the FHIT gene.
CONCLUSIONS: We have identified epigenetic silencing of the FHIT tumour suppressor gene as a frequent inactivation mechanism which is likely to contribute to functional deficiencies in DNA damage response of
BCCs
.
[MeSH-major]
Acid Anhydride Hydrolases / genetics.
Carcinoma
,
Basal Cell
/ genetics. Gene Silencing. Genes, Tumor Suppressor.
Neoplasm
Proteins / genetics.
Skin
Neoplasms / genetics
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17107382.001).
[ISSN]
0007-0963
[Journal-full-title]
The British journal of dermatology
[ISO-abbreviation]
Br. J. Dermatol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
51.
Freier K, Pungs S, Flechtenmacher C, Hofele C:
[Activation of sonic hedgehog signaling in keratocystic odontogenic tumors].
HNO
; 2009 Apr;57(4):345-50
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Multiple
basal cell
carcinomas
of the
skin
are another typical feature of Gorlin-Goltz syndrome.
Aberrant activation of sonic hedgehog signaling has been reported for sporadic and hereditary
basal cell carcinoma
caused by specific genetic mutations, but for keratocystic odontogenic tumors, the role of aberrant sonic hedgehog signaling has not yet been evaluated in detail.
This
finding
underlines the neoplastic character of this intraosseous lesion.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cell. 1996 Jun 14;85(6):841-51
[
8681379.001
]
[Cites]
J Pathol. 2001 Aug;194(4):473-7
[
11523056.001
]
[Cites]
Cancer Res. 1997 Jun 15;57(12):2336-40
[
9192803.001
]
[Cites]
Br J Oral Maxillofac Surg. 1997 Feb;35(1):46-8
[
9043004.001
]
[Cites]
J Can Dent Assoc. 2008 Mar;74(2):165-165h
[
18353202.001
]
[Cites]
J Mol Med (Berl). 1999 Jun;77(6):459-68
[
10475061.001
]
[Cites]
Cancer. 1992 Dec 15;70(12):2988-94
[
1451083.001
]
[Cites]
Anticancer Res. 2003 Sep-Oct;23(5A):3971-7
[
14666705.001
]
[Cites]
J Oral Maxillofac Surg. 2006 Mar;64(3):379-83
[
16487797.001
]
[Cites]
Am J Pathol. 2006 Sep;169(3):806-14
[
16936257.001
]
[Cites]
J Clin Pathol. 2001 Dec;54(12):897-910
[
11729208.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Jun 10;100(12 ):7331-6
[
12777630.001
]
[Cites]
Int J Oral Maxillofac Surg. 2004 Sep;33(6):584-92
[
15308259.001
]
[Cites]
Development. 1998 Aug;125(15):2803-11
[
9655803.001
]
[Cites]
Nat Med. 1998 Jul;4(7):844-7
[
9662379.001
]
[Cites]
Mund Kiefer Gesichtschir. 2006 Jan;10(1):1-2
[
16328532.001
]
[Cites]
J Oral Pathol. 1988 Jan;17(1):39-42
[
3131508.001
]
[Cites]
Pathol Int. 1999 Aug;49(8):687-94
[
10504535.001
]
[Cites]
Am J Med Genet. 1997 Mar 31;69(3):299-308
[
9096761.001
]
[Cites]
Hum Mol Genet. 2001 Apr;10 (7):757-62
[
11257109.001
]
[Cites]
Oncol Rep. 2006 May;15(5):1141-5
[
16596176.001
]
[Cites]
Mund Kiefer Gesichtschir. 2002 Nov;6(6):394-401
[
12447651.001
]
[Cites]
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Jul;86(1):42-7
[
9690244.001
]
(PMID = 19082818.001).
[ISSN]
1433-0458
[Journal-full-title]
HNO
[ISO-abbreviation]
HNO
[Language]
ger
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Hedgehog Proteins
52.
Farley RL, Manolidis S, Ratner D:
Aggressive basal cell carcinoma with invasion of the parotid gland, facial nerve, and temporal bone.
Dermatol Surg
; 2006 Feb;32(2):307-15; discussion 315
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Aggressive
basal cell carcinoma
with invasion of the parotid gland, facial nerve, and temporal bone.
Aggressive variants
of basal cell carcinoma
(
BCC
), such as infiltrating, morpheaform, and basosquamous types, are associated with invasion of underlying tissues and are often difficult to treat.1
BCCs
located in embryonic fusion planes, such as the periauricular region, are thought to exhibit deep extension and, subsequently, high recurrence rates, although this theory has been challenged and remains controversial.2-4 Despite the known features of aggressive
BCC
, parotid gland invasion and temporal bone and facial nerve involvement are rarely reported occurrences.
We describe two patients with morpheaform
BCC
in the periauricular region demonstrating direct invasion of the parotid gland and concomitant facial nerve involvement.
These patients require
complex
surgical management, as highlighted in this report.
[MeSH-major]
Bone Neoplasms / pathology.
Carcinoma
,
Basal Cell
/ pathology. Head and Neck Neoplasms / pathology. Nervous System Neoplasms / pathology. Parotid Neoplasms / pathology
[MeSH-minor]
Aged. Facial Nerve / pathology. Humans. Male.
Neoplasm
Invasiveness. Otorhinolaryngologic Surgical Procedures.
Skin
Neoplasms / pathology.
Skin
Neoplasms / surgery. Temporal Bone / pathology
MedlinePlus Health Information.
consumer health - Bone Cancer
.
MedlinePlus Health Information.
consumer health - Head and Neck Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16442061.001).
[ISSN]
1076-0512
[Journal-full-title]
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
[ISO-abbreviation]
Dermatol Surg
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
53.
Mohammadi A, Rosa M, Rhatigan R:
Eyelid basal cell carcinoma associated with solitary neurofibroma.
J Cutan Pathol
; 2010 Jun;37(6):707-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Eyelid
basal cell carcinoma
associated with solitary neurofibroma.
[MeSH-major]
Carcinoma
,
Basal Cell
/ complications. Eyelid Neoplasms / complications. Neurofibroma / complications
Genetic Alliance.
consumer health - Neurofibroma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19614728.001).
[ISSN]
1600-0560
[Journal-full-title]
Journal of cutaneous pathology
[ISO-abbreviation]
J. Cutan. Pathol.
[Language]
eng
[Publication-type]
Case Reports; Letter
[Publication-country]
Denmark
54.
Yamane GK:
Cancer incidence in the U.S. Air Force: 1989-2002.
Aviat Space Environ Med
; 2006 Aug;77(8):789-94
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cancer
incidence in the U.S. Air Force: 1989-2002.
BACKGROUND:
Cancer
incidence in U.S.
METHODS: Standardized incidence ratios (SIRs) for invasive
cancer
in AFAD personnel during 1989-2002 were determined using U.S. national incidence rates as the reference.
Cutaneous squamous and
basal cell
carcinomas
(CAs) were excluded.
RESULTS: There were 2750
cases
: 1986 in men and 764 in women.
Among men, the 10 most frequent cancers (77.6% of total) were, in descending order: melanoma; testicular CA; prostate CA; non-Hodgkin lymphoma; follicular/papillary thyroid CA; Hodgkin's
Disease
; colorectal CA; brain neuroepithelial CA; and (tied) bladder CA and oral squamous
cell
CA.
Among women, the 10 most frequent cancers (88.1% of total) were, in descending order:
breast
CA; cervical CA; follicular/papillary thyroid CA; melanoma; Hodgkin's
Disease
; colorectal CA;.
(tied) non-Hodgkin lymphoma and ovarian epithelial CA; vulvar CA; and (tied) brain neuroepithelial CA and oral squamous
cell
CA.
Compared with the U.S. population,
cancer
type-specific SIRs were significantly increased for cervical CA, prostate CA, and vulvar CA (range, 1.44-3.54).
SIRs were significantly decreased for bladder CA (men), brain neuroepithelial CA, colorectal CA (men), Hodgkin's
Disease
(men), non-Hodgkin lymphoma, oral squamous
cell
CA (men), and testicular CA (range, 0.31-0.68).
CONCLUSIONS:
The cancer
experience of the AFAD population differs substantially from that of the U.S. population.
MedlinePlus Health Information.
consumer health - Occupational Health
.
MedlinePlus Health Information.
consumer health - Veterans and Military Health
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16909871.001).
[ISSN]
0095-6562
[Journal-full-title]
Aviation, space, and environmental medicine
[ISO-abbreviation]
Aviat Space Environ Med
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
55.
Bernard P, Dupuy A, Sasco A, Brun P, Duru G, Nicoloyannis N, Grob JJ:
Basal cell carcinomas and actinic keratoses seen in dermatological practice in France: a cross-sectional survey.
Dermatology
; 2008;216(3):194-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Basal cell
carcinomas
and actinic keratoses seen in dermatological practice in France: a cross-sectional survey.
BACKGROUND: Most actinic keratoses (AKs) and a number
of basal cell
carcinomas
(
BCCs
) cannot be assessed by pathological records.
OBJECTIVE: To estimate prospectively the figures and characteristics of
BCCs
and AKs seen by French dermatologists, their medical load, and present a more realistic approach to their incidence.
Out-patients seen for 1 or more
BCCs
or AKs were recorded over 4 non-consecutive weeks.
RESULTS: Among 78,300 out-patients, 1,321 had 1 (or more)
BCC
, and 3,688 had 1 or more AKs (1 and 5% of consultations made by dermatologists).
When extrapolating, the medical load in France was estimated at 248,000 and 693,000 consultations/year leading to a clinical
diagnosis of
BCC
and AK, respectively.
A total of 1,655
BCCs
were diagnosed including 839 superficial (50.7%), 636 nodular (38.4%), 137 morpheiform (8.3%) and 43 other types (2.6%).
Superficial and nodular
BCCs
were more frequently diagnosed with a small size (<10 mm) than morpheiform
BCCs
.
CONCLUSION: Our study in France provides the first estimate of the clinical burden represented by AKs and
BCCs
in dermatology practice.
[MeSH-major]
Carcinoma
,
Basal Cell
/ epidemiology. Keratosis / epidemiology.
Skin
Neoplasms / epidemiology. Sunlight / adverse effects
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18182809.001).
[ISSN]
1421-9832
[Journal-full-title]
Dermatology (Basel, Switzerland)
[ISO-abbreviation]
Dermatology (Basel)
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Switzerland
56.
Fan XS, Wu HY, Yu HP, Zhou Q, Zhang YF, Huang Q:
Expression of Lgr5 in human colorectal carcinogenesis and its potential correlation with beta-catenin.
Int J Colorectal Dis
; 2010 May;25(5):583-90
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUNDS AND AIMS: Lgr5 is a member of the G protein receptor super-family and was shown recently to be a stem
cell
marker for cells with intestinal differentiation.
Its over-expression has been demonstrated in hepatocellular,
basal cell carcinoma
, and ovarian cancers but the underlying mechanisms are poorly understood.
METHODS: The study was carried out on a tissue microarray that consisted of 102 colorectal
carcinomas
(CRC; M:F = 55:47), 18 colon adenoma, and 12 colon normal mucosa
cases
.
Subsequently, expression of Lgr5 in tissue sections of tumor centre and invasive margins of 21
cases
of CRC certified to be immunoreactive of Lgr5 in TMA were evaluated and possible differences of Lgr5 expression between them were analyzed.
RESULTS: Lgr5 immunoreactivity was observed only in single cells in the base of normal colon mucosal crypts but high in 28% (five out of 18) adenomas, and significantly higher in 54% (55/102, p = 0.016) CRC
cases
.
In normal mucosa, adenoma, and CRC, beta-catenin expression was seen in 25% (three out of 12), 27% (five out of 18), and 81% (83/102)
cases
, respectively, in contrast to 0, 0, and 40% (41/102) for p53 expression, respectively.
[MeSH-minor]
Adenoma / metabolism. Adenoma / pathology. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Male. Middle Aged.
Neoplasm
Invasiveness. Tumor Suppressor Protein p53 / metabolism
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Anat. 2008 Jul;213(1):52-8
[
18638070.001
]
[Cites]
Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24
[
12781368.001
]
[Cites]
Nature. 2007 Oct 25;449(7165):1003-7
[
17934449.001
]
[Cites]
Nat Genet. 1998 Aug;19(4):379-83
[
9697701.001
]
[Cites]
Front Biosci. 2008 May 01;13:3352-63
[
18508437.001
]
[Cites]
Mol Endocrinol. 1998 Dec;12(12):1830-45
[
9849958.001
]
[Cites]
Hepatology. 2003 Mar;37(3):528-33
[
12601349.001
]
[Cites]
Mol Endocrinol. 2000 Feb;14(2):272-84
[
10674399.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Apr 26;102(17 ):6027-32
[
15837931.001
]
[Cites]
Science. 2004 Mar 12;303(5664):1684-6
[
15017003.001
]
[Cites]
J Clin Oncol. 2008 Jun 10;26(17):2862-70
[
18539965.001
]
[Cites]
Nature. 2005 Jun 16;435(7044):959-63
[
15959515.001
]
[Cites]
Int J Surg Pathol. 2007 Jan;15(1):38-52
[
17172496.001
]
[Cites]
World J Gastroenterol. 2006 Jan 21;12(3):363-71
[
16489634.001
]
[Cites]
Transl Res. 2008 Jan;151(1):10-6
[
18061123.001
]
[Cites]
Am J Pathol. 2008 Sep;173(3):835-43
[
18688030.001
]
[Cites]
Cell Signal. 2007 Dec;19(12):2428-33
[
17651940.001
]
[Cites]
Nature. 2009 Jan 29;457(7229):608-11
[
19092804.001
]
[Cites]
ScientificWorldJournal. 2008 Nov 23;8:1168-76
[
19030762.001
]
[Cites]
Nat Genet. 2004 Oct;36(10 ):1117-21
[
15378062.001
]
[Cites]
J Clin Oncol. 2008 Jun 10;26(17):2828-38
[
18539961.001
]
[Cites]
Nat Rev Cancer. 2008 May;8(5):387-98
[
18432252.001
]
[Cites]
Annu Rev Cell Dev Biol. 2007;23:675-99
[
17645413.001
]
[Cites]
Clin Cancer Res. 2007 Jul 15;13(14):4042-5
[
17634527.001
]
[Cites]
Annu Rev Physiol. 2009;71:241-60
[
18808327.001
]
[Cites]
Neurobiol Dis. 2007 Feb;25(2):217-29
[
17141509.001
]
[Cites]
Cold Spring Harb Symp Quant Biol. 2008;73:351-6
[
19478326.001
]
[Cites]
Adv Pathobiol. 1977;(6):141-52
[
899956.001
]
[Cites]
Mol Cell Biol. 2004 Nov;24(22):9736-43
[
15509778.001
]
[Cites]
Cancer Biol Ther. 2006 Apr;5(4):419-26
[
16575208.001
]
[Cites]
Pathobiology. 2006;73(5):213-23
[
17314492.001
]
[Cites]
Nat Rev Cancer. 2008 Oct;8(10):755-68
[
18784658.001
]
[Cites]
Science. 2005 Mar 25;307(5717):1904-9
[
15790842.001
]
[Cites]
Cancer Res. 2008 May 1;68(9):3304-13
[
18451157.001
]
(PMID = 20195621.001).
[ISSN]
1432-1262
[Journal-full-title]
International journal of colorectal disease
[ISO-abbreviation]
Int J Colorectal Dis
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / LGR5 protein, human; 0 / Receptors, G-Protein-Coupled; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin
57.
Chen WL, Li JS, Yang ZH, Huang ZQ, Wang JU, Zhang B:
Two submental island flaps for reconstructing oral and maxillofacial defects following cancer ablation.
J Oral Maxillofac Surg
; 2008 Jun;66(6):1145-56
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Two submental island flaps for reconstructing oral and maxillofacial defects following
cancer
ablation.
PURPOSE: The purpose of this study was to assess the reliability of 2 patterns of submental island flaps--the facial-submental artery island flap and the reverse facial-submental artery island flap--used for reconstruction of oral and maxillofacial defects following
cancer
ablation.
PATIENTS AND METHODS: Thirty-eight soft tissue defects were repaired with facial-submental artery island flaps and reverse facial-submental artery island flaps following
cancer
surgery.
The primary lesions included squamous
cell carcinoma
of the tongue (8
cases
), buccal mucosa (16), floor of the mouth (4), lower gingiva (3), oropharynx (2); recurrent squamous
cell carcinoma
of the palate (3); and
basal cell carcinoma of
the facial
skin
(2).
The clinical stage of the tumors was stage I in 5
cases
, stage II in 25, and stage III in 8.
Facial-submental artery island flaps were used in 20
cases
, reverse facial-submental artery island flaps in 18.
The size of the
skin
paddle varied from a minimum of 4 cm x 8 cm to a maximum of 5 cm x 15 cm.
RESULTS: The postoperative outcome for 2 patterns of submental flaps was 36
cases
surviving, 2 of complete necrosis, and one other of temporary palsy of the marginal mandibular branch of the facial nerve.
The follow-up period was 3 to 24 months, 1 patient died of tumor local recurrences and 2
cases
of cervical recurrence were observed.
[MeSH-major]
Chin / surgery. Facial Neoplasms / surgery. Mouth Neoplasms / surgery.
Skin
Transplantation / methods. Surgical Flaps / blood supply
[MeSH-minor]
Adult. Aged. Aged, 80 and over.
Carcinoma
,
Basal Cell
/ pathology.
Carcinoma
,
Basal Cell
/ surgery.
Carcinoma
, Squamous
Cell
/ pathology.
Carcinoma
, Squamous
Cell
/ surgery. Face / blood supply. Fatal Outcome. Female. Humans. Male. Middle Aged. Neck / blood supply. Neck / surgery.
Neoplasm
Staging. Oral Surgical Procedures / methods. Reconstructive Surgical Procedures / methods. Retrospective Studies
Genetic Alliance.
consumer health - Oral cancer
.
MedlinePlus Health Information.
consumer health - Oral Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18486779.001).
[ISSN]
1531-5053
[Journal-full-title]
Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
[ISO-abbreviation]
J. Oral Maxillofac. Surg.
[Language]
eng
[Publication-type]
Case Reports; Evaluation Studies; Journal Article
[Publication-country]
United States
58.
Hanavadi S, Monypenny IJ, Mansel RE:
Is mammography overused in male patients?
Breast
; 2006 Feb;15(1):123-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
There is no agreed protocol for the use of mammography in evaluating the male
breast
.
In order to define the role of mammography in men, we carried out a retrospective analysis of all male patients referred to
the breast
clinic with a history of
breast
lump between January 2001 and December 2003.
The impact of mammography in the evaluation of male
breast cancer cases
was studied.
A total of 220 male patients were referred to
the breast
clinic during this period.
Of these, 134 men had a mammographic examination, with majority (96%) being performed prior to their consultation with
the breast
clinician as per the clinic protocol.
There were 4
cases
of
breast cancer
diagnosed during this period.
Breast cancer
was suspected in all patients on clinical examination and was confirmed by biopsy.
Breast cancer
in men can be suspected on clinical examination in the majority of
cases
.
One should consider imaging only those with clinically suspicious
breast
lumps to avoid unnecessary imaging particularly in young male patients.
[MeSH-major]
Breast
Neoplasms, Male / radiography. Mammography / utilization
[MeSH-minor]
Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Biopsy.
Breast
Diseases / radiography. Child.
Diagnosis
, Differential. Humans. Male. Middle Aged. Retrospective Studies
MedlinePlus Health Information.
consumer health - Male Breast Cancer
.
MedlinePlus Health Information.
consumer health - Mammography
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16473746.001).
[ISSN]
0960-9776
[Journal-full-title]
Breast (Edinburgh, Scotland)
[ISO-abbreviation]
Breast
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Scotland
59.
Cherian P, Kumarasinghe P:
Giant basal cell carcinoma masquerading as an osteogenic sarcoma.
Australas J Dermatol
; 2009 Feb;50(1):60-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Giant
basal cell carcinoma
masquerading as an osteogenic sarcoma.
Superficial and deep biopsies yielded invasive
basal cell carcinoma
.
We explore the literature regarding the tumorigenic effects of peri-fracture cytokines on the biological behaviour
of basal cell
neoplasms.
[MeSH-major]
Bone Neoplasms /
diagnosis
.
Carcinoma
,
Basal Cell
/
diagnosis
. Clavicle / injuries. Fractures, Bone / complications. Osteosarcoma /
diagnosis
.
Skin
Neoplasms /
diagnosis
[MeSH-minor]
Aged, 80 and over. Biopsy. Cytokines / immunology.
Diagnosis
, Differential. Humans. Male. Treatment Outcome
MedlinePlus Health Information.
consumer health - Bone Cancer
.
MedlinePlus Health Information.
consumer health - Fractures
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19178496.001).
[ISSN]
1440-0960
[Journal-full-title]
The Australasian journal of dermatology
[ISO-abbreviation]
Australas. J. Dermatol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Australia
[Chemical-registry-number]
0 / Cytokines
60.
Aoyagi S, Hata H, Homma E, Shimizu H:
Controlling the histological margin for non-melanoma skin cancer conveniently using a double-bladed scalpel.
J Surg Oncol
; 2010 Feb 1;101(2):175-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Controlling the histological margin for non-melanoma
skin
cancer
conveniently using a double-bladed scalpel.
BACKGROUND: In some countries, intraoperative histological evaluation to control the surgical margin for non-melanoma
skin
cancer
is widely used instead of Mohs micrographic surgery.
OBJECTIVES: To evaluate the efficacy of double-bladed scalpel for intraoperative histological margin control for non-melanoma
skin
cancers.
METHODS: Between 2005 and 2009, 10
basal cell
carcinomas
and 5 squamous
cell
carcinomas
were underwent complete histological margin control in which a double-bladed scalpel was used during the surgery at the Hokkaido University Hospital in Japan.
RESULTS: The mean number of
re
-excisions required for complete tumor resection was 1.4 times.
Nine (60%) of the 15 patients obtained histological clearance of all surgical margins at the first
re
-excision.
[MeSH-major]
Carcinoma
,
Basal Cell
/ pathology.
Carcinoma
, Squamous
Cell
/ pathology.
Skin
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20082361.001).
[ISSN]
1096-9098
[Journal-full-title]
Journal of surgical oncology
[ISO-abbreviation]
J Surg Oncol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
61.
Yoo YS, Woo HY, Choi JH, Cho KR, Oh YT, Heo G:
Balloon catheter assisted excision of benign cervical cyst.
Auris Nasus Larynx
; 2010 Aug;37(4):504-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVES: Benign cystic masses that develop in the neck are easily excised with a wide
skin
incision.
METHODS: Two
cases
with a branchial cleft cyst (
BCC
) were removed using this method without recurrence.
The surgical technique includes a
skin
incision above the cyst, and fine dissection to expose the cyst wall.
The final pathological
diagnosis
was
BCC
in the two
cases
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
(PMID = 20053514.001).
[ISSN]
1879-1476
[Journal-full-title]
Auris, nasus, larynx
[ISO-abbreviation]
Auris Nasus Larynx
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Netherlands
[Number-of-references]
10
62.
Moehrle M, Breuninger H, Schippert W, Häfner HM:
Letter: Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular basal cell carcinomas before Mohs micrographic surgery: a randomized, double-blind, vehicle-controlled study.
Dermatol Surg
; 2010 Mar;36(3):428-30
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Letter: Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular
basal cell
carcinomas
before Mohs micrographic surgery: a randomized, double-blind, vehicle-controlled study.
[MeSH-major]
Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage.
Carcinoma
,
Basal Cell
/ drug therapy.
Carcinoma
,
Basal Cell
/ surgery. Mohs Surgery. Neoadjuvant Therapy. Nose Neoplasms / drug therapy. Nose Neoplasms / surgery.
Skin
Neoplasms / drug therapy.
Skin
Neoplasms / surgery
MedlinePlus Health Information.
consumer health - Nasal Cancer
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
Hazardous Substances Data Bank.
Imiquimod
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentOn]
Dermatol Surg. 2009 Jan;35(1):24-9
[
19018814.001
]
(PMID = 20402949.001).
[ISSN]
1524-4725
[Journal-full-title]
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
[ISO-abbreviation]
Dermatol Surg
[Language]
eng
[Publication-type]
Comment; Letter
[Publication-country]
United States
[Chemical-registry-number]
0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
63.
Otley CC:
Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face.
Arch Dermatol
; 2006 Sep;142(9):1235; author reply 1235-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cost-effectiveness of Mohs micrographic surgery vs surgical excision for
basal cell carcinoma of
the face.
[MeSH-major]
Carcinoma
,
Basal Cell
/ surgery.
Skin
Neoplasms / surgery
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentOn]
Arch Dermatol. 2006 Feb;142(2):187-94
[
16490846.001
]
(PMID = 16983019.001).
[ISSN]
0003-987X
[Journal-full-title]
Archives of dermatology
[ISO-abbreviation]
Arch Dermatol
[Language]
eng
[Publication-type]
Comment; Letter
[Publication-country]
United States
64.
Xie J:
Implications of hedgehog signaling antagonists for cancer therapy.
Acta Biochim Biophys Sin (Shanghai)
; 2008 Jul;40(7):670-80
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Implications of hedgehog signaling antagonists for
cancer
therapy.
The hedgehog (Hh) pathway, initially discovered in Drosophila by two Nobel laureates,
Dr
.
Eric Wieschaus and
Dr
.
Christiane Nusslein-Volhard, is a major regulator for
cell
differentiation, tissue polarity and
cell
proliferation.
Studies from many laboratories, including ours, reveal activation of this pathway in most
basal cell
carcinomas
and in approximately 30% of extracutaneous human cancers, including medulloblastomas, gastrointestinal, lung,
breast
and prostate cancers.
Even more exciting is the discovery and synthesis of specific signaling antagonists for the Hh pathway, which have significant clinical implications in novel
cancer
therapeutics.
This review discusses the major advances in the current understanding of Hh signaling activation in different types of human cancers, the molecular basis of Hh signaling activation, the major antagonists for Hh signaling inhibition and their potential clinical application in human
cancer
therapy.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Genes Dev. 2006 Nov 15;20(22):3161-73
[
17114586.001
]
[Cites]
PLoS Biol. 2006 Jul;4(8):e232
[
16895439.001
]
[Cites]
Nat Cell Biol. 2006 Dec;8(12):1415-23
[
17115028.001
]
[Cites]
Nat Rev Drug Discov. 2006 Dec;5(12):1026-33
[
17139287.001
]
[Cites]
Oncogene. 2007 Sep 27;26(44):6442-7
[
17452975.001
]
[Cites]
Cancer Res. 2008 Feb 15;68(4):961-4
[
18281468.001
]
[Cites]
Adv Exp Med Biol. 2008;624:241-51
[
18348461.001
]
[Cites]
Curr Oncol Rep. 2008 Mar;10(2):107-13
[
18377823.001
]
[Cites]
Nature. 2004 Dec 23;432(7020):1045-50
[
15616566.001
]
[Cites]
Cancer Res. 2002 Dec 15;62(24):7186-9
[
12499255.001
]
[Cites]
Dev Biol. 2003 Feb 1;254(1):1-18
[
12606278.001
]
[Cites]
Nature. 2003 Mar 20;422(6929):313-7
[
12629553.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4616-21
[
12679522.001
]
[Cites]
Dev Cell. 2003 Jun;4(6):799-812
[
12791266.001
]
[Cites]
Nature. 2003 Oct 23;425(6960):846-51
[
14520411.001
]
[Cites]
Nature. 2003 Oct 23;425(6960):851-6
[
14520413.001
]
[Cites]
Nature. 2003 Nov 6;426(6962):83-7
[
14603322.001
]
[Cites]
Dev Cell. 2004 Jun;6(6):801-13
[
15177029.001
]
[Cites]
J Biol. 2002 Nov 6;1(2):10
[
12437772.001
]
[Cites]
Endocrinology. 2004 Aug;145(8):3961-70
[
15132968.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10833-8
[
15249678.001
]
[Cites]
BMC Cancer. 2004 Aug 4;4:43
[
15294024.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6
[
15314219.001
]
[Cites]
Cancer Res. 2004 Sep 1;64(17):6071-4
[
15342389.001
]
[Cites]
Nature. 1996 Aug 15;382(6592):622-6
[
8757131.001
]
[Cites]
Nat Genet. 1996 Sep;14(1):78-81
[
8782823.001
]
[Cites]
Curr Biol. 1996 Mar 1;6(3):298-304
[
8805249.001
]
[Cites]
Science. 1996 Oct 11;274(5285):255-9
[
8824192.001
]
[Cites]
J Investig Dermatol Symp Proc. 1999 Sep;4(1):41-5
[
10537006.001
]
[Cites]
Nat Cell Biol. 1999 Sep;1(5):312-9
[
10559945.001
]
[Cites]
Development. 2000 Apr;127(8):1593-605
[
10725236.001
]
[Cites]
Nature. 2000 Jul 6;406(6791):86-90
[
10894547.001
]
[Cites]
J Biol Chem. 2000 Jul 21;275(29):21856-61
[
10806213.001
]
[Cites]
Hum Mol Genet. 2001 Apr;10(7):757-62
[
11257109.001
]
[Cites]
Med Pediatr Oncol. 2001 May;36(5):555-8
[
11340611.001
]
[Cites]
Cell. 2001 Jun 15;105(6):781-92
[
11440720.001
]
[Cites]
Nature. 2001 Jul 12;412(6843):194-8
[
11449277.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9255-9
[
11481486.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5442-7
[
11960000.001
]
[Cites]
Nat Genet. 2002 Jul;31(3):306-10
[
12068298.001
]
[Cites]
Curr Biol. 2002 Jun 25;12(12):983-95
[
12123571.001
]
[Cites]
Annu Rev Genomics Hum Genet. 2002;3:47-65
[
12142354.001
]
[Cites]
Science. 2002 Aug 30;297(5586):1559-61
[
12202832.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14071-6
[
12391318.001
]
[Cites]
Nature. 2002 Oct 31;419(6910):929-34
[
12410312.001
]
[Cites]
Genes Dev. 2002 Nov 1;16(21):2743-8
[
12414725.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):17900-7
[
15598741.001
]
[Cites]
Lab Invest. 2005 Jan;85(1):45-64
[
15580285.001
]
[Cites]
Mech Dev. 2005 Feb;122(2):223-30
[
15652709.001
]
[Cites]
Br J Dermatol. 2005 Jan;152(1):43-51
[
15656799.001
]
[Cites]
Mol Carcinog. 2005 Apr;42(4):183-92
[
15754313.001
]
[Cites]
Curr Top Med Chem. 2005;5(2):147-57
[
15853643.001
]
[Cites]
Breast Cancer Res. 2005;7(3):86-95
[
15987436.001
]
[Cites]
Mol Cell Biol. 2005 Aug;25(16):7042-53
[
16055716.001
]
[Cites]
Mol Cell Biol. 2005 Aug;25(16):7054-68
[
16055717.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11325-30
[
16061793.001
]
[Cites]
Cancer Biol Ther. 2005 Jul;4(7):728-33
[
15970691.001
]
[Cites]
Differentiation. 2005 Oct;73(8):397-405
[
16316410.001
]
[Cites]
Development. 2006 Jan;133(1):3-14
[
16339192.001
]
[Cites]
Genes Dev. 2006 Jan 1;20(1):22-7
[
16357211.001
]
[Cites]
J Biol Chem. 2006 Jan 6;281(1):9-12
[
16293631.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):33-8
[
16371461.001
]
[Cites]
Genes Dev. 2006 Feb 1;20(3):276-81
[
16421275.001
]
[Cites]
Dev Cell. 2006 Feb;10(2):177-86
[
16459297.001
]
[Cites]
Dev Cell. 2006 Feb;10(2):187-97
[
16459298.001
]
[Cites]
Hum Mutat. 2006 Mar;27(3):215-9
[
16419085.001
]
[Cites]
Cancer Biol Ther. 2006 Jan;5(1):111-7
[
16397407.001
]
[Cites]
Carcinogenesis. 2006 Apr;27(4):748-57
[
16339184.001
]
[Cites]
Pancreas. 2006 Mar;32(2):119-29
[
16552330.001
]
[Cites]
Future Oncol. 2005 Jun;1(3):331-8
[
16556007.001
]
[Cites]
Mol Cell Biol. 2006 May;26(9):3365-77
[
16611981.001
]
[Cites]
Cell. 2006 Apr 21;125(2):343-57
[
16630821.001
]
[Cites]
Mol Cell Biol. 2006 May;26(10):3764-72
[
16648472.001
]
[Cites]
Cell. 2006 May 5;125(3):439-42
[
16678091.001
]
[Cites]
Dev Cell. 2006 May;10(5):657-65
[
16647303.001
]
[Cites]
Dev Cell. 2006 May;10(5):647-56
[
16647304.001
]
[Cites]
Cancer Res. 2006 Jun 15;66(12):6063-71
[
16778178.001
]
[Cites]
Carcinogenesis. 2006 Jul;27(7):1334-40
[
16501253.001
]
[Cites]
World J Gastroenterol. 2006 Jul 7;12(25):3965-9
[
16810741.001
]
[Cites]
Gastroenterology. 2006 Jul;131(1):14-29
[
16831586.001
]
[Cites]
Cancer Res. 2006 Jul 15;66(14):6964-71
[
16849540.001
]
[Cites]
Cancer Biol Ther. 2006 Jun;5(6):674-83
[
16855373.001
]
[Cites]
Mol Cell Biol. 2006 Aug;26(16):6283-98
[
16880536.001
]
[Cites]
Mol Cell Biol. 2006 Sep;26(17):6609-22
[
16914743.001
]
[Cites]
J Pathol. 2006 Sep;210(1):42-8
[
16794990.001
]
[Cites]
Nat Rev Genet. 2006 Nov;7(11):841-50
[
17047684.001
]
[Cites]
Gene Ther. 2006 Nov;13(22):1587-94
[
16826192.001
]
[Cites]
Nature. 2006 Nov 16;444(7117):369-73
[
17086203.001
]
[Cites]
Nature. 1996 Oct 3;383(6599):407-13
[
8837770.001
]
[Cites]
Nature. 1996 Nov 14;384(6605):129-34
[
8906787.001
]
[Cites]
Cancer Res. 1997 Mar 1;57(5):842-5
[
9041183.001
]
[Cites]
Development. 1997 Apr;124(7):1313-22
[
9118802.001
]
[Cites]
Cancer Res. 1997 Jun 15;57(12):2369-72
[
9192811.001
]
[Cites]
Science. 1997 Aug 22;277(5329):1109-13
[
9262482.001
]
[Cites]
Nature. 1998 Jan 1;391(6662):90-2
[
9422511.001
]
[Cites]
Cancer Res. 1998 May 1;58(9):1798-803
[
9581815.001
]
[Cites]
Nat Med. 1998 May;4(5):619-22
[
9585239.001
]
[Cites]
Science. 1998 Jun 5;280(5369):1603-7
[
9616123.001
]
[Cites]
Nature. 1998 Jul 2;394(6688):85-8
[
9665133.001
]
[Cites]
Nat Genet. 1998 Sep;20(1):54-7
[
9731531.001
]
[Cites]
Oncogene. 1999 Jan 21;18(3):833-6
[
9989836.001
]
[Cites]
Nature. 1999 Feb 18;397(6720):617-21
[
10050855.001
]
[Cites]
Genes Dev. 1999 Aug 15;13(16):2072-86
[
10465785.001
]
[Cites]
Genes Dev. 1999 Sep 15;13(18):2375-87
[
10500095.001
]
[Cites]
Development. 1999 Nov;126(21):4873-84
[
10518503.001
]
[Cites]
Mol Cancer. 2004 Oct 13;3:29
[
15482598.001
]
[Cites]
N Engl J Med. 1960 May 5;262:908-12
[
13851319.001
]
[Cites]
Carcinogenesis. 2005 Oct;26(10):1698-705
[
15905200.001
]
[Cites]
Nature. 2005 Oct 13;437(7061):1018-21
[
16136078.001
]
[Cites]
PLoS Genet. 2005 Oct;1(4):e53
[
16254602.001
]
[Cites]
Int J Cancer. 2006 Jan 1;118(1):139-48
[
16003737.001
]
[Cites]
Dev Biol. 2005 Nov 15;287(2):378-89
[
16229832.001
]
[Cites]
Oncology. 2006;70(5):378-89
[
17179732.001
]
[Cites]
Mol Cancer. 2006;5:74
[
17173689.001
]
[Cites]
Curr Biol. 2007 Jan 23;17(2):165-72
[
17196391.001
]
[Cites]
Semin Liver Dis. 2007 Feb;27(1):55-76
[
17295177.001
]
[Cites]
Cancer Res. 2007 Mar 1;67(5):2187-96
[
17332349.001
]
[Cites]
Clin Cancer Res. 2007 Mar 1;13(5):1389-98
[
17332280.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4048-53
[
17360475.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5103-8
[
17372229.001
]
[Cites]
World J Gastroenterol. 2007 Feb 21;13(7):1010-7
[
17373734.001
]
[Cites]
Oncol Rep. 2007 May;17(5):1051-5
[
17390043.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5895-900
[
17392427.001
]
[Cites]
Pancreas. 2007 Apr;34(3):340-6
[
17414057.001
]
[Cites]
Genes Dev. 2007 May 15;21(10):1231-43
[
17504940.001
]
[Cites]
Genes Dev. 2007 May 15;21(10):1244-57
[
17504941.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 May 15;104(20):8455-60
[
17494766.001
]
[Cites]
J Clin Invest. 2007 Jun;117(6):1575-84
[
17525797.001
]
[Cites]
Cell Cycle. 2006 Nov 1;5(21):2457-63
[
17102630.001
]
[Cites]
Nat Med. 2007 Aug;13(8):944-51
[
17632527.001
]
[Cites]
Oncogene. 2007 Aug 23;26(39):5752-61
[
17353902.001
]
[Cites]
Breast Cancer Res Treat. 2007 Oct;105(2):139-55
[
17295047.001
]
[Cites]
Nature. 2004 Oct 7;431(7009):707-12
[
15361885.001
]
[Cites]
Cancer Res. 2004 Oct 15;64(20):7545-52
[
15492281.001
]
[Cites]
Nature. 1980 Oct 30;287(5785):795-801
[
6776413.001
]
[Cites]
Medicine (Baltimore). 1987 Mar;66(2):98-113
[
3547011.001
]
[Cites]
Nature. 1988 Mar 24;332(6162):371-4
[
2832761.001
]
[Cites]
Mol Cell Biol. 1988 Aug;8(8):3104-13
[
2850480.001
]
[Cites]
Mol Cell Biol. 1990 Feb;10(2):634-42
[
2105456.001
]
[Cites]
Cell. 1992 Apr 3;69(1):111-7
[
1348213.001
]
[Cites]
Am J Med Genet. 1993 May 15;46(3):317-34
[
8488879.001
]
[Cites]
Cell. 1993 Dec 31;75(7):1401-16
[
8269518.001
]
[Cites]
Cell. 1993 Dec 31;75(7):1417-30
[
7916661.001
]
[Cites]
Cell. 1993 Dec 31;75(7):1431-44
[
8269519.001
]
[Cites]
Cell. 1994 Feb 25;76(4):761-75
[
8124714.001
]
[Cites]
Science. 1994 Dec 2;266(5190):1528-37
[
7985023.001
]
[Cites]
Nature. 1995 Mar 23;374(6520):363-6
[
7885476.001
]
[Cites]
Development. 1994 Nov;120(11):3339-53
[
7720571.001
]
[Cites]
Genes Dev. 1996 Feb 1;10(3):301-12
[
8595881.001
]
[Cites]
Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1571-6
[
8643673.001
]
[Cites]
Science. 1996 Jun 14;272(5268):1668-71
[
8658145.001
]
[Cites]
Cell. 1996 Jun 14;85(6):841-51
[
8681379.001
]
(PMID = 18604459.001).
[ISSN]
1745-7270
[Journal-full-title]
Acta biochimica et biophysica Sinica
[ISO-abbreviation]
Acta Biochim. Biophys. Sin. (Shanghai)
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA094160; United States / NCI NIH HHS / CA / R01 CA094160-06A2; United States / NCI NIH HHS / CA / CA94160
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
[Publication-country]
China
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Hedgehog Proteins
[Number-of-references]
149
[Other-IDs]
NLM/ NIHMS56053; NLM/ PMC2515624
65.
Koutlas IG, Koch CA, Vickers RA, Brouwers FM, Vortmeyer AO:
An unusual ostensible example of intraoral basal cell carcinoma.
J Cutan Pathol
; 2009 Apr;36(4):464-70
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
An unusual ostensible example of intraoral
basal cell carcinoma
.
An example of oral
basal cell carcinoma
is presented originating on the posterior mandibular mucosa and gingiva of a 67-year-old female.
Tissue samples of the tumor were evaluated with monoclonal antibody Ber-EP4 and were compared with examples of oral mucosa,
skin
, oral and cutaneous squamous
cell carcinoma
, peripheral ameloblastoma, ameloblastoma and cutaneous
basal cell carcinoma
(
BCC
).
Only neoplastic
basal
cells showed positive immunohistochemical staining.
PTCH gene mutations are reported in patients with Gorlin syndrome and sporadic cutaneous
BCCs
.
These observations support the inclusion of
BCC
in the differential
diagnosis of
appropriate oral mucosal neoplasms.
[MeSH-major]
Carcinoma
,
Basal Cell
/ pathology. Mouth Neoplasms / pathology.
Neoplasm
Recurrence, Local / pathology
[MeSH-minor]
Aged. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Loss of Heterozygosity. Receptors,
Cell
Surface / genetics
MedlinePlus Health Information.
consumer health - Oral Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19278434.001).
[ISSN]
1600-0560
[Journal-full-title]
Journal of cutaneous pathology
[ISO-abbreviation]
J. Cutan. Pathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Denmark
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Receptors, Cell Surface; 0 / human epithelial antigen-125; 0 / patched receptors
66.
Taneja S, Evans AJ, Rakha EA, Green AR, Ball G, Ellis IO:
The mammographic correlations of a new immunohistochemical classification of invasive breast cancer.
Clin Radiol
; 2008 Nov;63(11):1228-35
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The mammographic correlations of a new immunohistochemical classification of invasive
breast cancer
.
AIM: Recent protein expression profiling of
breast cancer
has identified specific subtypes with clinical, biological, and therapeutic implications.
The aim of this study was to identify the mammographic correlates of these novel molecular classes of invasive
breast cancer
.
MATERIALS AND METHODS: The mammographic findings of 415 patients with operable
breast cancer
were correlated with the previously described protein expression classes identified by our group using immunohistochemical (IHC) assessment of a large series of
breast cancer cases
prepared as tissue microarrays (TMAs).
Twenty-five proteins of known relevance in
breast cancer
were assessed, including hormone receptors, HER-2 status,
basal
and luminal markers, p53 expression, and E-cadherin.
Groups characterized by HER-2 overexpression,
basal
characteristics, and E-cadherin positivity had a significantly higher proportion of ill-defined masses.
CONCLUSION: The mammographic features of
breast cancer
show significant correlation with molecular classes of invasive
breast cancer
identified by protein expression IHC analysis.
[MeSH-major]
Biomarkers, Tumor / metabolism.
Breast
Neoplasms / metabolism.
Breast
Neoplasms / radiography
[MeSH-minor]
Adult. Aged. Cadherins / metabolism. Female. Humans. Lymphatic Metastasis. Mammography. Middle Aged.
Neoplasm
Invasiveness.
Neoplasm
Proteins / metabolism. Receptor, ErbB-2 / metabolism. Retrospective Studies. Tumor Suppressor Protein p53 / metabolism
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18929040.001).
[ISSN]
1365-229X
[Journal-full-title]
Clinical radiology
[ISO-abbreviation]
Clin Radiol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
67.
Rollison DE, Giuliano AR, Sellers TA, Laronga C, Sweeney C, Risendal B, Baumgartner KB, Byers T, Slattery ML:
Population-based case-control study of diabetes and breast cancer risk in Hispanic and non-Hispanic White women living in US southwestern states.
Am J Epidemiol
; 2008 Feb 15;167(4):447-56
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Population-based
case
-control study of diabetes and
breast cancer
risk in Hispanic and non-Hispanic White women living in US southwestern states.
Diabetes mellitus has been associated with
breast cancer
, although no studies appear to have adequately assessed the association in Hispanic women, a population with a high prevalence of diabetes.
The authors investigated this association in a population-based
case
-control study of Hispanic and non-Hispanic White women living in the southwestern United States.
Breast cancer cases
diagnosed in 1999-2004 were identified through state
cancer
registries (1,526 non-Hispanic Whites, 798 Hispanics).
Having any type of diabetes was not associated with
breast cancer
overall (odds ratio = 0.94, 95% confidence interval: 0.78, 1.12).
Type 2 diabetes was observed among 19% of Hispanics and 9% of non-Hispanic Whites but was not associated with
breast cancer
in either group.
Gestational diabetes was inversely associated with
breast cancer
in both ethnic groups, especially when first diagnosed at age < or =35 years (odds ratio = 0.54, 95% confidence interval: 0.37, 0.79).
In this study, diabetes was not associated with
breast cancer
overall, although the inverse association with gestational diabetes warrants further investigation.
Genetic Alliance.
consumer health - Diabetes
.
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Diabetes
.
MedlinePlus Health Information.
consumer health - Hispanic American Health
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Diabetes Care. 2003 Apr;26(4):1047-51
[
12663571.001
]
[Cites]
Breast Cancer Res Treat. 2008 Mar;108(1):129-35
[
17476589.001
]
[Cites]
Int J Epidemiol. 1999 Oct;28(5):816-23
[
10597976.001
]
[Cites]
J Natl Cancer Inst. 1970 Mar;44(3):673-86
[
11515436.001
]
[Cites]
JAMA. 2002 Jan 16;287(3):356-9
[
11790215.001
]
[Cites]
Cancer Causes Control. 2001 Dec;12(10):875-80
[
11808705.001
]
[Cites]
Am J Epidemiol. 2002 Aug 15;156(4):349-52
[
12181105.001
]
[Cites]
Cancer. 2004 Jan 1;100(1):149-55
[
14692035.001
]
[Cites]
Cancer Causes Control. 2004 Apr;15(3):267-75
[
15090721.001
]
[Cites]
Diabetes Care. 2004 May;27(5):1194-9
[
15111544.001
]
[Cites]
Am J Epidemiol. 2004 Jun 15;159(12):1160-7
[
15191933.001
]
[Cites]
Int J Cancer. 1974 Aug 15;14(2):153-60
[
4378317.001
]
[Cites]
J Chronic Dis. 1982;35(1):13-9
[
7068798.001
]
[Cites]
J Chronic Dis. 1985;38(5):435-41
[
3998058.001
]
[Cites]
Diabetes Metab Rev. 1990 Feb;6(1):29-45
[
2192854.001
]
[Cites]
Eur J Cancer. 1990;26(7):781-5
[
2145895.001
]
[Cites]
Int J Gynaecol Obstet. 1991 May;35(1):13-8
[
1680070.001
]
[Cites]
Diabetes Care. 1991 Jul;14(7):695-705
[
1914821.001
]
[Cites]
Am J Epidemiol. 1992 May 1;135(9):965-73
[
1595695.001
]
[Cites]
Epidemiology. 1994 Jan;5(1):102-8
[
8117767.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1995 Dec;4(8):807-11
[
8634649.001
]
[Cites]
Prev Med. 1997 Jan-Feb;26(1):144-53
[
9010910.001
]
[Cites]
Int J Cancer. 1997 May 2;71(3):360-3
[
9139868.001
]
[Cites]
Br J Cancer. 1997;75(11):1699-703
[
9184190.001
]
[Cites]
J Natl Cancer Inst. 1997 Sep 17;89(18):1360-5
[
9308706.001
]
[Cites]
Lancet. 1998 May 9;351(9113):1393-6
[
9593409.001
]
[Cites]
Diabetes. 1998 Aug;47(8):1302-10
[
9703332.001
]
[Cites]
Am J Epidemiol. 1998 Oct 1;148(7):683-92
[
9778175.001
]
[Cites]
Epidemiology. 1998 Nov;9(6):641-7
[
9799175.001
]
[Cites]
J Intern Med. 1997 Jun;241(6):471-5
[
10497622.001
]
[Cites]
JAMA. 2005 Jan 12;293(2):194-202
[
15644546.001
]
[Cites]
J Natl Cancer Inst. 2005 Mar 16;97(6):439-48
[
15770008.001
]
[Cites]
Br J Cancer. 2005 Jun 6;92(11):2070-5
[
15886700.001
]
[Cites]
Diabetes Care. 2006 Jun;29(6):1263-8
[
16732006.001
]
[Cites]
Asian Pac J Cancer Prev. 2006 Apr-Jun;7(2):253-9
[
16839219.001
]
[Cites]
Breast Cancer Res Treat. 2006 Aug;98(3):349-56
[
16541321.001
]
[Cites]
Arch Intern Med. 2006 Sep 25;166(17):1871-7
[
17000944.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):142-50
[
17220343.001
]
[Cites]
Cancer Causes Control. 2007 Jun;18(5):505-15
[
17437179.001
]
[Cites]
Int J Cancer. 2007 Aug 15;121(4):856-62
[
17397032.001
]
[Cites]
Breast Cancer Res Treat. 2007 Mar;102(1):85-101
[
17080310.001
]
[Cites]
Carcinogenesis. 2007 Jul;28(7):1561-6
[
17440036.001
]
[Cites]
Breast Cancer Res Treat. 2007 Aug;104(2):197-209
[
17051426.001
]
[Cites]
Diabetes Care. 2003 Jun;26(6):1752-8
[
12766105.001
]
(PMID = 18033764.001).
[ISSN]
1476-6256
[Journal-full-title]
American journal of epidemiology
[ISO-abbreviation]
Am. J. Epidemiol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA078682-07; United States / NCI NIH HHS / CA / CA078682; United States / NCI NIH HHS / CA / R01 CA078552; United States / NCI NIH HHS / CA / R01 CA078762; United States / NCI NIH HHS / CA / CA078682-07; United States / NCI NIH HHS / CA / R01 CA078802; United States / NCI NIH HHS / CA / R01 CA078682; United States / NCI NIH HHS / CA / CA078552; United States / NCI NIH HHS / PC / N01-PC-67000; United States / NCI NIH HHS / CA / CA078762; United States / NCI NIH HHS / CA / CA078802
[Publication-type]
Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
[Other-IDs]
NLM/ NIHMS50878; NLM/ PMC2925515
68.
Centers for Disease Control and Prevention (CDC):
Decline in breast cancer incidence--United States, 1999-2003.
MMWR Morb Mortal Wkly Rep
; 2007 Jun 8;56(22):549-53
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Decline in
breast cancer
incidence--United States, 1999-2003.
Breast cancer
is the most commonly diagnosed
cancer
among females in the United States.
The 2006 Annual Report to the Nation on the Status of
Cancer
described a stabilization in female
breast cancer
incidence rates during 2001-2003, ending increases that began in the 1980s, and a decline in the number of
breast cancer cases
diagnosed in 2003.
In addition, researchers who used 1990-2003 data from the National
Cancer
Institute's (NCI's) Surveillance, Epidemiology, and End Results (SEER) program, representing approximately 14% of the U.S. population, reported a 7% decrease in invasive
breast cancer
rates from 2002 to 2003.
To further assess
breast cancer
annual incidence rates during 1999-2003, CDC analyzed data collected by CDC's National Program of
Cancer
Registries (NPCR) and the NCI SEER program.
The results of this analysis indicated that age-adjusted incidence rates for invasive
breast cancer
decreased each year during 1999-2003, with the greatest decrease (6.1%) occurring from 2002 to 2003; women aged > or = 50 years experienced a significant decrease during this period.
Rates of in situ (i.e., noninvasive)
breast cancer
increased each year during 1999-2002 and then decreased from 2002 to 2003; women aged 50-79 years experienced a significant decrease during this period.
[MeSH-major]
Breast
Neoplasms / epidemiology
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17557070.001).
[ISSN]
1545-861X
[Journal-full-title]
MMWR. Morbidity and mortality weekly report
[ISO-abbreviation]
MMWR Morb. Mortal. Wkly. Rep.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
69.
Sellers TA, Jensen LE, Vierkant RA, Fredericksen ZS, Brandt KR, Giuliano AR, Pankratz VS, Cerhan JR, Vachon CM:
Association of diabetes with mammographic breast density and breast cancer in the Minnesota breast cancer family study.
Cancer Causes Control
; 2007 Jun;18(5):505-15
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Association of diabetes with mammographic
breast
density and
breast cancer
in the Minnesota
breast cancer
family study.
Data from the Minnesota
Breast Cancer
Family Study cohort (n=6,130 women) were used to examine the association of type II diabetes with mammographic percent density and incident
breast cancer
(BC).
The first set of analyses evaluated diabetes (DM) as a risk factor for
breast cancer
.
A total of 403 women (6.6%) reported a
diagnosis of
type II diabetes and 333 women reported an incident
breast cancer
.
Women who reported type II diabetes had an age-adjusted relative risk (RR) for
breast cancer
of 1.44 (95% CI 0.89-2.32) compared to those who did not.
Breast cancer cases
with diabetes did not have a significantly higher percent density than
cases
without diabetes.
Our findings suggest that
breast cancer
risk may be increased among women with type II diabetes, but that type II diabetes does not significantly influence mammographic
breast
density.
[MeSH-major]
Breast
Neoplasms / complications.
Breast
Neoplasms / epidemiology. Diabetes Mellitus, Type 2 / epidemiology. Mammography
Genetic Alliance.
consumer health - Diabetes
.
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Diabetes Type 2
.
MedlinePlus Health Information.
consumer health - Mammography
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17437179.001).
[ISSN]
0957-5243
[Journal-full-title]
Cancer causes & control : CCC
[ISO-abbreviation]
Cancer Causes Control
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Netherlands
70.
Rajadhyaksha M:
Confocal microscopy of skin cancers: translational advances toward clinical utility.
Conf Proc IEEE Eng Med Biol Soc
; 2009;2009:3231-3
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Confocal microscopy
of skin
cancers: translational advances toward clinical utility.
Recent advances in translational research in and technology for confocal microscopy
of skin
cancers, toward clinical applications, are described.
Advances in translational research are in
diagnosis of
melanoma in vivo, pre-operative mapping of lentigo maligna melanoma margins to guide surgery and intra-operative imaging of residual
basal cell
carcinomas
to guide shave-biopsy.
Advances in technology include mosaicing microscopy for detection
of basal cell
carcinomas
in large areas of excised tissue, toward rapid pathology-at-the-bedside, and development of small, simple and low-cost line-scanning confocal microscopes for worldwide use in diverse primary healthcare settings.
[MeSH-major]
Microscopy, Confocal / methods.
Skin
Neoplasms /
diagnosis
.
Skin
Neoplasms / pathology
[MeSH-minor]
Algorithms. Biopsy. Dermatology / instrumentation. Dermatology / methods. Dermoscopy / methods. Equipment Design. Humans. Hutchinson's Melanotic Freckle /
diagnosis
. Hutchinson's Melanotic Freckle / pathology. Melanoma /
diagnosis
. Melanoma / pathology. Reproducibility of Results. Sensitivity and Specificity. Ultraviolet Rays
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Appl Opt. 2007 Apr 1;46(10):1843-51
[
17356629.001
]
[Cites]
J Am Acad Dermatol. 2007 Oct;57(4):644-58
[
17630045.001
]
[Cites]
J Invest Dermatol. 2007 Dec;127(12):2759-65
[
17657243.001
]
[Cites]
J Biomed Opt. 2008 Sep-Oct;13(5):054001
[
19021381.001
]
[Cites]
J Invest Dermatol. 2009 Jan;129(1):131-8
[
18633444.001
]
[Cites]
J Microsc. 2009 Jan;233(1):149-59
[
19196421.001
]
[Cites]
Opt Lett. 2006 Apr 1;31(7):942-4
[
16599219.001
]
[Cites]
J Biomed Opt. 2009 May-Jun;14(3):034012
[
19566305.001
]
[Cites]
J Biomed Opt. 2009 May-Jun;14(3):034050
[
19566342.001
]
[Cites]
Arch Dermatol. 2001 Jul;137(7):923-9
[
11453812.001
]
[Cites]
J Am Acad Dermatol. 2004 Dec;51(6):923-30
[
15583584.001
]
[Cites]
Br J Dermatol. 2005 Nov;153(5):1031-6
[
16225620.001
]
[Cites]
Br J Dermatol. 2009 Jun;160(6):1242-50
[
19416248.001
]
(PMID = 19964286.001).
[ISSN]
1557-170X
[Journal-full-title]
Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
[ISO-abbreviation]
Conf Proc IEEE Eng Med Biol Soc
[Language]
eng
[Grant]
United States / NIBIB NIH HHS / EB / R01 EB002715; United States / NIBIB NIH HHS / EB / R01EB002715; United States / NCI NIH HHS / CA / R43 CA093106; United States / NIBIB NIH HHS / EB / R01EB006947; United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / R44 CA093106; United States / NIBIB NIH HHS / EB / R01 EB006947
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Other-IDs]
NLM/ NIHMS582452; NLM/ PMC4040219
71.
Aulmann C, Seufert P, Sandherr M, Schlimok G, Schulze R, Oruzio D:
[A 65-year-old female patient with breast cancer accompanied by thrombocytopenia and hyperfibrinolysis].
Internist (Berl)
; 2007 Sep;48(9):1015-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[A 65-year-old female patient with
breast cancer
accompanied by thrombocytopenia and hyperfibrinolysis].
Low platelet counts and hyperfibrinolysis led to the
diagnosis of
recurrent
breast cancer
in this
case
.
A tumour
disease
with disturbed hemostasis caused by both plasmatic coagulation and thrombocytopenia has not yet been reported.
[MeSH-major]
Breast
Neoplasms / complications.
Breast
Neoplasms /
diagnosis
. Fibrinolysis. Hemorrhagic Disorders / complications. Hemorrhagic Disorders /
diagnosis
. Thrombocytopenia / complications. Thrombocytopenia /
diagnosis
[MeSH-minor]
Aged. Female. Humans. Paraneoplastic Syndromes / complications. Paraneoplastic Syndromes /
diagnosis
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Clin Oncol. 1999 Aug;22(4):411-3
[
10440202.001
]
[Cites]
South Med J. 2002 Nov;95(11):1335-7
[
12540004.001
]
[Cites]
Thromb Haemost. 2001 Sep;86(3):828-33
[
11583315.001
]
[Cites]
Am J Clin Pathol. 1979 Jan;71(1):10-6
[
420161.001
]
[Cites]
Am J Clin Oncol. 2000 Feb;23(1):74-7
[
10683084.001
]
[Cites]
Respir Med. 2004 Feb;98(2):93-8
[
14971870.001
]
[Cites]
Semin Thromb Hemost. 1996;22(6):459-78
[
9122711.001
]
[Cites]
J Cancer Res Clin Oncol. 1997;123(10):555-9
[
9393589.001
]
[Cites]
Jpn J Clin Oncol. 2001 Aug;31(8):388-94
[
11574632.001
]
[Cites]
N Engl J Med. 1994 Nov 3;331(18):1207-11
[
7935660.001
]
[Cites]
Blood Coagul Fibrinolysis. 2004 Jan;15(1):9-13
[
15166937.001
]
(PMID = 17704902.001).
[ISSN]
0020-9554
[Journal-full-title]
Der Internist
[ISO-abbreviation]
Internist (Berl)
[Language]
ger
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Germany
72.
Mosterd K, Arits AH, Thissen MR, Kelleners-Smeets NW:
Histology-based treatment of basal cell carcinoma.
Acta Derm Venereol
; 2009;89(5):454-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Histology-based treatment
of basal cell carcinoma
.
Basal cell carcinoma
is the most common type
of skin
cancer
and its incidence is still rising.
Selection criteria were histological subtype, primary or recurrent
basal cell carcinoma
and tumour localization.
Although surgery remains the preferred treatment for most
basal cell
carcinomas
, patient and tumour characteristics should be taken into account when choosing the most suitable treatment.
[MeSH-major]
Antineoplastic Agents / therapeutic use.
Carcinoma
,
Basal Cell
/ pathology.
Carcinoma
,
Basal Cell
/ therapy. Cryotherapy. Mohs Surgery. Photochemotherapy.
Skin
Neoplasms / pathology.
Skin
Neoplasms / therapy
[MeSH-minor]
Evidence-Based Medicine. Humans.
Neoplasm
Invasiveness. Patient Selection. Randomized Controlled Trials as Topic. Treatment Outcome
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Acta Derm Venereol. 2009;89(5):450-2
[
19734965.001
]
[ErratumIn]
Acta Derm Venereol. 2009 Nov;89(6):667
(PMID = 19734968.001).
[ISSN]
1651-2057
[Journal-full-title]
Acta dermato-venereologica
[ISO-abbreviation]
Acta Derm. Venereol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
Sweden
[Chemical-registry-number]
0 / Antineoplastic Agents
[Number-of-references]
36
73.
Venkatesan A:
Pigmented lesions of the vulva.
Dermatol Clin
; 2010 Oct;28(4):795-805
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Given the risk of melanomas and pigmented vulvar intraepithelial neoplasia (squamous
cell carcinoma
in situ), proper evaluation of vulvar pigmented lesions is critical.
[MeSH-major]
Condylomata Acuminata / pathology. Nevus, Pigmented / pathology.
Skin
Neoplasms /
diagnosis
.
Skin
Neoplasms / pathology. Vulva / pathology. Vulvar Diseases / pathology. Vulvar Neoplasms / pathology
[MeSH-minor]
Acanthosis Nigricans.
Carcinoma
in Situ /
diagnosis
.
Carcinoma
in Situ / pathology.
Carcinoma
,
Basal Cell
/ pathology.
Carcinoma
, Squamous
Cell
/
diagnosis
.
Carcinoma
, Squamous
Cell
/ pathology.
Diagnosis
, Differential. Female. Humans. Hyperpigmentation. Keratosis, Seborrheic. Melanoma /
diagnosis
. Melanoma / pathology. Melanosis. Pigmentation Disorders
MedlinePlus Health Information.
consumer health - Genital Warts
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
MedlinePlus Health Information.
consumer health - Vulvar Cancer
.
MedlinePlus Health Information.
consumer health - Vulvar Disorders
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright © 2010 Elsevier Inc. All rights reserved.
(PMID = 20883921.001).
[ISSN]
1558-0520
[Journal-full-title]
Dermatologic clinics
[ISO-abbreviation]
Dermatol Clin
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
74.
Megehee JA, Hosler JP, Lundrigan MD:
Evidence for a cytochrome bcc-aa3 interaction in the respiratory chain of Mycobacterium smegmatis.
Microbiology
; 2006 Mar;152(Pt 3):823-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Evidence for a cytochrome
bcc
-aa3 interaction in the respiratory chain of Mycobacterium smegmatis.
Spectroscopic analysis of membranes isolated from Mycobacterium smegmatis, along with analysis of its genome, indicates that the cytochrome c branch of its respiratory pathway consists of a modified bc1
complex
that contains two cytochromes c in its c1 subunit, similar to other acid-fast bacteria, and an aa3-type cytochrome c oxidase.
A functional association of the cytochrome
bcc
and aa3 complexes was indicated by the findings that levels of detergent sufficient to completely disrupt isolated membranes failed to inhibit quinol-driven O2 reduction, but known inhibitors of the bc1
complex
did inhibit quinol-driven O2 reduction.
However, high
concentrations
of monovalent salts had no effect on O2 reduction, suggesting that ionic interactions between extramembrane domains do not play the major role in stabilizing
the bcc
-aa3 interaction.
The results indicate that hydrophobic interactions are the primary forces maintaining
the bcc
-aa3 interaction, but ionic interactions may assist in aligning the two complexes for efficient electron transfer.
[MeSH-major]
Electron Transport
Complex
III / metabolism. Electron Transport
Complex
IV / metabolism. Mycobacterium smegmatis / physiology
[MeSH-minor]
Cell
Membrane / enzymology. Electron Transport. Hydrophobic and Hydrophilic Interactions. Oxygen Consumption
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16514162.001).
[ISSN]
1350-0872
[Journal-full-title]
Microbiology (Reading, England)
[ISO-abbreviation]
Microbiology (Reading, Engl.)
[Language]
eng
[Grant]
United States / NIGMS NIH HHS / GM / GM56824
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
England
[Chemical-registry-number]
EC 1.10.2.2 / Electron Transport Complex III; EC 1.9.3.1 / Electron Transport Complex IV
75.
Jahagirdar SS, Thakre TP, Kale SM, Kulkarni H, Mamtani M:
A clinicopathological study of eyelid malignancies from central India.
Indian J Ophthalmol
; 2007 Mar-Apr;55(2):109-12
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The treatment depends on the invasiveness of
the cancer
which in turn depends on the type of malignancy.
MATERIALS AND METHODS: We report a series of 27
cases
of eyelid malignancies.
In the same
case
series, we also include
a case
of
malignant
hemangiopericytoma which is an extremely rare form of eyelid malignancy worldwide.
RESULTS: We observed that sebaceous
cell carcinoma
(approximately 37%) was almost as prevalent as
basal cell carcinoma
(approximately 44%) in the study subjects and had an earlier age of occurrence and a more rapid clinical course.
CONCLUSIONS: Sebaceous
cell carcinoma
of the eyelid is almost as common as
basal cell carcinoma
in a large tertiary care centre in central India.
[MeSH-minor]
Adenocarcinoma, Sebaceous / epidemiology. Adenocarcinoma, Sebaceous / pathology. Adenocarcinoma, Sebaceous / surgery. Biopsy, Fine-Needle.
Carcinoma
,
Basal Cell
/ epidemiology.
Carcinoma
,
Basal Cell
/ pathology.
Carcinoma
,
Basal Cell
/ surgery.
Carcinoma
, Squamous
Cell
/ epidemiology.
Carcinoma
, Squamous
Cell
/ pathology.
Carcinoma
, Squamous
Cell
/ surgery.
Diagnosis
, Differential. Female. Hemangiopericytoma / epidemiology. Hemangiopericytoma / pathology. Hemangiopericytoma / surgery. Humans. India / epidemiology. Male. Middle Aged.
Neoplasm
Staging. Ophthalmologic Surgical Procedures / methods. Prevalence. Prognosis. Retrospective Studies
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17322599.001).
[ISSN]
0301-4738
[Journal-full-title]
Indian journal of ophthalmology
[ISO-abbreviation]
Indian J Ophthalmol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
India
76.
Zarineh A, Kozovska ME, Brown WG, Elder DE, Rabkin MS:
Smooth muscle hamartoma associated with a congenital pattern melanocytic nevus, a case report and review of the literature.
J Cutan Pathol
; 2008 Oct;35 Suppl 1:83-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Smooth muscle hamartoma associated with a congenital pattern melanocytic nevus,
a case
report and review of the literature.
Unlike a recently reported
case
of SMH combined with a melanocytic nevus and
basal cell carcinoma
, the current lesion did not occur in association with a Becker's nevus.
[MeSH-minor]
Actins / metabolism. Antigens,
Neoplasm
/ metabolism. Calmodulin-Binding Proteins / metabolism. Humans. Immunohistochemistry. MART-1 Antigen. Male. Melanoma-Specific Antigens. Middle Aged.
Neoplasm
Proteins / metabolism
Genetic Alliance.
consumer health - Nevus
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright Blackwell Munksgaard 2008.
(PMID = 18544054.001).
[ISSN]
1600-0560
[Journal-full-title]
Journal of cutaneous pathology
[ISO-abbreviation]
J. Cutan. Pathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Denmark
[Chemical-registry-number]
0 / Actins; 0 / Antigens, Neoplasm; 0 / Calmodulin-Binding Proteins; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
77.
Kolár Z, Geierová M, Bouchal J, Pazdera J, Zboril V, Tvrdý P:
Immunohistochemical analysis of the biological potential of odontogenic keratocysts.
J Oral Pathol Med
; 2006 Feb;35(2):75-80
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
RESULTS: Nevoid
basal cell carcinoma
syndrome (NBCCS) keratocysts were characterized by higher expression of Bcl-2, p27Kip1 and c-erbB-2 as well as by lower proliferative activity measured by Ki-67 in
basal cell
epithelium and by a lower inflammatory response in comparison with sporadic keratocysts.
Dentigerous, radicular and non-specified odontogenic cysts differed from both NBCCS and sporadic keratocysts in a wide spectrum of apoptosis and/or
cell
cycle-related protein expressions, higher proliferation in the
basal cell
layer, and vice versa, lower proliferation in the suprabasal
cell
layer.
[MeSH-minor]
Apoptosis / physiology. Apoptosis Regulatory Proteins / analysis.
Basal Cell
Nevus Syndrome / metabolism.
Basal Cell
Nevus Syndrome / pathology. Biology. Biomarkers / analysis.
Cell
Cycle Proteins / analysis.
Cell
Proliferation. Cyclin-Dependent Kinase Inhibitor p27 / analysis. Dentigerous Cyst / chemistry. Dentigerous Cyst / pathology.
Diagnosis
, Differential. Epithelium / chemistry. Epithelium / pathology. Humans. Immunohistochemistry. Immunophenotyping. Ki-67 Antigen / analysis. Prognosis. Protein Kinase Inhibitors / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Radicular Cyst / chemistry. Radicular Cyst / pathology. Receptor, ErbB-2 / analysis
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16430736.001).
[ISSN]
0904-2512
[Journal-full-title]
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
[ISO-abbreviation]
J. Oral Pathol. Med.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Denmark
[Chemical-registry-number]
0 / Apoptosis Regulatory Proteins; 0 / Biomarkers; 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins c-bcl-2; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.7.10.1 / Receptor, ErbB-2
78.
Thievessen I, Wolter M, Prior A, Seifert HH, Schulz WA:
Hedgehog signaling in normal urothelial cells and in urothelial carcinoma cell lines.
J Cell Physiol
; 2005 May;203(2):372-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Hedgehog signaling in normal urothelial cells and in urothelial
carcinoma cell
lines.
Constitutive activation of hedgehog signaling, often caused by PTCH1 inactivation and leading to inappropriate activation of GLI target genes, is crucial for the development of several human tumors including
basal cell carcinoma of
the
skin
and medulloblastoma.
The PTCH1 gene at 9q22 is also considered as a candidate tumor suppressor in transitional
cell carcinoma
(TCC), of which >50% show LOH in this region.
We have therefore investigated GLI-dependent promoter activity and expression of hedgehog pathway components in TCC
cell
lines and proliferating normal urothelial cells.
[MeSH-major]
Carcinoma
, Transitional
Cell
/ metabolism.
Cell
Transformation, Neoplastic / metabolism. Gene Expression Regulation, Neoplastic / physiology. Signal Transduction / physiology. Trans-Activators / metabolism. Urinary Bladder Neoplasms / metabolism. Urothelium / metabolism
[MeSH-minor]
Cell
Line, Tumor.
Cell
Proliferation / drug effects. Genes, Tumor Suppressor. Hedgehog Proteins. Humans. Membrane Proteins / genetics. Membrane Proteins / metabolism. Promoter Regions, Genetic / genetics. RNA, Messenger / metabolism. Receptors,
Cell
Surface / genetics. Receptors,
Cell
Surface / metabolism. Transcription Factors / genetics. Transcription Factors / metabolism. Veratrum Alkaloids / pharmacology
MedlinePlus Health Information.
consumer health - Bladder Cancer
.
Hazardous Substances Data Bank.
CYCLOPAMINE
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2004 Wiley-Liss, Inc.
(PMID = 15521068.001).
[ISSN]
0021-9541
[Journal-full-title]
Journal of cellular physiology
[ISO-abbreviation]
J. Cell. Physiol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / SHH protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Veratrum Alkaloids; 0 / patched receptors; ZH658AJ192 / cyclopamine
79.
Turkovic L, Gurrin LC, Bahlo M, Dite GS, Southey MC, Hopper JL:
Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age.
BMC Cancer
; 2010;10:466
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with
breast cancer
before 40 years of age.
BACKGROUND: BRCA1 and BRCA2 mutations are found in a proportion of families with multiple early-onset
breast
cancers.
METHODS: DNA sequence data for BRCA1 and BRCA2 was obtained from 571 participants from the Australian
Breast Cancer
Family Study.
CONCLUSIONS: We observed differences in the frequency of common genetic variants of the BRCA1 and BRCA2 and their haplotypes between early-onset
breast cancer cases
who did and did not carry deleterious mutations in these genes.
[MeSH-major]
BRCA1 Protein / genetics. BRCA2 Protein / genetics.
Breast
Neoplasms / genetics. Genetic Predisposition to
Disease
. Germ-Line Mutation / genetics. Haplotypes / genetics. Polymorphism, Genetic / genetics
[MeSH-minor]
Adolescent. Adult. Australia.
Case
-Control Studies. Female. Founder Effect. Humans. Middle Aged.
Neoplasm
Staging. Prognosis. Risk Factors. Survival Rate. Young Adult
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Genome Res. 2001 Jan;11(1):143-51
[
11156623.001
]
[Cites]
Breast Cancer Res Treat. 2009 Jul;116(2):379-86
[
18704680.001
]
[Cites]
Am J Hum Genet. 2002 Feb;70(2):425-34
[
11791212.001
]
[Cites]
Hum Mutat. 2002 Jul;20(1):65-73
[
12112659.001
]
[Cites]
J Natl Cancer Inst. 2003 Mar 19;95(6):448-57
[
12644538.001
]
[Cites]
Eur J Hum Genet. 2003 Jun;11(6):489-92
[
12774043.001
]
[Cites]
Am J Hum Genet. 2003 Nov;73(5):1162-9
[
14574645.001
]
[Cites]
Am J Hum Genet. 2004 Jan;74(1):106-20
[
14681826.001
]
[Cites]
Am J Hum Genet. 2004 Jul;75(1):35-43
[
15148658.001
]
[Cites]
Hum Mol Genet. 2004 Oct 15;13(20):2431-41
[
15317758.001
]
[Cites]
Hum Mol Genet. 1997 Feb;6(2):285-9
[
9063749.001
]
[Cites]
J Natl Cancer Inst. 1998 Apr 1;90(7):532-6
[
9539249.001
]
[Cites]
Bioinformatics. 2005 Jan 15;21(2):263-5
[
15297300.001
]
[Cites]
Breast Cancer Res. 2005;7(2):R171-5
[
15743496.001
]
[Cites]
Cancer Res. 2005 Aug 15;65(16):7516-22
[
16103107.001
]
[Cites]
Am J Hum Genet. 2001 Apr;68(4):978-89
[
11254454.001
]
(PMID = 20807450.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / BRCA1 Protein; 0 / BRCA1 protein, human; 0 / BRCA2 Protein; 0 / BRCA2 protein, human
[Other-IDs]
NLM/ PMC2940805
80.
Silva Idos S, De Stavola B, McCormack V, Collaborative Group on Pre-Natal Risk Factors and Subsequent Risk of Breast Cancer:
Birth size and breast cancer risk: re-analysis of individual participant data from 32 studies.
PLoS Med
; 2008 Sep 30;5(9):e193
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Birth size and
breast cancer
risk:
re
-analysis of individual participant data from 32 studies.
BACKGROUND: Birth size, perhaps a proxy for prenatal environment, might be a correlate of subsequent
breast cancer
risk, but findings from epidemiological studies have been inconsistent.
We
re
-analysed individual participant data from published and unpublished studies to obtain more precise estimates of the magnitude and shape of the birth size-
breast cancer
association.
Individual participant data from 32 studies, comprising 22,058
breast cancer cases
, were obtained.
Birth weight was positively associated with
breast cancer
risk in studies based on birth records (pooled relative risk [RR] per one standard deviation [SD] [= 0.5 kg] increment in birth weight: 1.06; 95% confidence interval [CI] 1.02-1.09) and parental recall when the participants were children (1.02; 95% CI 0.99-1.05), but not in those based on adult self-reports, or maternal recall during the woman's adulthood (0.98; 95% CI 0.95-1.01) (p for heterogeneity between data sources = 0.003).
Birth length and head circumference from birth records were also positively associated with
breast cancer
risk (pooled RR per one SD increment: 1.06 [95% CI 1.03-1.10] and 1.09 [95% CI 1.03-1.15], respectively).
The birth size effects did not appear to be confounded or mediated by established
breast cancer
risk factors and were not modified by age or menopausal status.
The cumulative incidence of
breast cancer
per 100 women by age 80 y in the study populations was estimated to be 10.0, 10.0, 10.4, and 11.5 in those who were, respectively, in the bottom, second, third, and top fourths of the birth length distribution.
CONCLUSIONS: This pooled analysis of individual participant data is consistent with birth size, and in particular birth length, being an independent correlate of
breast cancer
risk in adulthood.
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Birth Weight
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Br J Cancer. 2003 Nov 3;89(9):1664-6
[
14583767.001
]
[Cites]
Int J Cancer. 2003 Dec 20;107(6):997-1000
[
14601061.001
]
[Cites]
Br J Cancer. 2004 Nov 1;91(9):1666-8
[
15477861.001
]
[Cites]
Br J Cancer. 1988 Apr;57(4):437-9
[
3390382.001
]
[Cites]
Lancet. 1990 Apr 21;335(8695):939-40
[
1970028.001
]
[Cites]
Lancet. 1992 Oct 24;340(8826):1015-8
[
1357410.001
]
[Cites]
Biometrics. 1992 Sep;48(3):795-806
[
1420842.001
]
[Cites]
Epidemiology. 1996 Jan;7(1):34-7
[
8664398.001
]
[Cites]
Lancet. 1996 Dec 7;348(9041):1542-6
[
8950880.001
]
[Cites]
J Natl Cancer Inst. 1997 Jan 1;89(1):71-6
[
8978409.001
]
[Cites]
J Pediatr Gastroenterol Nutr. 1997 May;24(5):497-505
[
9161941.001
]
[Cites]
J Clin Endocrinol Metab. 1997 Oct;82(10):3281-4
[
9329354.001
]
[Cites]
Paediatr Perinat Epidemiol. 1998 Oct;12(4):397-407
[
9805713.001
]
[Cites]
J Clin Endocrinol Metab. 1999 Mar;84(3):1145-8
[
10084609.001
]
[Cites]
Am J Epidemiol. 1999 Apr 15;149(8):726-9
[
10206622.001
]
[Cites]
Cancer Causes Control. 1999 Feb;10(1):85-94
[
10334647.001
]
[Cites]
Pediatr Nurs. 1999 Jan-Feb;25(1):13-7
[
10335245.001
]
[Cites]
Breast Cancer Res. 2004;6(6):R656-67
[
15535848.001
]
[Cites]
Int J Cancer. 2005 Apr 10;114(3):461-4
[
15551343.001
]
[Cites]
Int J Cancer. 2005 Jul 1;115(4):611-7
[
15700315.001
]
[Cites]
Diabetologia. 2005 Sep;48(9):1736-42
[
16052327.001
]
[Cites]
Cancer Causes Control. 2006 May;17(4):395-401
[
16596291.001
]
[Cites]
Am J Epidemiol. 2006 Jun 1;163(11):1053-64
[
16624970.001
]
[Cites]
Br J Cancer. 2006 Jun 5;94(11):1734-7
[
16641898.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1469-72
[
16896034.001
]
[Cites]
Obesity (Silver Spring). 2006 Jul;14(7):1257-63
[
16899807.001
]
[Cites]
Int J Cancer. 2006 Nov 1;119(9):2136-41
[
16804898.001
]
[Cites]
Int J Cancer. 2006 Nov 1;119(9):2007-25
[
16823839.001
]
[Cites]
Trends Endocrinol Metab. 2006 Nov;17(9):340-8
[
16997567.001
]
[Cites]
Carcinogenesis. 2006 Dec;27(12):2464-8
[
16777984.001
]
[Cites]
Breast Cancer Res. 2007;9(3):R29
[
17501995.001
]
[Cites]
Int J Cancer. 2008 Feb 1;122(3):481-5
[
18022897.001
]
[Cites]
Lancet Oncol. 2007 Dec;8(12):1088-100
[
18054879.001
]
[Cites]
Epidemiology. 2008 Mar;19(2):197-203
[
18300695.001
]
[Cites]
Breast Cancer Res. 2008;10(1):R8
[
18205956.001
]
[Cites]
Pediatr Res. 1999 Nov;46(5):491-5
[
10541308.001
]
[Cites]
Epidemiology. 2000 May;11(3):315-9
[
10784250.001
]
[Cites]
J Natl Cancer Inst. 2000 May 17;92(10):840-1
[
10814680.001
]
[Cites]
Br J Cancer. 2000 Oct;83(7):964-8
[
10970703.001
]
[Cites]
Am J Epidemiol. 2000 Sep 15;152(6):514-27
[
10997541.001
]
[Cites]
J Natl Cancer Inst. 2001 Jan 3;93(1):60-2
[
11136844.001
]
[Cites]
Int J Cancer. 2001 Jan 15;91(2):248-51
[
11146453.001
]
[Cites]
Am J Epidemiol. 2000 Dec 15;152(12):1121-8
[
11130617.001
]
[Cites]
Br J Cancer. 2001 May 4;84(9):1193-8
[
11336470.001
]
[Cites]
Stat Med. 2001 Jul 30;20(14):2115-30
[
11439425.001
]
[Cites]
Acta Obstet Gynecol Scand. 2001 Oct;80(10):931-6
[
11580738.001
]
[Cites]
Br J Cancer. 2001 Nov 30;85(11):1680-4
[
11742488.001
]
[Cites]
Br J Cancer. 2002 Jan 7;86(1):84-8
[
11857016.001
]
[Cites]
Br J Cancer. 2002 Jan 7;86(1):89-91
[
11857017.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2002 Feb;11(2):207-10
[
11867509.001
]
[Cites]
Pediatrics. 2002 Jun;109(6):1131-5
[
12042554.001
]
[Cites]
Semin Perinatol. 2002 Aug;26(4):260-7
[
12211616.001
]
[Cites]
Br J Cancer. 2002 Nov 18;87(11):1234-45
[
12439712.001
]
[Cites]
Am J Epidemiol. 2003 Feb 1;157(3):258-66
[
12543626.001
]
[Cites]
J Clin Endocrinol Metab. 2003 Dec;88(12):5656-60
[
14671149.001
]
[Cites]
Br J Cancer. 2004 Aug 2;91(3):519-24
[
15266328.001
]
[Cites]
Obstet Gynecol. 2004 Oct;104(4):671-7
[
15458884.001
]
[Cites]
Obstet Gynecol. 2004 Oct;104(4):720-6
[
15458892.001
]
[Cites]
N Engl J Med. 2004 Oct 14;351(16):1619-26
[
15483280.001
]
[Cites]
BMJ. 2003 Feb 1;326(7383):248
[
12560272.001
]
[Cites]
Breast Cancer Res. 2003;5(1):42-4
[
12559045.001
]
[Cites]
Cancer Causes Control. 2003 Feb;14(1):61-4
[
12708726.001
]
[Cites]
Cancer Causes Control. 2003 May;14(4):347-55
[
12846366.001
]
[Cites]
BMJ. 2003 Sep 6;327(7414):557-60
[
12958120.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):860-5
[
14504195.001
]
[CommentIn]
PLoS Med. 2008 Sep 30;5(9):e194
[
18828668.001
]
(PMID = 18828667.001).
[ISSN]
1549-1676
[Journal-full-title]
PLoS medicine
[ISO-abbreviation]
PLoS Med.
[Language]
ENG
[Grant]
United Kingdom / Cancer Research UK / / C14292/A5609; United Kingdom / Cancer Research UK / / C150/A5660
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Other-IDs]
NLM/ PMC2553821
81.
Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE:
Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women.
J Natl Cancer Inst
; 2006 Oct 4;98(19):1406-15
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Endogenous steroid hormone
concentrations
and risk of
breast cancer
among premenopausal women.
BACKGROUND: Higher levels of endogenous sex steroid hormones are associated with increased risks of
breast cancer
in postmenopausal women.
We prospectively evaluated associations between plasma sex hormone levels and
breast cancer
risk among premenopausal women in
a case
-control study nested within the Nurses' Health Study II.
A total of 197
cases
of
breast cancer
were diagnosed among these women after blood collection and before June 1, 2003; these
case
subjects were matched to 394 control subjects.
Logistic regression models, controlling for
breast cancer
risk factors, were used to calculate relative risks (RRs) and 95% confidence intervals (CIs).
RESULTS: Women in the highest (versus the lowest) quartiles of follicular total and free estradiol levels had statistically significantly increased risks of
breast cancer
(RR = 2.1 [95% CI = 1.1 to 4.1], P(trend) = .08, and RR = 2.4 [95% CI = 1.3 to 4.5], P(trend) = .01, respectively); the associations were stronger for invasive
breast cancer
and for estrogen and progesterone receptor-positive (ER+/PR+) tumors.
Luteal estradiol levels were not associated with
breast cancer
risk.
Higher levels of total and free testosterone and androstenedione in both menstrual cycle phases were associated with modest, non-statistically significant increases in overall risk of
breast cancer
and with stronger, statistically significant increases in risks of invasive and ER+/PR+ cancers (e.g., RR of invasive cancers for the top [versus bottom] quartile of luteal total testosterone levels = 2.0 [95% CI = 1.1 to 3.6], P(trend) = .05, and RR of ER+/PR+ cancers = 2.9 [95% CI = 1.4 to 6.0], P(trend) = .02).
Levels of estrone, estrone sulfate, progesterone, and sex hormone-binding globulin were not associated with
breast cancer
risk.
The absolute number of
cases
observed over 3 years were 30 among women in the lowest 25% of follicular total estradiol levels and 50 among women in the highest 25%.
CONCLUSIONS: Levels of circulating estrogens and androgens may be important in the etiology of premenopausal
breast cancer
.
[MeSH-major]
Breast
Neoplasms / epidemiology.
Breast
Neoplasms / metabolism. Gonadal Steroid Hormones / blood. Premenopause
[MeSH-minor]
Adult. Androgens / blood.
Case
-Control Studies. Estradiol / blood. Estradiol / metabolism. Estrogens / blood. Female. Humans. Logistic Models. Nurses / statistics & numerical data. Odds Ratio. Ovarian Follicle / metabolism. Prospective Studies. Risk Assessment. Risk Factors. Sex Hormone-Binding Globulin / metabolism. Surveys and Questionnaires. United States / epidemiology
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
ESTRADIOL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
J Natl Cancer Inst. 2007 Mar 7;99(5):408-9; author reply 409-10
[
17341734.001
]
(PMID = 17018787.001).
[ISSN]
1460-2105
[Journal-full-title]
Journal of the National Cancer Institute
[ISO-abbreviation]
J. Natl. Cancer Inst.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA50385; United States / NCI NIH HHS / CA / CA67262; United States / NCI NIH HHS / CA / R25 CA098566-02; United States / NCI NIH HHS / CA / T32 CA090001-281
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Androgens; 0 / Estrogens; 0 / Gonadal Steroid Hormones; 0 / Sex Hormone-Binding Globulin; 4TI98Z838E / Estradiol
82.
Smeets R, Kolk A, Gerressen M, Driemel O, Maciejewski O, Hermanns-Sachweh B, Riediger D, Stein JM:
A new biphasic osteoinductive calcium composite material with a negative Zeta potential for bone augmentation.
Head Face Med
; 2009;5:13
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The aim of the present study was to analyze the osteogenic potential of a biphasic calcium composite material (
BCC
) with a negative surface charge for maxillary sinus floor augmentation.
In a 61 year old patient,
the BCC
material was used in a bilateral sinus floor augmentation procedure.
The BCC
was biocompatible and replaced by new mineralized bone after being resorbed completely.
Hazardous Substances Data Bank.
CALCIUM, ELEMENTAL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Int J Oral Maxillofac Implants. 1999 Nov-Dec;14(6):869-78
[
10612926.001
]
[Cites]
Acta Biomater. 2008 Mar;4(2):397-402
[
18054299.001
]
[Cites]
J Biomed Mater Res. 2001 Jun 5;55(3):387-95
[
11255192.001
]
[Cites]
Clin Oral Implants Res. 2001 Aug;12(4):379-84
[
11488868.001
]
[Cites]
J Periodontol. 2001 Jul;72(7):911-20
[
11495140.001
]
[Cites]
J Biomed Mater Res. 2001 Dec 5;57(3):366-73
[
11523031.001
]
[Cites]
Int J Oral Maxillofac Implants. 2001 Sep-Oct;16(5):681-92
[
11669251.001
]
[Cites]
J Dent Res. 2001 Oct;80(10):1925-9
[
11706953.001
]
[Cites]
Eur Spine J. 2001 Oct;10 Suppl 2:S96-101
[
11716023.001
]
[Cites]
Int J Periodontics Restorative Dent. 2002 Oct;22(5):503-8
[
12449310.001
]
[Cites]
J Biomed Mater Res B Appl Biomater. 2004 Feb 15;68(2):199-208
[
14737769.001
]
[Cites]
J Biomed Mater Res A. 2004 Sep 1;70(3):436-41
[
15293317.001
]
[Cites]
J Oral Surg. 1980 Aug;38(8):613-6
[
6993637.001
]
[Cites]
Dent Clin North Am. 1986 Apr;30(2):207-29
[
3516738.001
]
[Cites]
Clin Orthop Relat Res. 1988 Jul;(232):127-38
[
2838207.001
]
[Cites]
J Oral Maxillofac Surg. 1989 Mar;47(3):238-42
[
2646403.001
]
[Cites]
Int J Oral Maxillofac Implants. 1988 Fall;3(3):209-14
[
3074053.001
]
[Cites]
Int J Oral Maxillofac Implants. 1993;8(5):523-8
[
8112791.001
]
[Cites]
Calcif Tissue Int. 1994 Aug;55(2):151-8
[
7953981.001
]
[Cites]
J Biomed Mater Res. 1997 Mar 15;34(4):507-17
[
9054534.001
]
[Cites]
Biochem Cell Biol. 1997;75(1):81-7
[
9192077.001
]
[Cites]
Clin Oral Implants Res. 1998 Feb;9(1):59-64
[
9590946.001
]
[Cites]
Clin Oral Implants Res. 1998 Apr;9(2):107-16
[
9663038.001
]
[Cites]
Int J Periodontics Restorative Dent. 1998 Jun;18(3):227-39
[
9728105.001
]
[Cites]
Int J Oral Maxillofac Implants. 1998 Nov-Dec;13(6):866-73
[
9857600.001
]
[Cites]
Orthop Clin North Am. 1999 Oct;30(4):615-23
[
10471766.001
]
[Cites]
Clin Oral Implants Res. 2004 Dec;15(6):724-32
[
15533134.001
]
[Cites]
Biomaterials. 2005 Jun;26(17):3395-404
[
15621228.001
]
[Cites]
Biomaterials. 2005 Dec;26(34):6818-26
[
15955555.001
]
[Cites]
Int J Periodontics Restorative Dent. 2006 Feb;26(1):79-85
[
16515099.001
]
[Cites]
Int J Periodontics Restorative Dent. 2006 Apr;26(2):113-25
[
16642900.001
]
[Cites]
Implant Dent. 2006 Jun;15(2):197-207
[
16766904.001
]
[Cites]
Int J Oral Maxillofac Surg. 2006 Aug;35(8):708-13
[
16690249.001
]
[Cites]
Int J Periodontics Restorative Dent. 2006 Oct;26(5):471-81
[
17073357.001
]
[Cites]
J Mater Sci Mater Med. 2008 Feb;19(2):667-75
[
17619955.001
]
[Cites]
Clin Oral Implants Res. 2000 Jun;11(3):217-29
[
11168213.001
]
(PMID = 19523239.001).
[ISSN]
1746-160X
[Journal-full-title]
Head & face medicine
[ISO-abbreviation]
Head Face Med
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Bone Substitutes; SY7Q814VUP / Calcium
[Other-IDs]
NLM/ PMC2706807
83.
Dong X, Reddy GB:
Soil bacterial communities in constructed wetlands treated with swine wastewater using PCR-DGGE technique.
Bioresour Technol
; 2010 Feb;101(4):1175-82
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The results showed that the bacterial colony forming units (CFU) and the average
concentrations
of total nitrogen, NH(4)(+), total phosphorous (TP) and PO(4)(3-) from the influent to the effluent decreased.
The NH(4)(+) and the PO(4)(3-)
concentrations
showed the most dramatic changes, with decreases of 39.97% and 16.92%, respectively.
Bacterium species distributions strongly correlated with
the concentrations
of TP, NH(4)(+) and the PO(4)(3-).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19822421.001).
[ISSN]
1873-2976
[Journal-full-title]
Bioresource technology
[ISO-abbreviation]
Bioresour. Technol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
England
[Chemical-registry-number]
0 / RNA, Ribosomal, 16S
84.
Scheithauer BK, Wos-Oxley ML, Ferslev B, Jablonowski H, Pieper DH:
Characterization of the complex bacterial communities colonizing biliary stents reveals a host-dependent diversity.
ISME J
; 2009 Jul;3(7):797-807
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Characterization of
the complex
bacterial communities colonizing
biliary
stents reveals a host-dependent diversity.
This study provides a comprehensive survey of the spatial and temporal bacterial composition of
biliary
stent biofilms.
The bacterial diversity, distribution and dynamics of 59
biliary
and 4 pancreatic stent communities from 40 patients being treated at two different hospitals, which implant stents either simultaneously or consecutively, were characterized by single-strand conformation polymorphism (SSCP) analysis.
Co-colonization of Veillonella sp., Streptococcus anginosus and organisms closely related to Fusobacterium nucleatum revealed a potentially important attachment and survival strategy that has yet to be reported in
biliary
stents.
This work reveals a more complete survey of the identities of bacterial species that form biofilms in
biliary
stents, their co-colonization patterns and the natural variation in species composition between different patients, hospitals and locations along the stent.
SILVA.
SILVA SSU Database
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19360025.001).
[ISSN]
1751-7370
[Journal-full-title]
The ISME journal
[ISO-abbreviation]
ISME J
[Language]
eng
[Databank-accession-numbers]
GENBANK/ EU704129/ EU704130/ EU704131/ EU704132/ EU704133/ EU704134/ EU704135/ EU704136/ EU704137/ EU704138/ EU704139/ EU704140/ EU704141/ EU704142/ EU704143/ EU704144/ EU704145/ EU704146/ EU704147/ EU704148/ EU704149/ EU704150/ EU704151/ EU704152/ EU704153/ EU704154/ EU704155/ EU704156/ EU704157/ EU704158/ EU704159/ EU704160/ EU704161/ EU704162/ EU704163/ EU704164/ EU704165/ EU704166/ EU704167/ EU704168/ EU704169/ EU704170/ EU704171/ EU704172/ EU704173/ EU704174/ EU704175/ EU704176/ EU704177/ EU704178/ EU704179/ EU704180/ EU704181/ EU704182/ EU704183/ EU704184/ EU704185/ EU704186/ EU704187/ EU704188/ EU704189/ EU704190/ EU704191/ EU704192/ EU704193/ EU704194/ EU704195/ EU704196/ EU704197/ EU704198/ EU704199/ EU704200/ EU704201/ EU704202/ EU704203/ EU704204/ EU704205/ EU704206/ EU704207/ EU704208/ EU704209/ EU704210/ EU704211/ EU704212/ EU704213/ EU704214/ EU704215/ EU704216/ EU704217/ EU704218/ EU704219/ EU704220/ EU704221/ EU704222/ EU704223/ EU704224/ EU704225/ EU704226/ EU704227/ EU704228/ EU704229/ EU704230/ EU704231/ EU704232/ EU704233/ EU704234/ EU704235/ EU704236/ EU704237/ EU704238/ EU704239/ EU704240/ EU704241/ EU704242/ EU704243/ EU704244/ EU704245/ EU704246/ EU704247/ EU704248/ EU704249/ EU704250/ EU915501/ EU915502/ EU915503/ EU915504
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / DNA, Ribosomal; 0 / RNA, Ribosomal, 16S
85.
Wang Z, Xu Y, Tang J, Ma H, Qin J, Lu C, Wang X, Hu Z, Wang X, Shen H:
A polymorphism in Werner syndrome gene is associated with breast cancer susceptibility in Chinese women.
Breast Cancer Res Treat
; 2009 Nov;118(1):169-75
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A polymorphism in Werner syndrome gene is associated with
breast cancer
susceptibility in Chinese women.
RecQ helicases play a central role in maintaining genome stability and may interact with some important
cancer
-related proteins such as BRCA1.
Mutations of the human RecQ helicase genes WRN and BLM lead to rare autosomal recessive disorders, Werner and Bloom syndromes, which are associated with premature aging and
cancer
predisposition, including
breast cancer
.
In this
case
-control study of 1,004
breast cancer cases
and 1,008 controls, we tested the hypothesis that non-conservative amino acid exchanges in WRN (leu1074Phe), BLM (Met298Thr) and BRCA1 (Pro871Leu) are independently or jointly associated with the risk of
breast cancer
in Chinese women.
We found that the variant genotype of WRN Leu1074Phe was associated with a 1.36-fold significantly increased risk of
breast cancer
(OR = 1.36, 95% CI = 1.06-1.74).
Subjects carrying Phe/Phe genotype and with earlier age at menarche had 3.58-fold increased risk of
breast cancer
(OR = 3.58, 95% CI = 2.54-5.05).
These findings indicate that WRN leu1074Phe variant may contribute to the susceptibility of
breast cancer
in Chinese women.
[MeSH-major]
Breast
Neoplasms / genetics. Exodeoxyribonucleases / genetics. Genes,
Neoplasm
. Menarche / genetics.
Neoplasm
Proteins / genetics. Polymorphism, Single Nucleotide. RecQ Helicases / genetics. Werner Syndrome / genetics
[MeSH-minor]
Adult. Aged. Amino Acid Substitution.
Case
-Control Studies. China / epidemiology. Female. Genes, BRCA1. Genetic Predisposition to
Disease
. Genotype. Humans. Menopause. Middle Aged. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Risk
Genetic Alliance.
consumer health - Werner's syndrome
.
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19205873.001).
[ISSN]
1573-7217
[Journal-full-title]
Breast cancer research and treatment
[ISO-abbreviation]
Breast Cancer Res. Treat.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Neoplasm Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 3.1.- / Exodeoxyribonucleases; EC 3.6.1.- / Bloom syndrome protein; EC 3.6.1.- / WRN protein, human; EC 3.6.4.12 / RecQ Helicases
86.
Kuo WH, Yen AM, Lee PH, Chen KM, Wang J, Chang KJ, Chen TH, Tsau HS:
Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women.
Br J Cancer
; 2009 Feb 24;100(4):563-70
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cumulative survival in early-onset unilateral and bilateral
breast cancer
: an analysis of 1907 Taiwanese women.
As the epidemiological pattern of
breast cancer
in modernising Asian countries differs greatly from that in Western countries, it is worthwhile to investigate the long-term prognoses of unilateral and bilateral
breast cancer
in these nations.
A retrospective cohort study composed of 1907 Taiwanese women was conducted to follow 1863 unilateral and 44 bilateral
cases
of
breast cancer
.
Time-dependent Cox regression was used to assess the risk of
breast cancer
death by considering the time course of unilateral and bilateral tumour development.
The 15-year survival rates were 68.37, 62.63, and 26.42% for unilateral, synchronous bilateral, and metachronous bilateral
breast cancer
, respectively.
After adjusting for significant prognostic factors, the risk of death for overall bilateral
breast cancer
was 2.50-fold greater (95% CI, 1.43-4.37) compared to unilateral
breast cancer
.
The corresponding figures were 1.12-fold (95% CI, 0.42-3.02) and 6.11-fold (95% CI, 3.14-11.89) for synchronous and metachronous bilateral
breast cancer
, respectively.
Taiwanese women, who are frequently diagnosed with
breast cancer
before 50 years of age, showed poorer survival for metachronous bilateral than for synchronous bilateral or unilateral
breast cancer
.
[MeSH-major]
Breast
Neoplasms / mortality.
Breast
Neoplasms / pathology
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Lancet. 2000 May 27;355(9218):1869-74
[
10866443.001
]
[Cites]
Eur J Cancer. 2008 Dec;44(18):2774-80
[
19027287.001
]
[Cites]
World J Surg. 2001 Sep;25(9):1117-24
[
11571945.001
]
[Cites]
Int J Cancer. 2004 Mar 1;108(6):901-6
[
14712495.001
]
[Cites]
Arch Surg. 2004 Jan;139(1):27-30; discussion 31
[
14718270.001
]
[Cites]
Cancer. 1984 Dec 15;54(12):3002-11
[
6498774.001
]
[Cites]
Aust N Z J Surg. 1989 Jan;59(1):35-7
[
2913992.001
]
[Cites]
J Natl Cancer Inst. 1993 Nov 17;85(22):1819-27
[
8230262.001
]
[Cites]
Cancer. 1993 Dec 15;72(12):3629-35
[
8252478.001
]
[Cites]
Am J Epidemiol. 1995 Dec 15;142(12):1255-64
[
7503045.001
]
[Cites]
N Engl J Med. 1996 Jan 18;334(3):143-9
[
8531968.001
]
[Cites]
Int J Epidemiol. 1996 Feb;25(1):40-5
[
8666502.001
]
[Cites]
Am J Clin Oncol. 1997 Dec;20(6):541-5
[
9391536.001
]
[Cites]
Int J Oncol. 1999 Jun;14(6):1103-9
[
10339665.001
]
[Cites]
Fam Cancer. 2004;3(3-4):249-57
[
15516849.001
]
[Cites]
Int J Cancer. 2005 Jan 10;113(2):302-6
[
15386413.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):243-50
[
15668501.001
]
[Cites]
Lancet. 2005 May 14-20;365(9472):1687-717
[
15894097.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1986-90
[
16103449.001
]
[Cites]
Lancet. 2005 Dec 17;366(9503):2087-106
[
16360786.001
]
[Cites]
Breast Cancer Res Treat. 2006 Sep;99(2):221-8
[
16544057.001
]
[Cites]
BMC Cancer. 2006;6:261
[
17078893.001
]
[Cites]
J Clin Oncol. 2007 Jun 10;25(17):2360-8
[
17515570.001
]
[Cites]
Int J Cancer. 2007 Sep 1;121(5):1017-20
[
17471561.001
]
[Cites]
N Engl J Med. 2007 Jul 12;357(2):115-23
[
17625123.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1437-42
[
17627009.001
]
[Cites]
J Clin Oncol. 2007 Sep 20;25(27):4210-6
[
17878475.001
]
[Cites]
J Clin Oncol. 2008 Jul 10;26(20):3324-30
[
18612148.001
]
[Cites]
Cancer Detect Prev. 2008;32(2):156-61
[
18632223.001
]
[Cites]
Cancer. 2001 May 15;91(10):1845-53
[
11346865.001
]
(PMID = 19190627.001).
[ISSN]
1532-1827
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Other-IDs]
NLM/ PMC2653740
87.
Melchor L, Honrado E, Huang J, Alvarez S, Naylor TL, GarcÃa MJ, Osorio A, Blesa D, Stratton MR, Weber BL, Cigudosa JC, Rahman N, Nathanson KL, BenÃtez J:
Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer.
Clin Cancer Res
; 2007 Dec 15;13(24):7305-13
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Estrogen receptor status could modulate the genomic pattern in familial and sporadic
breast cancer
.
PURPOSE: Familial
breast cancer
represents 5% to 10% of all
breast
tumors.
Mutations in the two known major
breast cancer
susceptibility genes, BRCA1 and BRCA2, account for a minority of familial
breast cancer
, whereas families without mutations in these genes (BRCAX group) account for 70% of familial
breast cancer cases
.
EXPERIMENTAL DESIGN: To better characterize and define the genomic differences between the three classes of familial tumors and sporadic malignancies, we have analyzed 19 BRCA1, 24 BRCA2, and 31 BRCAX samples from familial
breast cancer
patients and 19 sporadic
breast
tumors using a 1-Mb resolution bacterial artificial chromosome array-based comparative genomic hybridization.
There were common genomic alterations present in all
breast cancer
groups, such as gains of 1q and 16p or losses of 8ptel-p12 and 16q.
[MeSH-major]
Breast
Neoplasms / genetics.
Breast
Neoplasms / metabolism. Genes, BRCA1. Genes, BRCA2. Genomic Instability. Receptors, Estrogen / metabolism
[MeSH-minor]
Chromosomes, Artificial, Bacterial. Female. Genetic Predisposition to
Disease
. Humans. Mutation. Nucleic Acid Hybridization
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18094411.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Receptors, Estrogen
88.
Homaei-Shandiz F, Ghavam-Nassiri MR, Sharifi N, Homaei-Shandiz AH, Taghizadeh-Kermani A, Torshizi SA, Ghafarzadegan K:
Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer.
Saudi Med J
; 2006 Dec;27(12):1810-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with
breast cancer
.
OBJECTIVE: The human epidermal growth factor receptor-2 (HER-2)/neu is a proto-oncogene that is amplified in 10-30% of
breast
cancers.
We studied the relationship between its amplification and different histological gradings of
breast cancer
.
METHODS: We studied 196 patients diagnosed with
breast cancer
in 2005 at the Omid and Ghaem Training Hospital, Mashhad Medical University, Iran.
RESULTS: Sixty-seven (34.2%)
cases
were HER-2/neu positive and 129 (65.8%)
cases
were HER-2/neu negative.
Overexpression of HER-2/neu was significantly higher in
breast cancer
patients <30 years (50% versus 33.3%, p=0.034).
Twelve (17.5%) of HER-2/neu positive
cases
were metastatic and only 4 (3.1%) of HER-2/neu negative
cases
had metastasis (p=0.051).
CONCLUSION: HER-2/neu gene amplification or its overexpression is detected in approximately 34.2% of
breast cancer cases
.
Patients with HER-2/neu positive
breast cancer
have higher stage and grade diseases.
[MeSH-major]
Breast
Neoplasms / genetics.
Breast
Neoplasms / pathology. Gene Amplification. Gene Expression Regulation, Neoplastic / genetics. Receptor, ErbB-2 / genetics
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Saudi Med J. 2007 Sep;28(9):1462; author reply 1462
[
17768488.001
]
[CommentIn]
Saudi Med J. 2007 Jun;28(6):986; author reply 986
[
17530133.001
]
(PMID = 17143354.001).
[ISSN]
0379-5284
[Journal-full-title]
Saudi medical journal
[ISO-abbreviation]
Saudi Med J
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Saudi Arabia
[Chemical-registry-number]
EC 2.7.10.1 / Receptor, ErbB-2
89.
Kleinerman RA:
Radiation-sensitive genetically susceptible pediatric sub-populations.
Pediatr Radiol
; 2009 Feb;39 Suppl 1:S27-31
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Major advances in pediatric
cancer
treatment have resulted in substantial improvements in survival.
However, concern has emerged about the late effects of
cancer
therapy, especially radiation-related second cancers.
Studies of childhood
cancer
patients with inherited
cancer
syndromes can provide insights into the interaction between radiation and genetic susceptibility to multiple cancers.
Children with retinoblastoma (Rb), neurofibromatosis type 1 (NF1), Li-Fraumeni syndrome (LFS), and nevoid
basal cell carcinoma
syndrome (NBCCS) are at substantial risk of developing radiation-related second and third cancers.
Studies of NF1 patients irradiated for optic pathway gliomas have reported increased risks of developing another
cancer
associated with radiotherapy.
Children with NBCCS are very sensitive to radiation and develop multiple
basal cell
cancers in irradiated areas.
[MeSH-major]
Genetic Predisposition to
Disease
. Neoplasms, Radiation-Induced / genetics. Neoplasms, Second Primary / genetics. Neoplastic Syndromes, Hereditary / radiotherapy
[MeSH-minor]
Basal Cell
Nevus Syndrome / genetics.
Basal Cell
Nevus Syndrome / radiotherapy. Child. Humans. Li-Fraumeni Syndrome. Neurofibromatosis 1 / genetics. Neurofibromatosis 1 / radiotherapy. Radiation Dosage. Retinal Neoplasms / genetics. Retinal Neoplasms / radiotherapy. Retinoblastoma / genetics. Retinoblastoma / radiotherapy
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Ann Intern Med. 1969 Oct;71(4):747-52
[
5360287.001
]
[Cites]
Health Phys. 2003 Jul;85(1):47-59
[
12852471.001
]
[Cites]
Cancer. 1986 May 15;57(10):2006-21
[
3082508.001
]
[Cites]
Br J Cancer. 1986 May;53(5):661-71
[
3718823.001
]
[Cites]
Medicine (Baltimore). 1987 Mar;66(2):98-113
[
3547011.001
]
[Cites]
Cancer Res. 1988 Sep 15;48(18):5358-62
[
3409256.001
]
[Cites]
N Engl J Med. 1988 Oct 20;319(16):1033-9
[
3173432.001
]
[Cites]
Science. 1990 Nov 30;250(4985):1233-8
[
1978757.001
]
[Cites]
Br J Cancer. 1991 Nov;64(5):959-61
[
1931625.001
]
[Cites]
N Engl J Med. 1992 May 14;326(20):1309-15
[
1565144.001
]
[Cites]
Radiat Res. 1995 Mar;141(3):259-77
[
7871153.001
]
[Cites]
Radiat Res. 1996 May;145(5):595-601
[
8619025.001
]
[Cites]
Int J Cancer. 1996 Aug 7;67(4):515-9
[
8759610.001
]
[Cites]
JAMA. 1997 Oct 15;278(15):1262-7
[
9333268.001
]
[Cites]
Cancer Causes Control. 1997 Nov;8(6):865-71
[
9427429.001
]
[Cites]
J Natl Cancer Inst. 1998 Apr 15;90(8):606-11
[
9554443.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):583-93
[
15667981.001
]
[Cites]
J Clin Oncol. 2005 Apr 1;23(10):2272-9
[
15800318.001
]
[Cites]
Cancer Cell. 2005 Oct;8(4):271-3
[
16226702.001
]
[Cites]
J Med Genet. 2006 Apr;43(4):289-94
[
16155191.001
]
[Cites]
J Clin Oncol. 2006 Jun 1;24(16):2570-5
[
16735710.001
]
[Cites]
Pediatr Radiol. 2006 Sep;36 Suppl 2:121-5
[
16862418.001
]
[Cites]
Int J Cancer. 2006 Nov 1;119(9):2001-6
[
16642469.001
]
[Cites]
J Natl Cancer Inst. 2007 Jan 3;99(1):24-31
[
17202110.001
]
[Cites]
J Med Genet. 2007 Feb;44(2):81-8
[
17105749.001
]
[Cites]
Ann Neurol. 2007 Mar;61(3):189-98
[
17387725.001
]
[Cites]
Int J Cancer. 2007 Nov 15;121(10):2233-40
[
17557301.001
]
[Cites]
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
[
18287387.001
]
[Cites]
J Natl Cancer Inst. 2008 Mar 19;100(6):428-36
[
18334707.001
]
[Cites]
JAMA. 2008 Mar 19;299(11):1315-9
[
18349092.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):228-35
[
18571337.001
]
[Cites]
Otolaryngol Head Neck Surg. 2000 May;122(5):667-72
[
10793343.001
]
[Cites]
J Pediatr Hematol Oncol. 2001 Oct;23(7):431-6
[
11878577.001
]
[Cites]
J Med Genet. 2002 May;39(5):311-4
[
12011145.001
]
[Cites]
Nat Rev Cancer. 2002 Feb;2(2):124-32
[
12635175.001
]
[Cites]
Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3
[
5279523.001
]
(PMID = 19083227.001).
[ISSN]
0301-0449
[Journal-full-title]
Pediatric radiology
[ISO-abbreviation]
Pediatr Radiol
[Language]
eng
[Grant]
United States / Intramural NIH HHS / / Z01 CP010131-12
[Publication-type]
Journal Article; Research Support, N.I.H., Intramural; Review
[Publication-country]
Germany
[Number-of-references]
39
[Other-IDs]
NLM/ NIHMS75740; NLM/ PMC2656401
90.
Gurgel CA, Ramos EA, Azevedo RA, Sarmento VA, da Silva Carvalho AM, dos Santos JN:
Expression of Ki-67, p53 and p63 proteins in keratocyst odontogenic tumours: an immunohistochemical study.
J Mol Histol
; 2008 Jun;39(3):311-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: Immunohistochemical technique was performed using the EnVision System in 37
cases
of KOTs.
No difference in the immunostaining for these proteins was observed between primary and recurrent KOTs (Ki-67: P = 0.5591; p53: P = 0.9847; p63: P = 0.9127), or between KOTs associated with Nevoid
Basal Cell Carcinoma
Syndrome (NBCCS) and sporadic KOTs (Ki-67: P = 0.7013; p53: P = 0.3197; p63: P = 0.2427).
In addition, p63 immunostaining may represent immaturity of keratinocytes in KOTs, and suggests that this protein may participate in the regulation of epithelial
cell
differentiation.
[MeSH-minor]
Antibodies.
Cell
Count. Humans. Immunohistochemistry. Transcription Factors
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Cell Sci. 1989 Jan;92 ( Pt 1):123-30
[
2674163.001
]
[Cites]
Histopathology. 2005 Dec;47(6):582-6
[
16324195.001
]
[Cites]
J Clin Pathol. 1992 Nov;45(11):1007-10
[
1452774.001
]
[Cites]
J Oral Pathol Med. 1995 Oct;24(9):393-7
[
8537911.001
]
[Cites]
J Invest Dermatol. 1999 Dec;113(6):1099-105
[
10594758.001
]
[Cites]
Nature. 1991 Jun 6;351(6326):453-6
[
2046748.001
]
[Cites]
J Pathol. 1998 Apr;184(4):348-50
[
9664899.001
]
[Cites]
J Endod. 2001 Jul;27(7):459-61
[
11503996.001
]
[Cites]
Oral Oncol. 2002 Jun;38(4):323-31
[
12076694.001
]
[Cites]
Oral Oncol. 2004 Nov;40(10):985-91
[
15509489.001
]
[Cites]
Exp Cell Res. 2006 Apr 1;312(6):695-706
[
16406339.001
]
[Cites]
Yonsei Med J. 2003 Oct 30;44(5):841-6
[
14584101.001
]
[Cites]
Int J Biochem Cell Biol. 2002 Jan;34(1):6-9
[
11733180.001
]
[Cites]
J Oral Pathol Med. 1995 May;24(5):221-6
[
7542341.001
]
[Cites]
Arch Pathol Lab Med. 2004 Mar;128(3):313-7
[
14987156.001
]
[Cites]
J Oral Maxillofac Surg. 2006 Feb;64(2):308-16
[
16413905.001
]
[Cites]
J Pathol. 2002 Dec;198(4):417-27
[
12434410.001
]
[Cites]
Cell. 2007 May 4;129(3):523-36
[
17482546.001
]
[Cites]
Arch Oral Biol. 1995 Dec;40(12):1081-4
[
8850645.001
]
[Cites]
Int J Oral Maxillofac Surg. 2005 Sep;34(6):668-73
[
16053892.001
]
[Cites]
Am J Pathol. 1991 Apr;138(4):867-73
[
2012175.001
]
[Cites]
Nature. 1999 Apr 22;398(6729):714-8
[
10227294.001
]
[Cites]
Oral Oncol. 2002 Jul;38(5):407-15
[
12110333.001
]
[Cites]
Histopathology. 1993 Apr;22(4):355-60
[
8514278.001
]
[Cites]
J Contemp Dent Pract. 2000 Feb 15;1(2):60-74
[
12167890.001
]
[Cites]
Mol Cell. 1998 Sep;2(3):305-16
[
9774969.001
]
[Cites]
J Dent Res. 1999 Jul;78(7):1345-53
[
10403462.001
]
[Cites]
Biochemistry (Mosc). 2005 Sep;70(9):955-71
[
16266265.001
]
[Cites]
Regen Med. 2006 Jan;1(1):45-57
[
17465819.001
]
[Cites]
J Oral Pathol Med. 2001 Aug;30(7):434-42
[
11488422.001
]
[Cites]
Oral Dis. 2004 Jan;10(1):22-6
[
14996290.001
]
[Cites]
J Oral Pathol Med. 2005 May;34(5):280-6
[
15817071.001
]
[Cites]
Biochem Biophys Res Commun. 2000 Jun 24;273(1):342-6
[
10873608.001
]
[Cites]
Curr Opin Genet Dev. 2006 Feb;16(1):38-44
[
16359856.001
]
[Cites]
Trends Genet. 2002 Feb;18(2):90-5
[
11818141.001
]
[Cites]
J Oral Pathol Med. 1996 May;25(5):249-55
[
8835823.001
]
[Cites]
Curr Biol. 1992 Nov;2(11):581-3
[
15336029.001
]
[Cites]
J Oral Pathol Med. 2006 Feb;35(2):75-80
[
16430736.001
]
[Cites]
Oral Oncol. 2002 Apr;38(3):219-26
[
11978543.001
]
[Cites]
Mol Cancer Res. 2006 Oct;4(10 ):759-68
[
17050669.001
]
[Cites]
Anticancer Res. 2006 Jan-Feb;26(1A):175-81
[
16475695.001
]
[Cites]
Int J Oral Maxillofac Surg. 2006 Jul;35(7):673-5
[
16687239.001
]
[Cites]
Int J Oral Maxillofac Surg. 2001 Feb;30(1):14-25
[
11289615.001
]
[Cites]
J Oral Pathol Med. 2000 Nov;29(10):477-82
[
11048963.001
]
(PMID = 18256893.001).
[ISSN]
1567-2379
[Journal-full-title]
Journal of molecular histology
[ISO-abbreviation]
J. Mol. Histol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Antibodies; 0 / Ki-67 Antigen; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins
91.
Newman MD, Weinberg JM:
Topical therapy in the treatment of actinic keratosis and basal cell carcinoma.
Cutis
; 2007 Apr;79(4 Suppl):18-28
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Topical therapy in the treatment of actinic keratosis and
basal cell carcinoma
.
Actinic keratosis (AK) is an evolving
malignant
cutaneous
neoplasm
.
AK also is known as solar keratosis and squamous
cell carcinoma
(SCC) in situ, either solar keratotic type or keratinocytic intraepidermal neoplasia.
Topical treatment
of basal cell carcinoma
(
BCC
) with imiquimod also will be discussed.
[MeSH-major]
Carcinoma
,
Basal Cell
/ drug therapy. Keratosis / drug therapy.
Skin
Neoplasms / drug therapy
MedlinePlus Health Information.
consumer health - Skin Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17508492.001).
[ISSN]
0011-4162
[Journal-full-title]
Cutis
[ISO-abbreviation]
Cutis
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Cyclooxygenase Inhibitors; 0 / Retinoids; 0 / Tubulin Modulators
[Number-of-references]
44
92.
Nugent Z, Demers AA, Wiseman MC, Mihalcioiu C, Kliewer EV:
Risk of second primary cancer and death following a diagnosis of nonmelanoma skin cancer.
Cancer Epidemiol Biomarkers Prev
; 2005 Nov;14(11 Pt 1):2584-90
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Risk of second primary
cancer
and death following a
diagnosis of
nonmelanoma
skin
cancer
.
Cancer
-free patients diagnosed with a first primary nonmelanoma
skin
cancer
(NMSC) offer an opportunity for studying the risk of a second primary
cancer
without the confounding effect of systemic treatment.
The objective of the study was to estimate the risk of second primary
cancer
in people with a history
of basal cell carcinoma
(
BCC
) or squamous
cell carcinoma
(SCC) and the risk of dying in
cancer
patients with a NMSC history.
BCC
and SCC
cases
diagnosed between 1956 and 2000 in Manitoba, Canada were followed-up for second primaries (other than NMSC).
Men [SIR, 1.06; 95% confidence interval (95% CI), 1.02-1.10] and women (SIR, 1.07; 95% CI, 1.02-1.12) with
a BCC
history as well as men (SIR, 1.15; 95% CI, 1.08-1.22) with a SCC history were at greater risk of a second primary
cancer
.
Overall, the increased risk was observed only in the first 4 years following a NMSC, although it remained increased for specific
cancer
sites.
People with a history of
BCC
(males: SMR, 1.09; 95% CI, 1.04-1.14; females: SMR, 1.24; 95% CI, 1.16-1.32) or SCC (males: SMR, 1.18; 95% CI, 1.09-1.27; females: SMR, 1.55; 95% CI, 1.35-1.79) had a greater risk of death following their second primaries.
Even if NMSC patients are at greater risk of a second
cancer
, it is not recommended to follow them up beyond the generally accepted periodic examination of the
skin
.
[MeSH-major]
Carcinoma
,
Basal Cell
/ complications.
Carcinoma
, Squamous
Cell
/ complications. Neoplasms, Second Primary / etiology. Neoplasms, Second Primary / mortality.
Skin
Neoplasms / complications
MedlinePlus Health Information.
consumer health - Skin Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16284382.001).
[ISSN]
1055-9965
[Journal-full-title]
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
[ISO-abbreviation]
Cancer Epidemiol. Biomarkers Prev.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
93.
Butler ST, Youker SR, Mandrell J, Flanagan KH, Fosko SW:
The importance of reviewing pathology specimens before Mohs surgery.
Dermatol Surg
; 2009 Mar;35(3):407-12
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The frequency with which this practice changes the
diagnosis
and management of patients undergoing Mohs surgery is undocumented in the literature.
OBJECTIVE: To investigate how often review of outside biopsies by an internal dermatopathologist changes patients' initial referral
diagnosis
and subsequent management.
The number of
cases
in which the
diagnosis
changed and how this change affected management were recorded.
RESULTS: Seventy-four of 3,345 (2.2%)
cases
were identified in which the
diagnosis
changed after review of the biopsy slides.
Management was affected in the majority (61%) of
cases
.
CONCLUSION: Review of outside biopsy slides before surgery can change the
diagnosis
in a large proportion of patients, with a resulting change in management.
[MeSH-major]
Mohs Surgery. Referral and Consultation.
Skin
Neoplasms / pathology.
Skin
Neoplasms / surgery
[MeSH-minor]
Aged. Biopsy / economics.
Carcinoma
,
Basal Cell
/
diagnosis
.
Carcinoma
,
Basal Cell
/ pathology.
Carcinoma
,
Basal Cell
/ surgery.
Carcinoma
, Squamous
Cell
/
diagnosis
.
Carcinoma
, Squamous
Cell
/ pathology.
Carcinoma
, Squamous
Cell
/ surgery. Female. Humans. Immunohistochemistry. Male. Melanoma /
diagnosis
. Melanoma / pathology. Melanoma / surgery. Retrospective Studies. S100 Proteins / metabolism. Unnecessary Procedures
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19175663.001).
[ISSN]
1524-4725
[Journal-full-title]
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
[ISO-abbreviation]
Dermatol Surg
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / S100 Proteins
94.
Friedrich RE, Giese M, Li L, Schenk Y, Schmelzle R:
Diagnosis, treatment and follow-up control in 124 patients with basal cell carcinoma of the maxillofacial region treated from 1992 to 1997.
Anticancer Res
; 2005 May-Jun;25(3A):1693-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Diagnosis
, treatment and follow-up control in 124 patients with
basal cell carcinoma of
the maxillofacial region treated from 1992 to 1997.
AIM: The aim of this study was to analyze diagnostic and therapeutic procedures and the outcome of patients treated for the most common
malignant
tumor of the facial
skin
,
basal cell carcinoma
.
PATIENTS AND METHODS: The files of patients with
basal cell carcinoma
(
BCC
) treated over a period of 6 years were evaluated.
RESULTS: One-hundred and twenty-four patients were treated for 216
basal cell
carcinomas
(solitary: 67%, multiple: 33%).
The tumors were predominantly located in the
skin
covering the middle third of the face.
Relative to the small number of sclerodermiform
BCC
, this subtype was the most frequent tumor that developed local recurrences.
CONCLUSION:
Basal cell carcinoma
is
a malignant
tumor, slowly growing and often showing wide extension to macroscopically non-affected sites.
[MeSH-major]
Carcinoma
,
Basal Cell
/
diagnosis
.
Carcinoma
,
Basal Cell
/ therapy. Face / pathology. Jaw / pathology.
Skin
Neoplasms /
diagnosis
.
Skin
Neoplasms / therapy
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16033084.001).
[ISSN]
0250-7005
[Journal-full-title]
Anticancer research
[ISO-abbreviation]
Anticancer Res.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Greece
95.
Ciralik H, Coban YK, Arican O:
A case of perforating pilomatricoma.
J Dermatol
; 2006 Jun;33(6):394-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A case
of perforating pilomatricoma.
Pilomatricoma is a rare
skin
neoplasm
, most commonly seen in the head and neck region, and occurring in the first two decades of life.
Perforating pilomatricoma is a rare clinical variant that presents as a draining, crusted nodule or
ulcer
, and is reported to arise faster than the classic pilomatricoma.
Herein, we report
a case
of 35-year-old female, who had a 4-month history of a growing mass on her leg.
The first histopathological analysis of a punch biopsy from the lesion was reported as
basal cell carcinoma
.
Punch or excisional biopsies are preferred as a method
of diagnosis
for the majority of cutaneous neoplasms.
If total excision is not the method of choice, multiple punch biopsies should be made from different areas in large
skin
tumors for correct
diagnosis
.
[MeSH-major]
Hair Diseases / pathology. Pilomatrixoma / pathology.
Skin
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Hair Problems
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16700828.001).
[ISSN]
0385-2407
[Journal-full-title]
The Journal of dermatology
[ISO-abbreviation]
J. Dermatol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
96.
Zhang G, Luo X, Sumithran E, Pua VS, Barnetson RS, Halliday GM, Khachigian LM:
Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression.
Oncogene
; 2006 Nov 23;25(55):7260-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Squamous
cell carcinoma
growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression.
Squamous
cell carcinoma
(SCC) is an invasive malignancy of epidermal keratinocytes.
The transcription factor c-Jun is expressed in human SCC and another common form of invasive
skin
cancer
,
basal cell carcinoma
together with the mitogenic marker-proliferating
cell
nuclear antigen.
These findings demonstrate that c-Jun regulates SCC growth and suggest that DNAzymes targeting this transcription factor may potentially be useful as inhibitors of cutaneous
carcinoma
.
[MeSH-major]
Carcinoma
, Squamous
Cell
/ pathology.
Cell
Division / physiology. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Proto-Oncogene Proteins c-jun / physiology
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16785994.001).
[ISSN]
0950-9232
[Journal-full-title]
Oncogene
[ISO-abbreviation]
Oncogene
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / DNA, Catalytic; 0 / Matrix Metalloproteinase Inhibitors; 0 / Proto-Oncogene Proteins c-jun; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
97.
Madan V, Lear JT, Szeimies RM:
Non-melanoma skin cancer.
Lancet
; 2010 Feb 20;375(9715):673-85
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Non-melanoma
skin
cancer
.
The rising incidence and morbidity of non-melanoma
skin
cancers has generated great interest in unravelling of their pathogenesis and in the search for new non-invasive treatments.
Whereas the role of cumulative sun exposure in pathogenesis of squamous-
cell carcinoma
seems clear, the relation between sun-exposure patterns and subtypes
of basal
-
cell carcinoma
remains undetermined.
Several
complex
genotypic, phenotypic, and environmental factors contribute to pathogenesis of non-melanoma
skin
cancers.
Unlike
basal
-
cell carcinoma
, squamous-
cell
carcinomas
can arise from precursor lesions.
Diagnosis of
non-melanoma
skin
cancer
is made clinically and confirmed by histological testing.
Prevention strategies aim at reduction of sun exposure, but are of unproven benefit, especially for
basal
-
cell carcinoma
.
Surgical excision with predetermined margins is the mainstay of treatment for squamous-
cell carcinoma
and for most
basal
-
cell
carcinomas
.
Of the new non-invasive treatments, only photodynamic therapy and topical imiquimod have become established treatments for specific subtypes
of basal
-
cell carcinoma
, and the search for more effective and tissue-salvaging therapies continues.
[MeSH-major]
Carcinoma
,
Basal Cell
.
Carcinoma
, Squamous
Cell
.
Skin
Neoplasms. Sunlight / adverse effects
[MeSH-minor]
Age Distribution. Age Factors. Environmental Exposure. Female. Humans. Incidence. Male.
Neoplasm
Staging. Population Surveillance. Prognosis. Registries. Risk. Risk Factors. Sex Factors
MedlinePlus Health Information.
consumer health - Skin Cancer
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2010 Elsevier Ltd. All rights reserved.
[CommentIn]
Lancet. 2010 Jul 17;376(9736):161-2; author reply 162
[
20638560.001
]
(PMID = 20171403.001).
[ISSN]
1474-547X
[Journal-full-title]
Lancet (London, England)
[ISO-abbreviation]
Lancet
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
98.
Reszec J, Sulkowski S:
The expression of P53 protein and infection of human papilloma virus in conjunctival and eyelid neoplasms.
Int J Mol Med
; 2005 Oct;16(4):559-64
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The aim of this study was to evaluate P53 protein expression and to detect HPV in the tissue samples of 45 benign (papillomas) and 38
malignant